

Henrik Zetterberg

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2424085/publications.pdf>

Version: 2024-02-01

1,898
papers

109,261
citations

228

145
h-index

750

250
g-index

2043
all docs

2043
docs citations

2043
times ranked

58843
citing authors

#	ARTICLE	IF	CITATIONS
1	Plasma biomarkers and genetics in the diagnosis and prediction of Alzheimer's disease. <i>Brain</i> , 2023, 146, 690-699.	3.7	44
2	Cerebrospinal fluid proteomic profiling of individuals with mild cognitive impairment and suspected non-Alzheimer's disease pathophysiology. <i>Alzheimer's and Dementia</i> , 2023, 19, 807-820.	0.4	4
3	Test-retest variability of plasma biomarkers in Alzheimer's disease and its effects on clinical prediction models. <i>Alzheimer's and Dementia</i> , 2023, 19, 797-806.	0.4	24
4	Genotypic effects of APOE- ϵ 4 on resting-state connectivity in cognitively intact individuals support functional brain compensation. <i>Cerebral Cortex</i> , 2023, 33, 2748-2760.	1.6	5
5	Comparative analytical performance of multiple plasma A β 242 and A β 240 assays and their ability to predict positron emission tomography amyloid positivity. <i>Alzheimer's and Dementia</i> , 2023, 19, 956-966.	0.4	24
6	Prediction of Outcome After Endovascular Embolectomy in Anterior Circulation Stroke Using Biomarkers. <i>Translational Stroke Research</i> , 2022, 13, 65-76.	2.3	17
7	Antibody Responses to Severe Acute Respiratory Syndrome Coronavirus 2 in the Serum and Cerebrospinal Fluid of Patients With Coronavirus Disease 2019 and Neurological Symptoms. <i>Journal of Infectious Diseases</i> , 2022, 225, 965-970.	1.9	15
8	Large-scale plasma proteomic profiling identifies a high-performance biomarker panel for Alzheimer's disease screening and staging. <i>Alzheimer's and Dementia</i> , 2022, 18, 88-102.	0.4	65
9	Interaction of amyloid and tau on cortical microstructure in cognitively unimpaired adults. <i>Alzheimer's and Dementia</i> , 2022, 18, 65-76.	0.4	18
10	Biomarkers of Cerebral Injury for Prediction of Postoperative Cognitive Dysfunction in Patients Undergoing Cardiac Surgery. <i>Journal of Cardiothoracic and Vascular Anesthesia</i> , 2022, 36, 125-132.	0.6	17
11	Dynamics of Selected Biomarkers in Cerebrospinal Fluid During Complex Endovascular Aortic Repair – A Pilot Study. <i>Annals of Vascular Surgery</i> , 2022, 78, 141-151.	0.4	1
12	Cardiac troponin T is elevated and increases longitudinally in ALS patients. <i>Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration</i> , 2022, 23, 58-65.	1.1	8
13	Detecting amyloid positivity in early Alzheimer's disease using combinations of plasma A β 242/A β 240 and p-tau. <i>Alzheimer's and Dementia</i> , 2022, 18, 283-293.	0.4	72
14	Cohort Analysis of the Association of Delirium Severity With Cerebrospinal Fluid Amyloid-Tau-Neurodegeneration Pathologies. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2022, 77, 494-501.	1.7	20
15	Cerebrospinal fluid metallomics in cerebral amyloid angiopathy: an exploratory analysis. <i>Journal of Neurology</i> , 2022, 269, 1470-1475.	1.8	5
16	Preclinical <i>in vivo</i> longitudinal assessment of KG207-M as a disease-modifying Alzheimer's disease therapeutic. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2022, 42, 788-801.	2.4	8
17	Exploring CSF neurofilament light as a biomarker for MS in clinical practice; a retrospective registry-based study. <i>Multiple Sclerosis Journal</i> , 2022, 28, 872-884.	1.4	10
18	Response to mitogen-activated protein kinase inhibition of neurodegeneration in Langerhans cell histiocytosis monitored by cerebrospinal fluid neurofilament light as a biomarker: a pilot study. <i>British Journal of Haematology</i> , 2022, 196, 248-254.	1.2	9

#	ARTICLE	IF	CITATIONS
19	Plasma proteins, cognitive decline, and 20-year risk of dementia in the Whitehall II and Atherosclerosis Risk in Communities studies. <i>Alzheimer's and Dementia</i> , 2022, 18, 612-624.	0.4	24
20	Apolipoprotein B is a novel marker for early tau pathology in Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2022, 18, 875-887.	0.4	22
21	Neuroimaging and biomarker evidence of neurodegeneration in asthma. <i>Journal of Allergy and Clinical Immunology</i> , 2022, 149, 589-598.e6.	1.5	24
22	Diagnostic and prognostic plasma biomarkers for preclinical Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2022, 18, 1141-1154.	0.4	89
23	Comparing the effect of xenon and sevoflurane anesthesia on postoperative neural injury biomarkers: a randomized controlled trial. <i>Medical Gas Research</i> , 2022, 12, 10.	1.2	8
24	Concussion and long-term cognitive function among rugby players – The BRAIN Study. <i>Alzheimer's and Dementia</i> , 2022, 18, 1164-1176.	0.4	11
25	Neurochemical Markers of Traumatic Brain Injury: Relevance to Acute Diagnostics, Disease Monitoring, and Neuropsychiatric Outcome Prediction. <i>Biological Psychiatry</i> , 2022, 91, 405-412.	0.7	17
26	Interactions between dietary patterns and genetic factors in relation to incident dementia among 70-year-olds. <i>European Journal of Nutrition</i> , 2022, 61, 871-884.	1.8	15
27	A data-driven disease progression model of fluid biomarkers in genetic frontotemporal dementia. <i>Brain</i> , 2022, 145, 1805-1817.	3.7	27
28	Alzheimer's disease related biomarkers in bipolar disorder – A longitudinal one-year case-control study. <i>Journal of Affective Disorders</i> , 2022, 297, 623-633.	2.0	13
29	Axonal Injury Partially Mediates Associations Between Increased Left Ventricular Mass Index and White Matter Damage. <i>Stroke</i> , 2022, 53, 808-816.	1.0	0
30	Stratifying the Presymptomatic Phase of Genetic Frontotemporal Dementia by Serum NfL and pNfH : A Longitudinal Multicentre Study. <i>Annals of Neurology</i> , 2022, 91, 33-47.	2.8	21
31	Plasma neurofilament light chain protein is not increased in treatment-resistant schizophrenia and first-degree relatives. <i>Australian and New Zealand Journal of Psychiatry</i> , 2022, 56, 1295-1305.	1.3	10
32	The extent of neuroradiological findings in COVID-19 shows correlation with blood biomarkers, Glasgow coma scale score and days in intensive care. <i>Journal of Neuroradiology</i> , 2022, 49, 421-427.	0.6	13
33	Ion concentrations in cerebrospinal fluid in wakefulness, sleep and sleep deprivation in healthy humans. <i>Journal of Sleep Research</i> , 2022, 31, e13522.	1.7	2
34	Association of Plasma p-tau181 and p-tau231 Concentrations With Cognitive Decline in Patients With Probable Dementia With Lewy Bodies. <i>JAMA Neurology</i> , 2022, 79, 32.	4.5	38
35	Blood-based biomarkers for Alzheimer's disease: towards clinical implementation. <i>Lancet Neurology</i> , 2022, 21, 66-77.	4.9	360
36	Validation of the LUMIPULSE automated immunoassay for the measurement of core AD biomarkers in cerebrospinal fluid. <i>Clinical Chemistry and Laboratory Medicine</i> , 2022, 60, 207-219.	1.4	44

#	ARTICLE	IF	CITATIONS
37	Neurofilament light in plasma is a potential biomarker of central nervous system involvement in systemic lupus erythematosus. <i>Journal of Neurology</i> , 2022, 269, 3064-3074.	1.8	8
38	Characterization of pre-analytical sample handling effects on a panel of Alzheimer's disease-related blood-based biomarkers: Results from the Standardization of Alzheimer's Blood Biomarkers (SABB) working group. <i>Alzheimer's and Dementia</i> , 2022, 18, 1484-1497.	0.4	84
39	GFAP and tau protein as predictors of neurological outcome after out-of-hospital cardiac arrest: A post hoc analysis of the COMACARE trial. <i>Resuscitation</i> , 2022, 170, 141-149.	1.3	13
40	A longitudinal and cross-sectional study of plasma neurofilament light chain concentration in Charcot-Marie-Tooth disease. <i>Journal of the Peripheral Nervous System</i> , 2022, 27, 50-57.	1.4	16
41	Plasma p-tau ₁₈₁ shows stronger network association to Alzheimer's disease dementia than neurofilament light and total tau. <i>Alzheimer's and Dementia</i> , 2022, 18, 1523-1536.	0.4	18
42	Quantification of the trans-synaptic partners neurexin-neuroligin in CSF of neurodegenerative diseases by parallel reaction monitoring mass spectrometry. <i>EBioMedicine</i> , 2022, 75, 103793.	2.7	4
43	N-terminal and mid-region tau fragments as fluid biomarkers in neurological diseases. <i>Brain</i> , 2022, 145, 2834-2848.	3.7	20
44	Plasma p-tau ₂₃₁ , p-tau ₁₈₁ , PET Biomarkers, and Cognitive Change in Older Adults. <i>Annals of Neurology</i> , 2022, 91, 548-560.	2.8	42
45	Functional brain activity constrained by structural connectivity reveals cohort-specific features for serum neurofilament light chain. <i>Communications Medicine</i> , 2022, 2, .	1.9	2
46	Central nervous system monoaminergic activity in hip osteoarthritis patients with disabling pain: associations with pain severity and central sensitization. <i>Pain Reports</i> , 2022, 7, e988.	1.4	8
47	Assessing Neurofilaments as Biomarkers of Neuroprotection in Progressive Multiple Sclerosis. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2022, 9, .	3.1	14
48	Prevalence Estimates of Amyloid Abnormality Across the Alzheimer Disease Clinical Spectrum. <i>JAMA Neurology</i> , 2022, 79, 228.	4.5	97
49	Differential levels of plasma biomarkers of neurodegeneration in Lewy body dementia, Alzheimer's disease, frontotemporal dementia and progressive supranuclear palsy. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2022, 93, 651-658.	0.9	64
50	Is amyloid involved in acute neuroinflammation? A CSF analysis in encephalitis. <i>Alzheimer's and Dementia</i> , 2022, , .	0.4	3
51	A Neuropsychological Perspective on Defining Cognitive Impairment in the Clinical Study of Alzheimer's Disease: Towards a More Continuous Approach. <i>Journal of Alzheimer's Disease</i> , 2022, 86, 511-524.	1.2	5
52	Elevated Cerebrospinal Fluid Anti-CD4 Autoantibody Levels in HIV Associate with Neuroinflammation. <i>Microbiology Spectrum</i> , 2022, 10, e0197521.	1.2	2
53	Association of APOE ε4 and Plasma p-tau ₁₈₁ with Preclinical Alzheimer's Disease and Longitudinal Change in Hippocampus Function. <i>Journal of Alzheimer's Disease</i> , 2022, 85, 1309-1320.	1.2	11
54	Isotopic N,N-dimethyl leucine tags for absolute quantification of clusterin and apolipoprotein E in Alzheimer's disease. <i>Journal of Proteomics</i> , 2022, 257, 104507.	1.2	3

#	ARTICLE	IF	CITATIONS
55	Cerebrospinal fluid neurofilament light chain differentiates primary psychiatric disorders from rapidly progressive, Alzheimer's disease and frontotemporal disorders in clinical settings. <i>Alzheimer's and Dementia</i> , 2022, 18, 2218-2233.	0.4	24
56	Crosswalk study on blood collectionâ€”tube types for Alzheimer's disease biomarkers. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2022, 14, e12266.	1.2	8
57	Amyloid-Î² peptide 37, 38 and 40 individually and cooperatively inhibit amyloid-Î² 42 aggregation. <i>Chemical Science</i> , 2022, 13, 2423-2439.	3.7	20
58	Cerebrospinal fluid biomarkers that reflect clinical symptoms in idiopathic normal pressure hydrocephalus patients. <i>Fluids and Barriers of the CNS</i> , 2022, 19, 11.	2.4	18
59	Early plasma biomarker dynamic profiles are associated with acute ischemic stroke outcomes. <i>European Journal of Neurology</i> , 2022, 29, 1630-1642.	1.7	9
60	Amyloid processing in <scp>COVID</scp>â€”associated neurological syndromes. <i>Journal of Neurochemistry</i> , 2022, 161, 146-157.	2.1	35
61	Serum biomarkers of brain injury after uncomplicated cardiac surgery: Secondary analysis from a randomized trial. <i>Acta Anaesthesiologica Scandinavica</i> , 2022, 66, 447-453.	0.7	14
62	Slowing gait speed precedes cognitive decline by several years. <i>Alzheimer's and Dementia</i> , 2022, 18, 1667-1676.	0.4	24
63	Protein tau concentration in blood increases after SCUBA diving: an observational study. <i>European Journal of Applied Physiology</i> , 2022, 122, 993-1005.	1.2	1
64	ASIC-E4: Interplay of Beta-Amyloid, Synaptic Density and Neuroinflammation in Cognitively Normal Volunteers With Three Levels of Genetic Risk for Late-Onset Alzheimer's Disease â€” Study Protocol and Baseline Characteristics. <i>Frontiers in Neurology</i> , 2022, 13, 826423.	1.1	7
65	Cerebrospinal fluid p-tau231 as an early indicator of emerging pathology in Alzheimer's disease. <i>EBioMedicine</i> , 2022, 76, 103836.	2.7	65
66	The accuracy and robustness of plasma biomarker models for amyloid PET positivity. <i>Alzheimer's Research and Therapy</i> , 2022, 14, 26.	3.0	49
67	Postoperative delirium and changes in the bloodâ€”brain barrier, neuroinflammation, and cerebrospinal fluid lactate: a prospective cohort study. <i>British Journal of Anaesthesia</i> , 2022, 129, 219-230.	1.5	55
68	Local Prefrontal Cortex TMS-Induced Reactivity Is Related to Working Memory and Reasoning in Middle-Aged Adults. <i>Frontiers in Psychology</i> , 2022, 13, 813444.	1.1	5
69	Comparing tau status determined via plasma pTau181, pTau231 and [18F]MK6240 tau-PET. <i>EBioMedicine</i> , 2022, 76, 103837.	2.7	34
70	Potential of heart fatty-acid binding protein, neurofilament light, interleukin-10 and S100 calcium-binding protein B in the acute diagnostics and severity assessment of traumatic brain injury. <i>Emergency Medicine Journal</i> , 2022, 39, 206-212.	0.4	7
71	Conceptual framework for the definition of preclinical and prodromal frontotemporal dementia. <i>Alzheimer's and Dementia</i> , 2022, 18, 1408-1423.	0.4	24
72	Plasma and CSF NFL are differentially associated with biomarker evidence of neurodegeneration in a communityâ€”based sample of 70â€”yearâ€”olds. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2022, 14, e12295.	1.2	11

#	ARTICLE	IF	CITATIONS
73	Bloodâ€‘brain barrier dysfunction and reduced cerebrospinal fluid levels of soluble amyloid precursor proteinâ€‘ β 2 in patients with subcortical smallâ€‘vessel disease. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2022, 14, e12296.	1.2	5
74	VALZâ€‘Pilot: Highâ€‘dose valacyclovir treatment in patients with earlyâ€‘stage Alzheimer's disease. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2022, 8, e12264.	1.8	11
75	Biofluidâ€‘based biomarkers for Alzheimer's diseaseâ€‘related pathologies: An update and synthesis of the literature. <i>Alzheimer's and Dementia</i> , 2022, 18, 1687-1693.	0.4	24
76	Higher levels of neurofilament light chain and total tau in CSF are associated with negative outcome after shunt surgery in patients with normal pressure hydrocephalus. <i>Fluids and Barriers of the CNS</i> , 2022, 19, 15.	2.4	7
77	Cerebral Biomarkers and Blood-Brain Barrier Integrity in Preeclampsia. <i>Cells</i> , 2022, 11, 789.	1.8	6
78	Serum Creatine, Not Neurofilament Light, Is Elevated in CHCHD10-Linked Spinal Muscular Atrophy. <i>Frontiers in Neurology</i> , 2022, 13, 793937.	1.1	4
79	CSF biomarkers and plasma pâ€‘tau181 as predictors of longitudinal tau accumulation: Implications for clinical trial design. <i>Alzheimer's and Dementia</i> , 2022, 18, 2614-2626.	0.4	22
80	Blood amyloid and tau biomarkers as predictors of cerebrospinal fluid profiles. <i>Journal of Neural Transmission</i> , 2022, 129, 231-237.	1.4	7
81	Diagnosing Alzheimerâ€‘s Disease from Circulating Blood Leukocytes Using a Fluorescent Amyloid Probe. <i>Journal of Alzheimer's Disease</i> , 2022, 85, 1721-1734.	1.2	3
82	Rare variants in IFFO1, DTNB, NLRC3 and SLC22A10 associate with Alzheimerâ€‘s disease CSF profile of neuronal injury and inflammation. <i>Molecular Psychiatry</i> , 2022, 27, 1990-1999.	4.1	9
83	Plasma biomarkers for Alzheimerâ€‘s Disease in relation to neuropathology and cognitive change. <i>Acta Neuropathologica</i> , 2022, 143, 487-503.	3.9	89
84	Finding Correspondence between Metabolomic Features in Untargeted Liquid Chromatographyâ€‘Mass Spectrometry Metabolomics Datasets. <i>Analytical Chemistry</i> , 2022, 94, 5493-5503.	3.2	9
85	New developments of biofluidâ€‘based biomarkers for routine diagnosis and disease trajectories in frontotemporal dementia. <i>Alzheimer's and Dementia</i> , 2022, 18, 2292-2307.	0.4	14
86	Sense of Coherence Mediates the Relationship Between Cognitive Reserve and Cognition in Middle-Aged Adults. <i>Frontiers in Psychology</i> , 2022, 13, 835415.	1.1	8
87	Exploring common genetic contributors to neuroprotection from amyloid pathology. <i>Brain Communications</i> , 2022, 4, fcac066.	1.5	10
88	Prediction and early biomarkers of cognitive decline in Parkinson disease and atypical parkinsonism: a population-based study. <i>Brain Communications</i> , 2022, 4, fcac040.	1.5	8
89	Serum neurofilament light levels are correlated to long-term neurocognitive outcome measures after cardiac arrest. <i>Brain Injury</i> , 2022, 36, 800-809.	0.6	7
90	Serum neurofilament light chain for individual prognostication of disease activity in people with multiple sclerosis: a retrospective modelling and validation study. <i>Lancet Neurology</i> , The, 2022, 21, 246-257.	4.9	210

#	ARTICLE	IF	CITATIONS
91	Neurofilament light chain: defining the analyte. <i>Brain Communications</i> , 2022, 4, fcac070.	1.5	1
92	Cerebrospinal fluid tau levels are associated with abnormal neuronal plasticity markers in Alzheimer's disease. <i>Molecular Neurodegeneration</i> , 2022, 17, 27.	4.4	30
93	Combining plasma phospho-tau and accessible measures to evaluate progression to Alzheimer's dementia in mild cognitive impairment patients. <i>Alzheimer's Research and Therapy</i> , 2022, 14, 46.	3.0	17
94	Genome-Wide Association Study of Alzheimer's Disease Brain Imaging Biomarkers and Neuropsychological Phenotypes in the European Medical Information Framework for Alzheimer's Disease Multimodal Biomarker Discovery Dataset. <i>Frontiers in Aging Neuroscience</i> , 2022, 14, 840651.	1.7	20
95	Age, sex and APOE- ϵ 4 modify the balance between soluble and fibrillar β -amyloid in non-demented individuals: topographical patterns across two independent cohorts. <i>Molecular Psychiatry</i> , 2022, 27, 2010-2018.	4.1	9
96	Cerebral biomarkers in neurologic complications of preeclampsia. <i>American Journal of Obstetrics and Gynecology</i> , 2022, 227, 298.e1-298.e10.	0.7	7
97	Shared CSF Biomarker Profile in Idiopathic Normal Pressure Hydrocephalus and Subcortical Small Vessel Disease. <i>Frontiers in Neurology</i> , 2022, 13, 839307.	1.1	8
98	CSF biomarkers for dementia. <i>Practical Neurology</i> , 2022, 22, 285-294.	0.5	3
99	Post-acute blood biomarkers and disease progression in traumatic brain injury. <i>Brain</i> , 2022, 145, 2064-2076.	3.7	37
100	Development of a sensitive trial-ready poly(GP) CSF biomarker assay for C9orf72-associated frontotemporal dementia and amyotrophic lateral sclerosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2022, 93, 761-771.	0.9	12
101	Cerebrospinal fluid catecholamines in Alzheimer's disease patients with and without biological disease. <i>Translational Psychiatry</i> , 2022, 12, 151.	2.4	16
102	Differences Between Plasma and Cerebrospinal Fluid p-tau181 and p-tau231 in Early Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2022, 87, 991-997.	1.2	10
103	Soluble TREM2 in CSF and its association with other biomarkers and cognition in autosomal-dominant Alzheimer's disease: a longitudinal observational study. <i>Lancet Neurology</i> , The, 2022, 21, 329-341.	4.9	72
104	Decreased Electroencephalography Global Field Synchronization in Slow-Frequency Bands Characterizes Synaptic Dysfunction in Amnesic Subtypes of Mild Cognitive Impairment. <i>Frontiers in Aging Neuroscience</i> , 2022, 14, 755454.	1.7	2
105	The Karolinska NeuroCOVID study protocol: Neurocognitive impairment, biomarkers and advanced imaging in critical care survivors. <i>Acta Anaesthesiologica Scandinavica</i> , 2022, , .	0.7	9
106	Clinical reporting following the quantification of cerebrospinal fluid biomarkers in Alzheimer's disease: An international overview. <i>Alzheimer's and Dementia</i> , 2022, 18, 1868-1879.	0.4	26
107	Correlation between cerebrospinal fluid and plasma neurofilament light protein in treated HIV infection: results from the COBRA study. <i>Journal of NeuroVirology</i> , 2022, 28, 54-63.	1.0	9
108	Structural amyloid plaque polymorphism is associated with distinct lipid accumulations revealed by trapped ion mobility mass spectrometry imaging. <i>Journal of Neurochemistry</i> , 2022, 160, 482-498.	2.1	17

#	ARTICLE	IF	CITATIONS
109	Î³â€Secretase modulators show selectivity for Î³â€secretaseâ€ mediated amyloid precursor protein intramembrane processing. <i>Journal of Cellular and Molecular Medicine</i> , 2022, 26, 880-892.	1.6	4
110	In-Depth Site-Specific O-Glycosylation Analysis of Glycoproteins and Endogenous Peptides in Cerebrospinal Fluid (CSF) from Healthy Individuals, Mild Cognitive Impairment (MCI), and Alzheimerâ€™s Disease (AD) Patients. <i>ACS Chemical Biology</i> , 2022, 17, 3059-3068.	1.6	9
111	Alzheimer's disease biomarkers in Black and nonâ€Hispanic White cohorts: A contextualized review of the evidence. <i>Alzheimer's and Dementia</i> , 2022, 18, 1545-1564.	0.4	29
112	Detection of Glial Fibrillary Acidic Protein in Patient Plasma Using On-Chip Graphene Field-Effect Biosensors, in Comparison with ELISA and Single-Molecule Array. <i>ACS Sensors</i> , 2022, 7, 253-262.	4.0	20
113	Plasma Neurofilament Light and p-tau181 and Risk of Psychosis in Parkinsonâ€™s Disease. <i>Journal of Parkinson's Disease</i> , 2022, , 1-12.	1.5	2
114	Detection of subarachnoid haemorrhage with spectrophotometry of cerebrospinal fluidâ€ a comparison of two methods. <i>Clinical Chemistry and Laboratory Medicine</i> , 2022, 60, 1053-1057.	1.4	0
115	Plasma Amyloid and in vivo Brain Amyloid in Late Middle-Aged Hispanics. <i>Journal of Alzheimer's Disease</i> , 2022, , 1-10.	1.2	0
116	Hippocampal-subfield microstructures and their relation to plasma biomarkers in Alzheimerâ€™s disease. <i>Brain</i> , 2022, 145, 2149-2160.	3.7	20
117	A Longitudinal Study of Plasma $p\tau_{181}$ in Mild Cognitive Impairment with Lewy Bodies and Alzheimer's Disease. <i>Movement Disorders</i> , 2022, 37, 1495-1504.	2.2	11
118	Blood biomarkers for Alzheimer's disease and related disorders. <i>Acta Neurologica Scandinavica</i> , 2022, 146, 51-55.	1.0	28
119	Blood biomarkers for HIV infection with focus on neurologic complicationsâ€ A review. <i>Acta Neurologica Scandinavica</i> , 2022, 146, 56-60.	1.0	2
120	Association Between EEG Patterns and Serum Neurofilament Light After Cardiac Arrest. <i>Neurology</i> , 2022, 98, .	1.5	7
121	Effect of Race on Prediction of Brain Amyloidosis by Plasma $A\beta_{42}/A\beta_{40}$, Phosphorylated Tau, and Neurofilament Light. <i>Neurology</i> , 2022, 99, .	1.5	63
122	Effects of age, amyloid, sex, and $APOE\epsilon_4$ on the CSF proteome in normal cognition. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2022, 14, e12286.	1.2	4
123	Cerebrospinal Fluid Neurofilament Light Predicts Risk of Dementia Onset in Cognitively Healthy Individuals and Rate of Cognitive Decline in Mild Cognitive Impairment: A Prospective Longitudinal Study. <i>Biomedicine</i> , 2022, 10, 1045.	1.4	1
124	Alzheimerâ€™s Disease Biomarkers Revisited From the Amyloid Cascade Hypothesis Standpoint. <i>Frontiers in Neuroscience</i> , 2022, 16, 837390.	1.4	12
125	Tau and neurofilament lightâ€chain as fluid biomarkers in spinocerebellar ataxia type 3. <i>European Journal of Neurology</i> , 2022, 29, 2439-2452.	1.7	25
126	Relationship between cerebrospinal fluid neurodegeneration biomarkers and temporal brain atrophy in cognitively healthy older adults. <i>Neurobiology of Aging</i> , 2022, 116, 80-91.	1.5	5

#	ARTICLE	IF	CITATIONS
127	Biomarker modeling of Alzheimer's disease using PET-based Braak staging. <i>Nature Aging</i> , 2022, 2, 526-535.	5.3	73
128	Cerebrospinal fluid markers of inflammation and brain injury in Lyme neuroborreliosis – a prospective follow-up study. <i>Clinical Chemistry and Laboratory Medicine</i> , 2022, 60, 1124-1132.	1.4	3
129	Principal components from untargeted cerebrospinal fluid metabolomics associated with Alzheimer's disease biomarkers. <i>Neurobiology of Aging</i> , 2022, 117, 12-23.	1.5	7
130	Alzheimer's Disease Plasma Biomarkers Distinguish Clinical Diagnostic Groups in Memory Clinic Patients. <i>Dementia and Geriatric Cognitive Disorders</i> , 2022, 51, 182-192.	0.7	16
131	Ante-mortem plasma phosphorylated tau (181) predicts Alzheimer's disease neuropathology and regional tau at autopsy. <i>Brain</i> , 2022, 145, 3546-3557.	3.7	15
132	Axonal injury in asymptomatic individuals preceding onset of multiple sclerosis. <i>Annals of Clinical and Translational Neurology</i> , 2022, 9, 882-887.	1.7	5
133	Diagnostic value of serum versus plasma phospho-tau for Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2022, 14, 65.	3.0	25
134	Young CSF restores oligodendrogenesis and memory in aged mice via Fgf17. <i>Nature</i> , 2022, 605, 509-515.	13.7	98
135	Plasma neurofilament light chain protein as a predictor of days in delirium and deep sedation, mortality and length of stay in critically ill patients. <i>EBioMedicine</i> , 2022, 80, 104043.	2.7	12
136	Cerebrospinal fluid amyloid precursor protein as a potential biomarker of fatigue in multiple sclerosis: A pilot study. <i>Multiple Sclerosis and Related Disorders</i> , 2022, 63, 103846.	0.9	3
137	Optimized sample preparation and data analysis for TMT proteomic analysis of cerebrospinal fluid applied to the identification of Alzheimer's disease biomarkers. <i>Clinical Proteomics</i> , 2022, 19, 13.	1.1	10
138	Blood phospho-tau in Alzheimer disease: analysis, interpretation, and clinical utility. <i>Nature Reviews Neurology</i> , 2022, 18, 400-418.	4.9	99
139	A translatable RNAi-driven gene therapy silences PMP22/Pmp22 genes and improves neuropathy in CMT1A mice. <i>Journal of Clinical Investigation</i> , 2022, 132, .	3.9	18
140	Screening for neurodegeneration in Langerhans cell histiocytosis with neurofilament light in plasma. <i>British Journal of Haematology</i> , 2022, , .	1.2	7
141	Combining biomarkers for prognostic modelling of Parkinson's disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2022, 93, 707-715.	0.9	9
142	Viral Antigen and Inflammatory Biomarkers in Cerebrospinal Fluid in Patients With COVID-19 Infection and Neurologic Symptoms Compared With Control Participants Without Infection or Neurologic Symptoms. <i>JAMA Network Open</i> , 2022, 5, e2213253.	2.8	35
143	Plasma neuregulin 1 as a synaptic biomarker in Alzheimer's disease: a discovery cohort study. <i>Alzheimer's Research and Therapy</i> , 2022, 14, .	3.0	12
144	Leveraging large multi-center cohorts of Alzheimer disease endophenotypes to understand the role of Klotho heterozygosity on disease risk. <i>PLoS ONE</i> , 2022, 17, e0267298.	1.1	9

#	ARTICLE	IF	CITATIONS
145	Brain alterations in the early Alzheimerâ€™s continuum with amyloid-Î², tau, glial and neurodegeneration CSF markers. <i>Brain Communications</i> , 2022, 4, .	1.5	12
146	A Pragmatic, Data-Driven Method to Determine Cutoffs for CSF Biomarkers of Alzheimer Disease Based on Validation Against PET Imaging. <i>Neurology</i> , 2022, 99, .	1.5	8
147	Plasma neurofilament light levels as a novel biomarker for neurological involvement in Wilsonâ€™s disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2022, 93, A6.2-A6.	0.9	0
148	Association of Plasma Biomarker Levels With Their CSF Concentration and the Number and Severity of Concussions in Professional Athletes. <i>Neurology</i> , 2022, 99, .	1.5	10
149	Quantification of SNAP-25 with mass spectrometry and Simoa: a method comparison in Alzheimerâ€™s disease. <i>Alzheimer's Research and Therapy</i> , 2022, 14, .	3.0	11
150	Serum neurofilament light chain concentration predicts disease worsening in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2022, 28, 1859-1870.	1.4	14
151	Commentary on Oeckl et al., â€œSerum β -Synuclein Is Higher in Down Syndrome and Precedes Rise of pTau181â€. <i>Annals of Neurology</i> , 2022, 92, 3-5.	2.8	1
152	Reply to â€œPathway for ascertaining the role of uric acid in neurodegenerative diseases,â€ Roman Youssef. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2022, 14, .	1.2	0
153	Alpha-2-adrenergic receptor agonists for the prevention of delirium and cognitive decline after open heart surgery (ALPHA2PREVENT): protocol for a multicentre randomised controlled trial. <i>BMJ Open</i> , 2022, 12, e057460.	0.8	4
154	Investigating the use of plasma pTau181 in retired contact sports athletes. <i>Journal of Neurology</i> , 2022, 269, 5582-5595.	1.8	4
155	Brain disconnectome mapping derived from white matter lesions and serum neurofilament light levels in multiple sclerosis: A longitudinal multicenter study. <i>NeuroImage: Clinical</i> , 2022, 35, 103099.	1.4	8
156	Inflammation, tau pathology, and synaptic integrity associated with sleep spindles and memory prior to Î²-amyloid positivity. <i>Sleep</i> , 2022, 45, .	0.6	22
157	Asthma amplifies dementia risk: Evidence from CSF biomarkers and cognitive decline. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2022, 8, .	1.8	5
158	Neurofilament Light in Cerebrospinal Fluid is Associated With Disease Staging in European Lyme Neuroborreliosis. <i>Journal of Central Nervous System Disease</i> , 2022, 14, 117957352210981.	0.7	2
159	Neurogranin and Neurofilament Light Chain as Preclinical Biomarkers in Scrapie. <i>International Journal of Molecular Sciences</i> , 2022, 23, 7182.	1.8	3
160	Association of plasma neurofilament light chain with disease activity in chronic inflammatory demyelinating polyradiculoneuropathy. <i>European Journal of Neurology</i> , 2022, 29, 3347-3357.	1.7	7
161	Biological correlates of elevated soluble TREM2 in cerebrospinal fluid. <i>Neurobiology of Aging</i> , 2022, 118, 88-98.	1.5	8
162	Establishment of reference values for plasma neurofilament light based on healthy individuals aged 5â€“90 years. <i>Brain Communications</i> , 2022, 4, .	1.5	57

#	ARTICLE	IF	CITATIONS
163	Increased CSF-decorin predicts brain pathological changes driven by Alzheimer's A β amyloidosis. Acta Neuropathologica Communications, 2022, 10, .	2.4	8
164	Altered Balance of Reelin Proteolytic Fragments in the Cerebrospinal Fluid of Alzheimer's Disease Patients. International Journal of Molecular Sciences, 2022, 23, 7522.	1.8	3
165	The relationship between plasma biomarkers and amyloid PET in dementia with Lewy bodies. Parkinsonism and Related Disorders, 2022, 101, 111-116.	1.1	7
166	Reactive astrogliosis is associated with higher cerebral glucose consumption in the early Alzheimer's continuum. European Journal of Nuclear Medicine and Molecular Imaging, 2022, 49, 4567-4579.	3.3	16
167	Thirty years after anorexia nervosa onset, serum neurofilament light chain protein concentration indicates neuronal injury. European Child and Adolescent Psychiatry, 2021, 30, 1907-1915.	2.8	11
168	Plasma phospho-tau181 in presymptomatic and symptomatic familial Alzheimer's disease: a longitudinal cohort study. Molecular Psychiatry, 2021, 26, 5967-5976.	4.1	76
169	Plasma metabolites associated with biomarker evidence of neurodegeneration in cognitively normal older adults. Journal of Neurochemistry, 2021, 159, 389-402.	2.1	20
170	Serum neurofilament light concentration does not increase following exposure to low velocity football heading. Science and Medicine in Football, 2021, 5, 1-7.	1.0	4
171	Brain and blood biomarkers of tauopathy and neuronal injury in humans and rats with neurobehavioral syndromes following blast exposure. Molecular Psychiatry, 2021, 26, 5940-5954.	4.1	56
172	Amyloid-beta modulates the association between neurofilament light chain and brain atrophy in Alzheimer's disease. Molecular Psychiatry, 2021, 26, 5989-6001.	4.1	28
173	Patient-specific Alzheimer-like pathology in trisomy 21 cerebral organoids reveals BACE2 as a gene dose-sensitive AD suppressor in human brain. Molecular Psychiatry, 2021, 26, 5766-5788.	4.1	63
174	CSF α -synuclein correlates with CSF neurogranin in late-life depression. International Journal of Neuroscience, 2021, 131, 357-361.	0.8	10
175	Biomarkers for Alzheimer's disease—preparing for a new era of disease-modifying therapies. Molecular Psychiatry, 2021, 26, 296-308.	4.1	205
176	Postanoxic electrographic status epilepticus and serum biomarkers of brain injury. Resuscitation, 2021, 158, 253-257.	1.3	14
177	Determining Amyloid- β Positivity Using ¹⁸ F-AZD4694 PET Imaging. Journal of Nuclear Medicine, 2021, 62, 247-252.	2.8	65
178	Decrease in sleep depth is associated with higher cerebrospinal fluid neurofilament light levels in patients with Alzheimer's disease. Sleep, 2021, 44, .	0.6	22
179	Plasma Neurofilament Light as a Biomarker of Neurological Involvement in Wilson's Disease. Movement Disorders, 2021, 36, 503-508.	2.2	15
180	No Changes in Human Immunodeficiency Virus (HIV) Suppression and Inflammatory Markers in Cerebrospinal Fluid in Patients Randomly Switched to Dolutegravir Plus Lamivudine (Spanish HIV/AIDS) Tj ETQq0 0 0.9gBT /Overlock 10 T		

#	ARTICLE	IF	CITATIONS
181	Neurofilament results for the phase II neuroprotection study of phenytoin in optic neuritis. <i>European Journal of Neurology</i> , 2021, 28, 587-594.	1.7	6
182	Fluid biomarkers in frontotemporal dementia: past, present and future. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2021, 92, 204-215.	0.9	62
183	Association between cerebrospinal fluid biomarkers of neuronal injury or amyloidosis and cognitive decline after major surgery. <i>British Journal of Anaesthesia</i> , 2021, 126, 467-476.	1.5	17
184	Molecular forms of neurogranin in cerebrospinal fluid. <i>Journal of Neurochemistry</i> , 2021, 157, 816-833.	2.1	6
185	Head-to-head comparison of clinical performance of CSF phospho-tau T181 and T217 biomarkers for Alzheimer's disease diagnosis. <i>Alzheimer's and Dementia</i> , 2021, 17, 755-767.	0.4	81
186	Individualized prognosis of cognitive decline and dementia in mild cognitive impairment based on plasma biomarker combinations. <i>Nature Aging</i> , 2021, 1, 114-123.	5.3	94
187	Plasma phosphorylated tau181 and neurodegeneration in Alzheimer's disease. <i>Annals of Clinical and Translational Neurology</i> , 2021, 8, 259-265.	1.7	25
188	Time course of phosphorylated-tau181 in blood across the Alzheimer's disease spectrum. <i>Brain</i> , 2021, 144, 325-339.	3.7	124
189	Untangling the association of amyloid- β and tau with synaptic and axonal loss in Alzheimer's disease. <i>Brain</i> , 2021, 144, 310-324.	3.7	123
190	Plasma glial fibrillary acidic protein and neurofilament light chain are measures of disease severity in semantic variant primary progressive aphasia. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2021, 92, 455-456.	0.9	11
191	ATN incorporating cerebrospinal fluid neurofilament light chain detects frontotemporal lobar degeneration. <i>Alzheimer's and Dementia</i> , 2021, 17, 822-830.	0.4	27
192	Association between plasma tau and postoperative delirium incidence and severity: a prospective observational study. <i>British Journal of Anaesthesia</i> , 2021, 126, 458-466.	1.5	75
193	Associations between mean arterial pressure during cardiopulmonary bypass and biomarkers of cerebral injury in patients undergoing cardiac surgery: secondary results from a randomized controlled trial. <i>Interactive Cardiovascular and Thoracic Surgery</i> , 2021, 32, 229-235.	0.5	11
194	Brevican and Neurocan Peptides as Potential Cerebrospinal Fluid Biomarkers for Differentiation Between Vascular Dementia and Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2021, 79, 729-741.	1.2	10
195	An examination of a novel multipanel of CSF biomarkers in the Alzheimer's disease clinical and pathological continuum. <i>Alzheimer's and Dementia</i> , 2021, 17, 431-445.	0.4	80
196	Cerebrospinal fluid brevican and neurocan fragment patterns in human traumatic brain injury. <i>Clinica Chimica Acta</i> , 2021, 512, 74-83.	0.5	8
197	Cerebrospinal Fluid and Plasma Lipopolysaccharide Levels in Human Immunodeficiency Virus Type 1 Infection and Associations With Inflammation, Blood-Brain Barrier Permeability, and Neuronal Injury. <i>Journal of Infectious Diseases</i> , 2021, 223, 1612-1620.	1.9	7
198	Plasma neurofilament light chain as a potential biomarker in Charcot-Marie-Tooth disease. <i>European Journal of Neurology</i> , 2021, 28, 974-981.	1.7	30

#	ARTICLE	IF	CITATIONS
199	Proinflammatory protein signatures in cryptogenic and large artery atherosclerosis stroke. <i>Acta Neurologica Scandinavica</i> , 2021, 143, 303-312.	1.0	9
200	Diagnostic performance and prediction of clinical progression of plasma phospho-tau181 in the Alzheimer's Disease Neuroimaging Initiative. <i>Molecular Psychiatry</i> , 2021, 26, 429-442.	4.1	186
201	Neurofilament light is a biomarker of brain involvement in lupus and primary Sjögren's syndrome. <i>Journal of Neurology</i> , 2021, 268, 1385-1394.	1.8	18
202	Serum neuroproteins, near-infrared spectroscopy, and cognitive outcome after beach chair shoulder surgery: Observational cohort study analyses. <i>Acta Anaesthesiologica Scandinavica</i> , 2021, 65, 26-33.	0.7	5
203	Neurofilament light as an outcome predictor after cardiac arrest: a post hoc analysis of the COMACARE trial. <i>Intensive Care Medicine</i> , 2021, 47, 39-48.	3.9	90
204	Impairment of episodic memory in genetic frontotemporal dementia: A GENFI study. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2021, 13, e12185.	1.2	11
205	Association of Early β -Amyloid Accumulation and Neuroinflammation Measured With [¹¹ C]PBR28 in Elderly Individuals Without Dementia. <i>Neurology</i> , 2021, 96, e1608-e1619.	1.5	30
206	A Non-APOE Polygenic Risk Score for Alzheimer's Disease Is Associated With Cerebrospinal Fluid Neurofilament Light in a Representative Sample of Cognitively Unimpaired 70-Year Olds. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2021, 76, 983-990.	1.7	18
207	Brain immune cells undergo cGAS/STING-dependent apoptosis during herpes simplex virus type 1 infection to limit type I IFN production. <i>Journal of Clinical Investigation</i> , 2021, 131, .	3.9	61
208	Method and Clinical Validation of Biomarkers for Neurodegenerative Diseases. <i>NeuroMethods</i> , 2021, , 163-173.	0.2	0
209	Cognitive Performance and Cerebrospinal Fluid Markers in Preclinical Alzheimer's Disease: Results from the Gothenburg H70 Birth Cohort Studies. <i>Journal of Alzheimer's Disease</i> , 2021, 79, 225-235.	1.2	4
210	Effects of pre-analytical procedures on blood biomarkers for Alzheimer's pathophysiology, glial activation, and neurodegeneration. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2021, 13, e12168.	1.2	52
211	Sex differences in CSF biomarkers for neurodegeneration and blood-brain barrier integrity. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2021, 13, e12141.	1.2	9
212	Blood neurofilament light in remote settings: Alternative protocols to support sample collection in challenging pre-analytical conditions. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2021, 13, e12145.	1.2	17
213	The relationship between white matter microstructure and self-perceived cognitive decline. <i>NeuroImage: Clinical</i> , 2021, 32, 102794.	1.4	9
214	Measurement batch differences and between-batch conversion of Alzheimer's disease cerebrospinal fluid biomarker values. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2021, 13, e12194.	1.2	2
215	Parkinson's disease with restless legs syndrome—an in vivo corneal confocal microscopy study. <i>Npj Parkinson's Disease</i> , 2021, 7, 4.	2.5	10
216	Cerebrospinal fluid biomarkers of glial and axonal injury in cervical spondylotic myelopathy. <i>Journal of Neurosurgery: Spine</i> , 2021, 34, 1-10.	0.9	7

#	ARTICLE	IF	CITATIONS
217	Abeta CSF LC-MS. <i>Neuromethods</i> , 2021, , 55-69.	0.2	0
218	Plasma metabolomics of presymptomatic <i>PSEN1</i> H163Y mutation carriers: a pilot study. <i>Annals of Clinical and Translational Neurology</i> , 2021, 8, 579-591.	1.7	0
219	A Western-style dietary pattern is associated with cerebrospinal fluid biomarker levels for preclinical Alzheimer's disease: A population-based cross-sectional study among 70-year-olds. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2021, 7, e12183.	1.8	11
220	Biomarkers for central nervous system injury in cerebrospinal fluid are elevated in COVID-19 and associated with neurological symptoms and disease severity. <i>European Journal of Neurology</i> , 2021, 28, 3324-3331.	1.7	109
221	Head-to-head comparison of amplified plasmonic exosome A β 242 platform and single-molecule array immunoassay in a memory clinic cohort. <i>European Journal of Neurology</i> , 2021, 28, 1479-1489.	1.7	11
222	Association between polygenic risk score of Alzheimer's disease and plasma phosphorylated tau in individuals from the Alzheimer's Disease Neuroimaging Initiative. <i>Alzheimer's Research and Therapy</i> , 2021, 13, 17.	3.0	35
223	Concordance of CSF measures of Alzheimer's pathology with amyloid PET status in a preclinical cohort: A comparison of Lumipulse and established immunoassays. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2021, 13, e12131.	1.2	19
224	Cerebrospinal fluid biomarker panel for synaptic dysfunction in Alzheimer's disease. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2021, 13, e12179.	1.2	35
225	Untangling the tau microtubule-binding region. <i>Brain</i> , 2021, 144, 359-362.	3.7	3
226	Plasma β -secretase1 concentrations correlate with basal forebrain atrophy and neurodegeneration in cognitively healthy individuals at risk for AD. <i>Alzheimer's and Dementia</i> , 2021, 17, 629-640.	0.4	10
227	Alzheimer's disease in primary care: new tools for improved and simplified diagnostics. <i>Journal of Internal Medicine</i> , 2021, 290, 477-479.	2.7	0
228	Brain-derived neurotrophic factor in cerebrospinal fluid and plasma is not a biomarker for Huntington's disease. <i>Scientific Reports</i> , 2021, 11, 3481.	1.6	12
229	Neuroigin-1 in brain and CSF of neurodegenerative disorders: investigation for synaptic biomarkers. <i>Acta Neuropathologica Communications</i> , 2021, 9, 19.	2.4	17
230	Moving fluid biomarkers for Alzheimer's disease from research tools to routine clinical diagnostics. <i>Molecular Neurodegeneration</i> , 2021, 16, 10.	4.4	101
231	Detection of β -amyloid positivity in Alzheimer's Disease Neuroimaging Initiative participants with demographics, cognition, MRI and plasma biomarkers. <i>Brain Communications</i> , 2021, 3, fcab008.	1.5	51
232	Cerebrospinal fluid N-224 tau helps discriminate Alzheimer's disease from subjective cognitive decline and other dementias. <i>Alzheimer's Research and Therapy</i> , 2021, 13, 38.	3.0	12
233	Associations between plasma neurofilament light, in vivo brain pathology, and cognition in non-demented individuals with autosomal dominant Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2021, 17, 813-821.	0.4	8
234	Age-Related Tau Burden and Cognitive Deficits Are Attenuated in KLOTHO KL-VS Heterozygotes. <i>Journal of Alzheimer's Disease</i> , 2021, 79, 1297-1305.	1.2	14

#	ARTICLE	IF	CITATIONS
235	Plasma p-tau ₂₃₁ : a new biomarker for incipient Alzheimer's disease pathology. <i>Acta Neuropathologica</i> , 2021, 141, 709-724.	3.9	285
236	Signs of neuroaxonal injury in preeclampsia—A case control study. <i>PLoS ONE</i> , 2021, 16, e0246786.	1.1	17
237	The influence of the R47H triggering receptor expressed on myeloid cells 2 variant on microglial exosome profiles. <i>Brain Communications</i> , 2021, 3, fcab009.	1.5	7
238	Predicting neurological outcome after out-of-hospital cardiac arrest with cumulative information; development and internal validation of an artificial neural network algorithm. <i>Critical Care</i> , 2021, 25, 83.	2.5	23
239	Neurodegenerative dementias: screening for major threats to healthy longevity with blood biomarkers. <i>The Lancet Healthy Longevity</i> , 2021, 2, e58-e59.	2.0	1
240	Association of weight change with cerebrospinal fluid biomarkers and amyloid positron emission tomography in preclinical Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2021, 13, 46.	3.0	9
241	Association of Depressive Symptoms With Postoperative Delirium and CSF Biomarkers for Alzheimer's Disease Among Hip Fracture Patients. <i>American Journal of Geriatric Psychiatry</i> , 2021, 29, 1212-1221.	0.6	16
242	Neurological symptoms and blood neurofilament light levels. <i>Acta Neurologica Scandinavica</i> , 2021, 144, 13-20.	1.0	12
243	Plasma p-tau ₁₈₁ to A β ₂₄₂ ratio is associated with brain amyloid burden and hippocampal atrophy in an Asian cohort of Alzheimer's disease patients with concomitant cerebrovascular disease. <i>Alzheimer's and Dementia</i> , 2021, 17, 1649-1662.	0.4	37
244	Cerebral amyloid β load is associated with neurodegeneration and gliosis: Mediation by p-tau and interactions with risk factors early in the Alzheimer's continuum. <i>Alzheimer's and Dementia</i> , 2021, 17, 788-800.	0.4	14
245	Comparison of CSF neurofilament light chain, neurogranin, and tau to MRI markers. <i>Alzheimer's and Dementia</i> , 2021, 17, 801-812.	0.4	18
246	Proteomic blood profiling in mild, severe and critical COVID-19 patients. <i>Scientific Reports</i> , 2021, 11, 6357.	1.6	72
247	2020 update on the clinical validity of cerebrospinal fluid amyloid, tau, and phospho-tau as biomarkers for Alzheimer's disease in the context of a structured 5-phase development framework. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 2121-2139.	3.3	43
248	The Alzheimer's Association international guidelines for handling of cerebrospinal fluid for routine clinical measurements of amyloid β and tau. <i>Alzheimer's and Dementia</i> , 2021, 17, 1575-1582.	0.4	51
249	Replication study of plasma proteins relating to Alzheimer's pathology. <i>Alzheimer's and Dementia</i> , 2021, 17, 1452-1464.	0.4	13
250	Mass spectrometry analysis of tau and amyloid β in iPSC-derived models of Alzheimer's disease and dementia. <i>Journal of Neurochemistry</i> , 2021, 159, 305-317.	2.1	8
251	Negligible influence of moderate to severe hyperthermia on blood-brain barrier permeability and neuronal parenchymal integrity in healthy men. <i>Journal of Applied Physiology</i> , 2021, 130, 792-800.	1.2	6
252	Plasma glial fibrillary acidic protein detects Alzheimer pathology and predicts future conversion to Alzheimer dementia in patients with mild cognitive impairment. <i>Alzheimer's Research and Therapy</i> , 2021, 13, 68.	3.0	117

#	ARTICLE	IF	CITATIONS
253	The validation status of blood biomarkers of amyloid and phospho-tau assessed with the 5-phase development framework for AD biomarkers. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 2140-2156.	3.3	83
254	Activated low-density granulocytes in peripheral and intervillous blood and neutrophil inflammation in placentas from SLE pregnancies. <i>Lupus Science and Medicine</i> , 2021, 8, e000463.	1.1	8
255	AAV9-mediated Schwann cell-targeted gene therapy rescues a model of demyelinating neuropathy. <i>Gene Therapy</i> , 2021, 28, 659-675.	2.3	32
256	Blood neurofilament light concentration at admittance: a potential prognostic marker in COVID-19. <i>Journal of Neurology</i> , 2021, 268, 3574-3583.	1.8	56
257	Plasma neurofilament light and phosphorylated tau 181 as biomarkers of Alzheimer's disease pathology and clinical disease progression. <i>Alzheimer's Research and Therapy</i> , 2021, 13, 65.	3.0	49
258	Neurofilament light chain as a potential biomarker for monitoring neurodegeneration in X-linked adrenoleukodystrophy. <i>Nature Communications</i> , 2021, 12, 1816.	5.8	33
259	Acute hyperglycaemia leads to altered frontal lobe brain activity and reduced working memory in type 2 diabetes. <i>PLoS ONE</i> , 2021, 16, e0247753.	1.1	16
260	Association of CSF proteins with tau and amyloid β levels in asymptomatic 70-year-olds. <i>Alzheimer's Research and Therapy</i> , 2021, 13, 54.	3.0	9
261	Plasma pTau181 predicts cortical brain atrophy in aging and Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2021, 13, 69.	3.0	34
262	Evaluation of plasma tau and neurofilament light chain biomarkers in a 12-year clinical cohort of human prion diseases. <i>Molecular Psychiatry</i> , 2021, 26, 5955-5966.	4.1	30
263	Plasma amyloid- β ratios in autosomal dominant Alzheimer's disease: the influence of genotype. <i>Brain</i> , 2021, 144, 2964-2970.	3.7	16
264	Cerebrospinal fluid CXCL10 is associated with the presence of low level CSF HIV during suppressive antiretroviral therapy. <i>Journal of Neuroimmunology</i> , 2021, 353, 577493.	1.1	4
265	No neurochemical evidence of neuronal injury or glial activation in children with Paediatric Acute-onset Neuropsychiatric Syndrome. An explorative pilot study. <i>World Journal of Biological Psychiatry</i> , 2021, 22, 800-804.	1.3	2
266	Time Trends of Cerebrospinal Fluid Biomarkers of Neurodegeneration in Idiopathic Normal Pressure Hydrocephalus. <i>Journal of Alzheimer's Disease</i> , 2021, 80, 1629-1642.	1.2	10
267	Diagnostic and prognostic value of plasma neurofilament light and total-tau in sporadic Creutzfeldt-Jakob disease. <i>Alzheimer's Research and Therapy</i> , 2021, 13, 86.	3.0	19
268	TREM2 expression in the brain and biological fluids in prion diseases. <i>Acta Neuropathologica</i> , 2021, 141, 841-859.	3.9	18
269	Synergistic Association between Plasma $A\beta_{42}$ and p-tau in Alzheimer's Disease but Not in Parkinson's Disease or Frontotemporal Dementia. <i>ACS Chemical Neuroscience</i> , 2021, 12, 1376-1383.	1.7	9
270	Plasma levels of phosphorylated tau 181 are associated with cerebral metabolic dysfunction in cognitively impaired and amyloid-positive individuals. <i>Brain Communications</i> , 2021, 3, fcab073.	1.5	15

#	ARTICLE	IF	CITATIONS
271	Longitudinal Associations of Blood Phosphorylated Tau181 and Neurofilament Light Chain With Neurodegeneration in Alzheimer Disease. <i>JAMA Neurology</i> , 2021, 78, 396.	4.5	146
272	Analysis of Brain Injury Biomarker Neurofilament Light and Neurodevelopmental Outcomes and Retinopathy of Prematurity Among Preterm Infants. <i>JAMA Network Open</i> , 2021, 4, e214138.	2.8	15
273	Postoperative troponin increases after noncardiac surgery are associated with raised neurofilament light: a prospective observational cohort study. <i>British Journal of Anaesthesia</i> , 2021, 126, 791-798.	1.5	15
274	One-Year Prospective Study of Plasma Biomarkers From CNS in Patients With Mild Traumatic Brain Injury. <i>Frontiers in Neurology</i> , 2021, 12, 643743.	1.1	20
275	Plasma neurofilament light chain levels predict improvement in late phase after stroke. <i>European Journal of Neurology</i> , 2021, 28, 2218-2228.	1.7	10
276	Saliva Neurofilament Light Chain Is Not a Diagnostic Biomarker for Neurodegeneration in a Mixed Memory Clinic Population. <i>Frontiers in Aging Neuroscience</i> , 2021, 13, 659898.	1.7	9
277	Restoring miR-132 expression rescues adult hippocampal neurogenesis and memory deficits in Alzheimer's disease. <i>Cell Stem Cell</i> , 2021, 28, 1805-1821.e8.	5.2	76
278	Characterization of monomeric and soluble aggregated A β in Down's syndrome and Alzheimer's disease brains. <i>Neuroscience Letters</i> , 2021, 754, 135894.	1.0	9
279	Seven day pre-analytical stability of serum and plasma neurofilament light chain. <i>Scientific Reports</i> , 2021, 11, 11034.	1.6	27
280	An amylin and calcitonin receptor agonist modulates alcohol behaviors by acting on reward-related areas in the brain. <i>Progress in Neurobiology</i> , 2021, 200, 101969.	2.8	19
281	Association of Aortic Stiffness With Biomarkers of Neuroinflammation, Synaptic Dysfunction, and Neurodegeneration. <i>Neurology</i> , 2021, 97, e329-e340.	1.5	24
282	Effects of amyloid pathology and the APOE ϵ 4 allele on the association between cerebrospinal fluid A β ²³⁸ and A β ²⁴⁰ and brain morphology in cognitively normal 70-years-olds. <i>Neurobiology of Aging</i> , 2021, 101, 1-12.	1.5	7
283	Evidence of upregulation of the cholinergic anti-inflammatory pathway in late-life depression. <i>Journal of Affective Disorders</i> , 2021, 286, 275-281.	2.0	9
284	Compartmentalization of cerebrospinal fluid inflammation across the spectrum of untreated HIV-1 infection, central nervous system injury and viral suppression. <i>PLoS ONE</i> , 2021, 16, e0250987.	1.1	30
285	Tripartite Relationship Among Synaptic, Amyloid, and Tau Proteins: An In Vivo and Postmortem Study. <i>Neurology</i> , 2021, , 10.1212/WNL.0000000000012145.	1.5	8
286	Prediction of future Alzheimer's disease dementia using plasma phospho-tau combined with other accessible measures. <i>Nature Medicine</i> , 2021, 27, 1034-1042.	15.2	236
287	Lumbar and ventricular CSF concentrations of extracellular matrix proteins before and after shunt surgery in idiopathic normal pressure hydrocephalus. <i>Fluids and Barriers of the CNS</i> , 2021, 18, 23.	2.4	10
288	Cerebrospinal Fluid Concentration of Neurogranin in Hip Fracture Patients with Delirium. <i>Journal of Alzheimer's Disease</i> , 2021, 81, 667-677.	1.2	2

#	ARTICLE	IF	CITATIONS
289	TMEM106B and CPOX are genetic determinants of cerebrospinal fluid Alzheimer's disease biomarker levels. <i>Alzheimer's and Dementia</i> , 2021, 17, 1628-1640.	0.4	23
290	Growth differentiation factor 15 increases in both cerebrospinal fluid and serum during pregnancy. <i>PLoS ONE</i> , 2021, 16, e0248980.	1.1	14
291	Plasma ACE2 species are differentially altered in COVID-19 patients. <i>FASEB Journal</i> , 2021, 35, e21745.	0.2	18
292	Complex Autoantibody Responses Occur following Moderate to Severe Traumatic Brain Injury. <i>Journal of Immunology</i> , 2021, 207, 90-100.	0.4	24
293	Common variants in Alzheimer's disease and risk stratification by polygenic risk scores. <i>Nature Communications</i> , 2021, 12, 3417.	5.8	140
294	Use of plasma biomarkers for AT(N) classification of neurodegenerative dementias. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2021, 92, 1206-1214.	0.9	30
295	Following spatial A β aggregation dynamics in evolving Alzheimer's disease pathology by imaging stable isotope labeling kinetics. <i>Science Advances</i> , 2021, 7, .	4.7	22
296	The phosphorylation cascade hypothesis of Alzheimer's disease. <i>Nature Aging</i> , 2021, 1, 498-499.	5.3	6
297	Clinical Utility of β -Amyloid PET Imaging in People Living With HIV With Cognitive Symptoms. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2021, 87, 826-833.	0.9	5
298	Multi-cohort profiling reveals elevated CSF levels of brain-enriched proteins in Alzheimer's disease. <i>Annals of Clinical and Translational Neurology</i> , 2021, 8, 1456-1470.	1.7	19
299	Increased immune activation and signs of neuronal injury in HIV-negative people on preexposure prophylaxis. <i>Aids</i> , 2021, 35, 2129-2136.	1.0	6
300	Plasma NfL, clinical subtypes and motor progression in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2021, 87, 41-47.	1.1	26
301	Spitting image: can saliva biomarkers reflect Alzheimer's disease?. <i>EBioMedicine</i> , 2021, 68, 103437.	2.7	9
302	Transitioning from cerebrospinal fluid to blood tests to facilitate diagnosis and disease monitoring in Alzheimer's disease. <i>Journal of Internal Medicine</i> , 2021, 290, 583-601.	2.7	54
303	Correlation between CSF and blood neurofilament light chain protein: a systematic review and meta-analysis. <i>BMJ Neurology Open</i> , 2021, 3, e000143.	0.7	46
304	A multicentre validation study of the diagnostic value of plasma neurofilament light. <i>Nature Communications</i> , 2021, 12, 3400.	5.8	219
305	Association of plasma P-tau181 with memory decline in non-demented adults. <i>Brain Communications</i> , 2021, 3, fcb136.	1.5	33
306	Neurodegeneration, Alzheimer's disease biomarkers, and longitudinal verbal learning and memory performance in late middle age. <i>Neurobiology of Aging</i> , 2021, 102, 151-160.	1.5	6

#	ARTICLE	IF	CITATIONS
307	<scp>CSF</scp> Protein Level of Neurotransmitter Secretion, Synaptic Plasticity, and Autophagy in <scp>PD</scp> and <scp>DLB</scp>. <i>Movement Disorders</i> , 2021, 36, 2595-2604.	2.2	15
308	Refining the amyloid $\hat{1}^2$ peptide and oligomer fingerprint ambiguities in Alzheimer's disease: Mass spectrometric molecular characterization in brain, cerebrospinal fluid, blood, and plasma. <i>Journal of Neurochemistry</i> , 2021, 159, 234-257.	2.1	8
309	Cognitively unimpaired individuals with a low burden of $\hat{1}^2$ pathology have a distinct CSF biomarker profile. <i>Alzheimer's Research and Therapy</i> , 2021, 13, 134.	3.0	8
310	Circulating granulocyte colony-stimulating factor and functional outcome after ischemic stroke: an observational study. <i>Neurological Research</i> , 2021, 43, 1013-1022.	0.6	0
311	Plasma Proteomic Biomarkers Relating to Alzheimer's Disease: A Meta-Analysis Based on Our Own Studies. <i>Frontiers in Aging Neuroscience</i> , 2021, 13, 712545.	1.7	16
312	Early rise in brain damage markers and high ICOS expression in CD4+ and CD8+ T cells during checkpoint inhibitor-induced encephalomyelitis. , 2021, 9, e002732.		12
313	Genome-scale metabolic network reconstruction of model animals as a platform for translational research. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	3.3	48
314	Circulating brain injury biomarkers increase after endoscopic surgery for pituitary tumors. <i>Journal of Clinical Neuroscience</i> , 2021, 89, 113-121.	0.8	5
315	Tau PET correlates with different Alzheimer's disease-related features compared to CSF and plasma \hat{p} biomarkers. <i>EMBO Molecular Medicine</i> , 2021, 13, e14398.	3.3	58
316	Reproductive period and preclinical cerebrospinal fluid markers for Alzheimer disease: a 25-year study. <i>Menopause</i> , 2021, 28, 1099-1107.	0.8	6
317	Neuroinflammation and Alzheimer's Disease: A Machine Learning Approach to CSF Proteomics. <i>Cells</i> , 2021, 10, 1930.	1.8	34
318	Associations of Fully Automated CSF and Novel Plasma Biomarkers With Alzheimer Disease Neuropathology at Autopsy. <i>Neurology</i> , 2021, 97, .	1.5	50
319	Severe COVID-19 in an APS1 patient with interferon autoantibodies treated with plasmapheresis. <i>Journal of Allergy and Clinical Immunology</i> , 2021, 148, 96-98.	1.5	47
320	Phosphorylated tau181 in plasma as a potential biomarker for Alzheimer's disease in adults with Down syndrome. <i>Nature Communications</i> , 2021, 12, 4304.	5.8	33
321	Cerebrospinal fluid neurofilament light levels in CLN2 disease patients treated with enzyme replacement therapy normalise after two years on treatment. <i>F1000Research</i> , 2021, 10, 614.	0.8	4
322	Plasma GFAP is an early marker of amyloid- $\hat{1}^2$ but not tau pathology in Alzheimer's disease. <i>Brain</i> , 2021, 144, 3505-3516.	3.7	198
323	Plasma interferon-alpha is associated with double-positivity for autoantibodies but is not a predictor of remission in early rheumatoid arthritis—a spin-off study of the NORD-STAR randomized clinical trial. <i>Arthritis Research and Therapy</i> , 2021, 23, 189.	1.6	5
324	Critical illness polyneuropathy, myopathy and neuronal biomarkers in COVID-19 patients: A prospective study. <i>Clinical Neurophysiology</i> , 2021, 132, 1733-1740.	0.7	94

#	ARTICLE	IF	CITATIONS
325	Amyloid- β positive individuals with subjective cognitive decline present increased CSF neurofilament light levels that relate to lower hippocampal volume. <i>Neurobiology of Aging</i> , 2021, 104, 24-31.	1.5	13
326	CSF Proteomic Alzheimer's Disease-Predictive Subtypes in Cognitively Intact Amyloid Negative Individuals. <i>Proteomes</i> , 2021, 9, 36.	1.7	9
327	Neurochemical signs of astrocytic and neuronal injury in acute COVID-19 normalizes during long-term follow-up. <i>EBioMedicine</i> , 2021, 70, 103512.	2.7	106
328	Microglial activation and tau propagate jointly across Braak stages. <i>Nature Medicine</i> , 2021, 27, 1592-1599.	15.2	235
329	Synaptic Molecular and Neurophysiological Markers Are Independent Predictors of Progression in Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2021, 83, 355-366.	1.2	1
330	Association of Apolipoprotein E ϵ 4 Allele With Clinical and Multimodal Biomarker Changes of Alzheimer Disease in Adults With Down Syndrome. <i>JAMA Neurology</i> , 2021, 78, 937.	4.5	32
331	Plasma Neurofilament Light Chain Predicts Cognitive Progression in Prodromal and Clinical Dementia with Lewy Bodies. <i>Journal of Alzheimer's Disease</i> , 2021, 82, 913-919.	1.2	27
332	Perivascular spaces are associated with tau pathophysiology and synaptic dysfunction in early Alzheimer's continuum. <i>Alzheimer's Research and Therapy</i> , 2021, 13, 135.	3.0	30
333	Cerebrospinal fluid proteomics targeted for central nervous system processes in bipolar disorder. <i>Molecular Psychiatry</i> , 2021, 26, 7446-7453.	4.1	5
334	Cognitive Effects of the BET Protein Inhibitor Apabetalone: A Prespecified Montreal Cognitive Assessment Analysis Nested in the BETonMACE Randomized Controlled Trial. <i>Journal of Alzheimer's Disease</i> , 2021, 83, 1703-1715.	1.2	15
335	Neurochemical biomarkers to study CNS effects of COVID-19: A narrative review and synthesis. <i>Journal of Neurochemistry</i> , 2021, 159, 61-77.	2.1	21
336	Extracellular fluid, cerebrospinal fluid and plasma biomarkers of axonal and neuronal injury following intracerebral hemorrhage. <i>Scientific Reports</i> , 2021, 11, 16950.	1.6	5
337	Blood Biomarkers for Alzheimer's Disease in Down Syndrome. <i>Journal of Clinical Medicine</i> , 2021, 10, 3639.	1.0	17
338	Serum markers of brain injury can predict good neurological outcome after out-of-hospital cardiac arrest. <i>Intensive Care Medicine</i> , 2021, 47, 984-994.	3.9	50
339	Ultra-Early Differential Diagnosis of Acute Cerebral Ischemia and Hemorrhagic Stroke by Measuring the Prehospital Release Rate of GFAP. <i>Clinical Chemistry</i> , 2021, 67, 1361-1372.	1.5	21
340	Head-to-Head Comparison of 8 Plasma Amyloid- β 42/40 Assays in Alzheimer Disease. <i>JAMA Neurology</i> , 2021, 78, 1375.	4.5	195
341	Oligonucleotides Targeting DNA Repeats Downregulate <i>Huntingtin</i> Gene Expression in Huntington's Patient-Derived Neural Model System. <i>Nucleic Acid Therapeutics</i> , 2021, 31, 443-456.	2.0	4
342	Glial fibrillary acidic protein: a blood biomarker to differentiate neurodegenerative from psychiatric diseases. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2021, 92, 1253-1253.	0.9	3

#	ARTICLE	IF	CITATIONS
343	Cerebrospinal fluid neurogranin in Alzheimer's disease studies: are immunoassay results interchangeable?. <i>Clinical Chemistry and Laboratory Medicine</i> , 2021, 60, e13-e17.	1.4	0
344	The circadian rest-activity pattern predicts cognitive decline among mild-moderate Alzheimer's disease patients. <i>Alzheimer's Research and Therapy</i> , 2021, 13, 161.	3.0	15
345	The localization of amyloid precursor protein to ependymal cilia in vertebrates and its role in cilogenesis and brain development in zebrafish. <i>Scientific Reports</i> , 2021, 11, 19115.	1.6	4
346	Comparison of Plasma Phosphorylated Tau Species With Amyloid and Tau Positron Emission Tomography, Neurodegeneration, Vascular Pathology, and Cognitive Outcomes. <i>JAMA Neurology</i> , 2021, 78, 1108.	4.5	114
347	Effects of Peroral Omega-3 Fatty Acid Supplementation on Cerebrospinal Fluid Biomarkers in Patients with Alzheimer's Disease: A Randomized Controlled Trial—The OmegAD Study. <i>Journal of Alzheimer's Disease</i> , 2021, 83, 1291-1301.	1.2	10
348	Association of deranged cerebrovascular reactivity with brain injury following cardiac arrest: a post-hoc analysis of the COMACARE trial. <i>Critical Care</i> , 2021, 25, 350.	2.5	17
349	Enhancing the Sensitivity of Memory Tests: Reference Data for the Free and Cued Selective Reminding Test and the Logical Memory Task from Cognitively Healthy Subjects with Normal Alzheimer's Disease Cerebrospinal Fluid Biomarker Levels. <i>Journal of Alzheimer's Disease</i> , 2021, 84, 119-128.	1.2	3
350	Amyloid pathology and synaptic loss in pathological aging. <i>Journal of Neurochemistry</i> , 2021, 159, 258-272.	2.1	6
351	A genome-wide association study with 1,126,563 individuals identifies new risk loci for Alzheimer's disease. <i>Nature Genetics</i> , 2021, 53, 1276-1282.	9.4	430
352	Plasma phosphorylated tau 217 and phosphorylated tau 181 as biomarkers in Alzheimer's disease and frontotemporal lobar degeneration: a retrospective diagnostic performance study. <i>Lancet Neurology</i> , The, 2021, 20, 739-752.	4.9	220
353	The blood biomarkers puzzle — A review of protein biomarkers in neurodegenerative diseases. <i>Journal of Neuroscience Methods</i> , 2021, 361, 109281.	1.3	14
354	Kappa free light chain index as a diagnostic biomarker in multiple sclerosis: A real-world investigation. <i>Journal of Neurochemistry</i> , 2021, 159, 618-628.	2.1	26
355	Axonal marker neurofilament light predicts long-term outcomes and progressive neurodegeneration after traumatic brain injury. <i>Science Translational Medicine</i> , 2021, 13, eabg9922.	5.8	74
356	Antiphospholipid antibodies and neurological manifestations in acute COVID-19: A single-centre cross-sectional study. <i>EClinicalMedicine</i> , 2021, 39, 101070.	3.2	21
357	Predicting progression and cognitive decline in amyloid-positive patients with Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2021, 13, 151.	3.0	9
358	D02...Cerebrospinal fluid amyloid beta and glial fibrillary acidic protein concentrations in huntington's disease. , 2021, , .		0
359	F05...Biological and clinical characteristics of gene carriers far from predicted onset in the hd-yas study: a cross-sectional analysis. , 2021, , .		0
360	CSF Synaptic Biomarkers in the Preclinical Stage of Alzheimer Disease and Their Association With MRI and PET. <i>Neurology</i> , 2021, 97, e2065-e2078.	1.5	40

#	ARTICLE	IF	CITATIONS
361	No evidence of neuronal damage as measured by neurofilament light chain in a HIV cure study utilising a kick-and-kill approach. <i>Journal of Virus Eradication</i> , 2021, 7, 100056.	0.3	1
362	Blood-based high sensitivity measurements of beta-amyloid and phosphorylated tau as biomarkers of Alzheimer's disease: a focused review on recent advances. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2021, 92, 1231-1241.	0.9	51
363	Association of CSF sTREM2, a marker of microglia activation, with cholinergic basal forebrain volume in major depressive disorder. <i>Journal of Affective Disorders</i> , 2021, 293, 429-434.	2.0	5
364	A genome-wide association study of plasma phosphorylated tau181. <i>Neurobiology of Aging</i> , 2021, 106, 304.e1-304.e3.	1.5	5
365	Sulfatide in health and disease. The evaluation of sulfatide in cerebrospinal fluid as a possible biomarker for neurodegeneration. <i>Molecular and Cellular Neurosciences</i> , 2021, 116, 103670.	1.0	17
366	Association of plasma A β 40/A β 42 ratio and brain A β 2 accumulation: testing a whole-brain PLS-VIP approach in individuals at risk of Alzheimer's disease. <i>Neurobiology of Aging</i> , 2021, 107, 57-69.	1.5	5
367	Brain injury markers in new-onset seizures in adults: A pilot study. <i>Seizure: the Journal of the British Epilepsy Association</i> , 2021, 92, 62-67.	0.9	11
368	Associations between air pollution and biomarkers of Alzheimer's disease in cognitively unimpaired individuals. <i>Environment International</i> , 2021, 157, 106864.	4.8	40
369	Amyotrophic lateral sclerosis transcriptomics reveals immunological effects of low-dose interleukin-2. <i>Brain Communications</i> , 2021, 3, fcab141.	1.5	17
370	Assessment of Protein as a in Rodent Models of Toxic-Induced Peripheral. <i>Neuromethods</i> , 2021, , 267-275.	0.2	0
371	Tau aggregation and increased neuroinflammation in athletes after sports-related concussions and in traumatic brain injury patients – A PET/MR study. <i>NeuroImage: Clinical</i> , 2021, 30, 102665.	1.4	29
372	The diagnostic and prognostic capabilities of plasma biomarkers in Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2021, 17, 1145-1156.	0.4	174
373	Familial Alzheimer's Disease Mutations in PSEN1 Lead to Premature Human Stem Cell Neurogenesis. <i>Cell Reports</i> , 2021, 34, 108615.	2.9	53
374	Polygenic risk scores for Alzheimer's disease are related to dementia risk in APOE ϵ 4 negatives. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2021, 13, e12142.	1.2	25
375	CSF metabolites associate with CSF tau and improve prediction of Alzheimer's disease status. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2021, 13, e12167.	1.2	2
376	Plasma glial fibrillary acidic protein is elevated in cognitively normal older adults at risk of Alzheimer's disease. <i>Translational Psychiatry</i> , 2021, 11, 27.	2.4	207
377	Longitudinal brain atrophy and CSF biomarkers in early-onset Alzheimer's disease. <i>NeuroImage: Clinical</i> , 2021, 32, 102804.	1.4	28
378	Neurofilament light predicts neurological outcome after subarachnoid haemorrhage. <i>Brain</i> , 2021, 144, 761-768.	3.7	22

#	ARTICLE	IF	CITATIONS
379	Neurofilament light plasma concentration positively associates with age and negatively associates with weight and height in the dog. <i>Neuroscience Letters</i> , 2021, 744, 135593.	1.0	6
380	Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Encephalitis Is a Cytokine Release Syndrome: Evidences From Cerebrospinal Fluid Analyses. <i>Clinical Infectious Diseases</i> , 2021, 73, e3019-e3026.	2.9	131
381	Serum and cerebrospinal fluid biomarker profiles in acute SARS-CoV-2-associated neurological syndromes. <i>Brain Communications</i> , 2021, 3, fcab099.	1.5	43
382	Preclinical and clinical biomarker studies of CT1812: A novel approach to Alzheimer's disease modification. <i>Alzheimer's and Dementia</i> , 2021, 17, 1365-1382.	0.4	43
383	Neurofilaments in progressive multiple sclerosis: a systematic review. <i>Journal of Neurology</i> , 2021, 268, 3212-3222.	1.8	47
384	OUP accepted manuscript. <i>Brain</i> , 2021, 144, 434-449.	3.7	54
385	CSF Biomarkers in Patients With COVID-19 and Neurologic Symptoms. <i>Neurology</i> , 2021, 96, e294-e300.	1.5	118
386	Plasma Tau and Neurofilament Light in Frontotemporal Lobar Degeneration and Alzheimer Disease. <i>Neurology</i> , 2021, 96, e671-e683.	1.5	84
387	The global Alzheimer's Association round robin study on plasma amyloid β^2 methods. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2021, 13, e12242.	1.2	17
388	Serum Neurofilament Light is elevated in COVID-19 Positive Adults in the ICU and is associated with Co-Morbid Cardiovascular Disease, Neurological Complications, and Acuity of Illness. <i>Cardiology and Cardiovascular Medicine</i> , 2021, 05, 551-565.	0.1	8
389	Differential chemokine alteration in the variants of primary progressive aphasia—a role for neuroinflammation. <i>Journal of Neuroinflammation</i> , 2021, 18, 224.	3.1	11
390	Neurofilament Light in CSF and Plasma Is a Marker of Neuronal Damage in HTLV-1-Associated Myelopathy and Correlates With Neuroinflammation. <i>Neurology: Neuroimmunology and Neuroinflammation</i> , 2021, 8, .	3.1	8
391	Differential Stimulation of Pluripotent Stem Cell-Derived Human Microglia Leads to Exosomal Proteomic Changes Affecting Neurons. <i>Cells</i> , 2021, 10, 2866.	1.8	6
392	Changes in Blood Biomarkers of Brain Injury and Degeneration Following Long-Duration Spaceflight. <i>JAMA Neurology</i> , 2021, 78, 1525.	4.5	19
393	Herpes Simplex Virus 1 and 2 Infections during Differentiation of Human Cortical Neurons. <i>Viruses</i> , 2021, 13, 2072.	1.5	5
394	Lower plasma total tau in adolescent psychosis: Involvement of the orbitofrontal cortex. <i>Journal of Psychiatric Research</i> , 2021, 144, 255-261.	1.5	3
395	Alzheimer's Disease-Related Dementias Summit 2019: National Research Priorities for the Investigation of Traumatic Brain Injury as a Risk Factor for Alzheimer's Disease and Related Dementias. <i>Journal of Neurotrauma</i> , 2021, 38, 3186-3194.	1.7	6
396	Infection of Brain Pericytes Underlying Neuropathology of COVID-19 Patients. <i>International Journal of Molecular Sciences</i> , 2021, 22, 11622.	1.8	41

#	ARTICLE	IF	CITATIONS
397	Association between CSF alpha-synuclein seeding activity and genetic status in Parkinson's disease and dementia with Lewy bodies. <i>Acta Neuropathologica Communications</i> , 2021, 9, 175.	2.4	49
398	P-tau235: a novel biomarker for staging preclinical Alzheimer's disease. <i>EMBO Molecular Medicine</i> , 2021, 13, e15098.	3.3	30
399	Differences Between Plasma and Cerebrospinal Fluid Glial Fibrillary Acidic Protein Levels Across the Alzheimer Disease Continuum. <i>JAMA Neurology</i> , 2021, 78, 1471.	4.5	204
400	Evidence of Neuroinflammation and Blood-Brain Barrier Disruption in Women with Preeclampsia and Eclampsia. <i>Cells</i> , 2021, 10, 3045.	1.8	11
401	Truncating tau reveals different pathophysiological actions of oligomers in single neurons. <i>Communications Biology</i> , 2021, 4, 1265.	2.0	4
402	Sex-Specific Metabolic Pathways Were Associated with Alzheimer's Disease (AD) Endophenotypes in the European Medical Information Framework for AD Multimodal Biomarker Discovery Cohort. <i>Biomedicine</i> , 2021, 9, 1610.	1.4	7
403	Neurofilament Light Chain Related to Longitudinal Decline in Frontotemporal Lobar Degeneration. <i>Neurology: Clinical Practice</i> , 2021, 11, 105-116.	0.8	5
404	Prodromal frontotemporal dementia: clinical features and predictors of progression. <i>Alzheimer's Research and Therapy</i> , 2021, 13, 188.	3.0	8
405	A panel of CSF proteins separates genetic frontotemporal dementia from presymptomatic mutation carriers: a GENFI study. <i>Molecular Neurodegeneration</i> , 2021, 16, 79.	4.4	9
406	Neurofilaments can differentiate ALS subgroups and ALS from common diagnostic mimics. <i>Scientific Reports</i> , 2021, 11, 22128.	1.6	31
407	Association between serum urate and CSF markers of Alzheimer's disease pathology in a population-based sample of 70-year-olds. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2021, 13, e12241.	1.2	3
408	Cerebrospinal Fluid Biomarkers, Brain Structural and Cognitive Performances Between Normotensive and Hypertensive Controlled, Uncontrolled and Untreated 70-Year-Old Adults. <i>Frontiers in Aging Neuroscience</i> , 2021, 13, 777475.	1.7	4
409	Fluid and Tissue Biomarkers of Lewy Body Dementia: Report of an LBDA Symposium. <i>Frontiers in Neurology</i> , 2021, 12, 805135.	1.1	12
410	Detecting amyloid positivity in early Alzheimer disease using plasma biomarkers. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	6
411	A high-performance biomarker panel for Alzheimer's disease screening and staging identified by large-scale plasma proteomic profiling. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	4
412	Clinical and analytical comparison of six Simoa assays for plasma P-tau isoforms P-tau181, P-tau217, and P-tau231. <i>Alzheimer's Research and Therapy</i> , 2021, 13, 198.	3.0	87
413	Neurofilament Light Regulates Axon Caliber, Synaptic Activity, and Organelle Trafficking in Cultured Human Motor Neurons. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 820105.	1.8	23
414	Plasma Cystatin C Correlates with Plasma NfL Levels and Predicts Disease Progression in Parkinson's Disease. <i>Neurodegenerative Diseases</i> , 2021, 21, 109-116.	0.8	2

#	ARTICLE	IF	CITATIONS
415	Tau368 in cerebrospinal fluid is associated with severity of tau pathology load in the Alzheimer's disease continuum. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	1
416	Developments in clinical testing of cerebrospinal fluid biomarkers of Alzheimer's disease in the UK. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	0
417	Favorable cognitive effects of the BET protein inhibitor apabetalone in patients 70 and older. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	1
418	Neurochemical signs of astrocytic and neuronal injury in acute COVID-19 normalizes during long-term follow-up. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	2
419	Associations between obstructive sleep apnea, Alzheimer's disease pathology, and objective daytime sleepiness measured by the psychomotor vigilance task in cognitively unimpaired adults. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	0
420	Decorin is an early CSF biomarker of Alzheimer's A β 2 amyloidosis. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	0
421	Inflammatory, degeneration and neuritic growth biomarkers predict cognitive decline and dementia in Parkinson's disease. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	0
422	CSF metabolites associated with CSF NeuroToolKit biomarkers. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	1
423	Measuring synaptic loss in early AD stages: Trajectories of SNAP25 and SYT1 using serial CSF sampling. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	0
424	Higher levels of the astrocytic marker CSF YKL40 are associated with better memory performance only in amyloid β -positive individuals with subjective cognitive decline. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	1
425	CSF amyloid, tau, and neurodegeneration biomarkers are associated with longitudinal cognitive decline in preclinical AD. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	1
426	CSF apolipoprotein B levels predict future visuospatial cognitive decline and synaptic pathology in cognitively unimpaired healthy elderly with a parental history of Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	1
427	The association between diabetes and Alzheimer's disease pathophysiology. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	0
428	Brain structural alterations in cognitively unimpaired individuals with discordant amyloid β PET and CSF A β 42 status: Findings using machine learning. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	0
429	Plasma glial fibrillary acidic protein is an early and specific marker of amyloid β 2 pathology in Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	1
430	Stress and Alzheimer's disease: Linking salivary cortisol to biomarkers of neurodegeneration and cognitive decline in a memory clinic cohort. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	1
431	Amyloid time: Quantifying the onset of abnormal biomarkers and cognitive impairment along the Alzheimer's disease continuum. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	2
432	CSF amyloid β , tau, and neurodegenerative and inflammatory biomarkers in cognitively unimpaired late middle-aged and older adult APOE ϵ 4 homozygotes, heterozygotes, and non-carriers from the Arizona APOE Cohort. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	1

#	ARTICLE	IF	CITATIONS
433	Machine learning on combined neuroimaging and plasma biomarkers for triaging participants of secondary prevention trials in Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	0
434	Imaging neurodegeneration markers are associated with multiple pathophysiological mechanisms in the early stages of the Alzheimer's continuum. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	0
435	CSF biomarkers and blood pressure trajectories in normotensive individuals and subjects with controlled and uncontrolled hypertension. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	0
436	NeuroCOVID: Does severe COVID-19 infection increase the risk for cognitive impairment?. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	0
437	A multimodal study on the effect of sex on Alzheimer's disease clinical and biomarker changes in adults with Down syndrome. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	0
438	Perivascular spaces are associated with tau pathophysiology and synaptic dysfunction in early Alzheimer's continuum. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	2
439	Microstructural alterations in medial temporal and frontal white matter tracts are associated with subjective cognitive decline. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	0
440	Positive clinical outcomes in two phase 2a studies: ADAS-COG in Alzheimer's and MDS-UPDRS in Parkinson's patients plus markers of toxic cascade that leads to nerve cell death. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	0
441	Clinical reporting following the quantification of cerebrospinal fluid biomarkers in Alzheimer's disease: An international overview. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	7
442	Plasma p-tau231 in the Alzheimer's disease continuum: A multi-cohort evaluation of diagnostic performance, detection of A β 2 pathology and preclinical application. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	0
443	Synergistic effects of CSF A β 42 and p-Tau on functional resting-state connectivity in cognitively unimpaired individuals. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	0
444	Subacute plasma neurofilament light predicts neurodegeneration after moderate-severe traumatic brain injury. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	0
445	Distinctive effect of biological sex in AD-related CSF and plasma biomarkers. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	2
446	Data-driven approach for early detection of pathological pathways in middle-aged adults with family history of sporadic Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	0
447	Brain atrophy and white matter hyperintensities are independently associated with plasma neurofilament light chain in an Asian cohort of patients with mixed pathology. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	0
448	Associations between plasma p-tau217, in vivo brain pathology and cognition in individuals with autosomal-dominant Alzheimer's disease: Findings from the Colombia-Boston (COLBOS) biomarker study. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	0
449	Amyloid aggregation in temporal regions is associated with longitudinal memory decline in cognitively unimpaired ϵ -ApoE ϵ -4 carriers. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	0
450	Plasma p-Tau181 and p-Tau231 offer complementary information to identify Alzheimer's disease pathophysiology. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	1

#	ARTICLE	IF	CITATIONS
451	Associations between mean apparent propagator MRI and cerebrospinal fluid markers of AD pathology, neurodegeneration, and glial activation, in cognitively unimpaired adults. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	0
452	Apolipoprotein ϵ genotype modifies the association between blood-brain barrier permeability and both grey and white matter integrity in older adults. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	0
453	Structural, metabolic and cognitive characteristics of cognitively unimpaired subjects with mismatching β -amyloid biomarkers. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	0
454	CSF and PET biomarkers for noradrenergic dysfunction in neurodegenerative disease: A systematic review and meta-analysis. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	0
455	Plasma biomarkers distinguish clinical diagnostic groups in memory clinic patients. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	0
456	Inflammatory biomarkers are associated with cerebral large artery thickening and dilatation in older adults. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	0
457	Associations between iron deposition in the brain and grey matter volumes in cognitively unimpaired adults. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	0
458	Baseline plasma total tau predicts longitudinal cognitive and functional decline in aging adults. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	1
459	Alzheimer's disease genetic risk variants show brain cell type-specific associations with protein levels in cerebrospinal fluid. <i>Alzheimer's and Dementia</i> , 2021, 17, e049531.	0.4	0
460	Amyloid status is associated with deficits in connected speech language. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	0
461	Interactions between dietary patterns and genetic factors in relation to incident dementia among 70-year-olds. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	0
462	Differential synaptic marker involvement in the different genetic forms of frontotemporal dementia. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	1
463	Association of body mass index with brain structure and biomarkers of inflammation in cognitively unimpaired middle-aged adults with and without evidence of β -amyloid pathology. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	0
464	NT1-Tau Is Increased in CSF and Plasma of CJD Patients, and Correlates with Disease Progression. <i>Cells</i> , 2021, 10, 3514.	1.8	4
465	Mass spectrometric measurement of six site-specific tau phosphorylations in CSF and blood of Alzheimer's disease patients. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	0
466	Microglial activation and tau propagate jointly across Braak stages. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	4
467	CSF sTREM2 predicts markers of blood brain barrier integrity and amyloid beta metabolism independent of ϵ 4 status. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	0
468	Associations of fully automated Elecsys CSF and novel plasma biomarkers with Alzheimer's disease neuropathology. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	0

#	ARTICLE	IF	CITATIONS
469	Association of cerebrospinal fluid and plasma biomarkers with longitudinal tau accumulation. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	0
470	Plasma and cerebrospinal fluid neurofilament light protein concentrations are differentially associated with biomarker evidence of neurodegeneration in a community-based population of 70-year-olds. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	0
471	Comparison of the prognostic value of cerebrospinal fluid and plasma neurofilament light in predicting longitudinal decline in white matter integrity among older adults. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	0
472	A novel antibody-free mass spectrometry panel of CSF biomarkers for synaptic dysfunction. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	1
473	CSF sphingomyelin metabolites in Alzheimer's disease, neurodegeneration, and neuroinflammation. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	4
474	Prediction of future Alzheimer's disease dementia using plasma phospho-tau combined with other accessible measures. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	2
475	Association of deep-learning-derived brain computed tomography measures with cognition and blood-based biomarkers of neurodegenerative diseases. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	0
476	Comparative analytical performance of multiple plasma amyloid-beta assays and their relationship to amyloid PET. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	1
477	Diet and <i>APOE</i> as moderators of the relationship between trimethylamine N-oxide and biomarkers of Alzheimer's disease and glial activation. <i>Alzheimer's and Dementia</i> , 2021, 17, e051827.	0.4	2
478	Effect of antiretroviral treatment on blood-brain barrier integrity in HIV-1 infection. <i>BMC Neurology</i> , 2021, 21, 494.	0.8	9
479	Impaired default mode network along with increased functional connectivity of the medial temporal lobe as a function of CSF τ /Ab42 ratio in cognitively unimpaired individuals. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	0
480	CSF and blood biomarkers: How strongly do they reflect Alzheimer's pathophysiology and are they dynamic?. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	0
481	Stability of the novel blood-based biomarkers under pre-analytical sample handling conditions: Results of the SABB-GBSC working group. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	0
482	Cerebrospinal fluid proteomic profiling of individuals with prodromal Alzheimer's disease classified using two different neurodegenerative biomarkers (N) in A/T/N classification. <i>Alzheimer's and Dementia</i> , 2021, 17, e053030.	0.4	0
483	A role for inflammaging in α -synuclein-associated breakdown of local sleep in the elderly.. <i>Alzheimer's and Dementia</i> , 2021, 17 Suppl 3, e054208.	0.4	0
484	Sex differences in blood-based biomarkers in individuals with autosomal dominant Alzheimer's disease.. <i>Alzheimer's and Dementia</i> , 2021, 17 Suppl 3, e055011.	0.4	0
485	Immune protein levels in cerebrospinal fluid: Associations with memory scores across the AD spectrum.. <i>Alzheimer's and Dementia</i> , 2021, 17 Suppl 3, e055451.	0.4	0
486	CSF $A\beta_{242}$ and $A\beta_{240}$ and their relation to brain soluble and insoluble $A\beta$ in the 5xFAD mouse model of Alzheimer's disease.. <i>Alzheimer's and Dementia</i> , 2021, 17 Suppl 3, e055684.	0.4	0

#	ARTICLE	IF	CITATIONS
487	The impact of social networks and ϵ 4 on dementia among older adults: tests of possible interactions. <i>Aging and Mental Health</i> , 2020, 24, 395-404.	1.5	12
488	Familial Alzheimer's disease patient-derived neurons reveal distinct mutation-specific effects on amyloid beta. <i>Molecular Psychiatry</i> , 2020, 25, 2919-2931.	4.1	99
489	Validity and Normative Data for the Biber Figure Learning Test: A Visual Supraspan Memory Measure. <i>Assessment</i> , 2020, 27, 1320-1334.	1.9	3
490	Acute symptomatic seizures and epilepsy after mechanical thrombectomy. <i>Epilepsy and Behavior</i> , 2020, 104, 106520.	0.9	25
491	Propagation of Tau Pathology: Integrating Insights From Postmortem and In Vivo Studies. <i>Biological Psychiatry</i> , 2020, 87, 808-818.	0.7	50
492	Modified ketogenic diet is associated with improved cerebrospinal fluid biomarker profile, cerebral perfusion, and cerebral ketone body uptake in older adults at risk for Alzheimer's disease: a pilot study. <i>Neurobiology of Aging</i> , 2020, 86, 54-63.	1.5	136
493	Plasma pNfH levels differentiate SBMA from ALS. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2020, 91, 215-217.	0.9	11
494	Dementia and CSF biomarkers for Alzheimer's disease predict mortality after acute hip fracture. <i>Acta Anaesthesiologica Scandinavica</i> , 2020, 64, 93-103.	0.7	19
495	Twin study shows association between monocyte chemoattractant protein-1 and kynurenic acid in cerebrospinal fluid. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2020, 270, 933-938.	1.8	4
496	Human cerebrospinal fluid promotes spontaneous gamma oscillations in the hippocampus in vitro. <i>Hippocampus</i> , 2020, 30, 101-113.	0.9	6
497	Synaptic, axonal damage and inflammatory cerebrospinal fluid biomarkers in neurodegenerative dementias. <i>Alzheimer's and Dementia</i> , 2020, 16, 262-272.	0.4	47
498	Cerebrospinal fluid neurogranin in an inducible mouse model of neurodegeneration: A translatable marker of synaptic degeneration. <i>Neurobiology of Disease</i> , 2020, 134, 104645.	2.1	16
499	Plasma neurofilament light in progressive multiple sclerosis. <i>Acta Neurologica Scandinavica</i> , 2020, 141, 14-15.	1.0	1
500	Chemical imaging of evolving amyloid plaque pathology and associated $A\beta$ peptide aggregation in a transgenic mouse model of Alzheimer's disease. <i>Journal of Neurochemistry</i> , 2020, 152, 602-616.	2.1	15
501	Neuroinflammatory markers associate with cognitive decline after major surgery: Findings of an explorative study. <i>Annals of Neurology</i> , 2020, 87, 370-382.	2.8	34
502	Protein aggregate formation permits millennium-old brain preservation. <i>Journal of the Royal Society Interface</i> , 2020, 17, 20190775.	1.5	11
503	Prescreening for European Prevention of Alzheimer Dementia (EPAD) trial-ready cohort: impact of AD risk factors and recruitment settings. <i>Alzheimer's Research and Therapy</i> , 2020, 12, 8.	3.0	12
504	Circulating levels of vascular endothelial growth factor and post-stroke long-term functional outcome. <i>Acta Neurologica Scandinavica</i> , 2020, 141, 405-414.	1.0	8

#	ARTICLE	IF	CITATIONS
505	Effects of acute sleep loss on diurnal plasma dynamics of CNS health biomarkers in young men. <i>Neurology</i> , 2020, 94, e1181-e1189.	1.5	59
506	Association of brain network dynamics with plasma biomarkers in subjective memory complainers. <i>Neurobiology of Aging</i> , 2020, 88, 83-90.	1.5	4
507	Diagnosis Across the Spectrum of Progressive Supranuclear Palsy and Corticobasal Syndrome. <i>JAMA Neurology</i> , 2020, 77, 377.	4.5	94
508	Low plasma neurofilament light levels associated with raised cortical microglial activation suggest inflammation acts to protect prodromal Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2020, 12, 3.	3.0	22
509	Plasma tau correlates with basal forebrain atrophy rates in people at risk for Alzheimer disease. <i>Neurology</i> , 2020, 94, e30-e41.	1.5	20
510	Cerebrospinal fluid tau fragment correlates with tau PET: a candidate biomarker for tangle pathology. <i>Brain</i> , 2020, 143, 650-660.	3.7	68
511	An update on fluid biomarkers for neurodegenerative diseases: recent success and challenges ahead. <i>Current Opinion in Neurobiology</i> , 2020, 61, 29-39.	2.0	67
512	Cerebrospinal Fluid Levels of Neurogranin in Parkinsonian Disorders. <i>Movement Disorders</i> , 2020, 35, 513-518.	2.2	22
513	Postoperative delirium is associated with increased plasma neurofilament light. <i>Brain</i> , 2020, 143, 47-54.	3.7	107
514	CSF sTREM2 and Tau Work Together in Predicting Increased Temporal Lobe Atrophy in Older Adults. <i>Cerebral Cortex</i> , 2020, 30, 2295-2306.	1.6	15
515	The novel seizure quality index for the antidepressant outcome prediction in electroconvulsive therapy: association with biomarkers in the cerebrospinal fluid. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2020, 270, 911-919.	1.8	12
516	Longitudinal change in regional brain volumes with exposure to repetitive head impacts. <i>Neurology</i> , 2020, 94, e232-e240.	1.5	37
517	Quality of life of ice hockey players after retirement due to concussions. <i>Concussion</i> , 2020, 5, CNC78.	1.2	5
518	Comparing Glial Fibrillary Acidic Protein (GFAP) in Serum and Plasma Following Mild Traumatic Brain Injury in Older Adults. <i>Frontiers in Neurology</i> , 2020, 11, 1054.	1.1	45
519	Obinutuzumab-Induced B Cell Depletion Reduces Spinal Cord Pathology in a CD20 Double Transgenic Mouse Model of Multiple Sclerosis. <i>International Journal of Molecular Sciences</i> , 2020, 21, 6864.	1.8	8
520	Biomarkers of neuronal damage in saturation diving—a controlled observational study. <i>European Journal of Applied Physiology</i> , 2020, 120, 2773-2784.	1.2	3
521	Amyloid-PET and 18F-FDG-PET in the diagnostic investigation of Alzheimer's disease and other dementias. <i>Lancet Neurology</i> , The, 2020, 19, 951-962.	4.9	254
522	β2-Secretase1 biological markers for Alzheimer's disease: state-of-art of validation and qualification. <i>Alzheimer's Research and Therapy</i> , 2020, 12, 130.	3.0	16

#	ARTICLE	IF	CITATIONS
523	Alpha-Synuclein Protofibrils in Cerebrospinal Fluid: A Potential Biomarker for Parkinson's Disease. <i>Journal of Parkinson's Disease</i> , 2020, 10, 1429-1442.	1.5	4
524	Cerebrospinal fluid biomarkers of brain injury, inflammation and synaptic autoimmunity predict long-term neurocognitive outcome in herpes simplex encephalitis. <i>Clinical Microbiology and Infection</i> , 2020, 27, 1131-1136.	2.8	15
525	Association of plasma YKL-40 with brain amyloid- β^2 levels, memory performance, and sex in subjective memory complainers. <i>Neurobiology of Aging</i> , 2020, 96, 22-32.	1.5	18
526	Cohort study of electroencephalography markers of amyloid-tau-neurodegeneration pathology. <i>Brain Communications</i> , 2020, 2, fcaa099.	1.5	9
527	Plasma glial fibrillary acidic protein and neurofilament light chain, but not tau, are biomarkers of sports-related mild traumatic brain injury. <i>Brain Communications</i> , 2020, 2, fcaa137.	1.5	22
528	Is There a Value of Neurofilament Light as a Biomarker for Neurodegeneration in Parkinson's Disease?. <i>Movement Disorders</i> , 2020, 35, 1111-1112.	2.2	9
529	CSF levels of the BACE1 substrate NRG1 correlate with cognition in Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2020, 12, 88.	3.0	20
530	NfL as a biomarker for neurodegeneration and survival in Parkinson disease. <i>Neurology</i> , 2020, 95, e827-e838.	1.5	73
531	Cell stemness is maintained upon concurrent expression of RB and the mitochondrial ribosomal protein S18-2. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 15673-15683.	3.3	19
532	Stage-specific links between plasma neurofilament light and imaging biomarkers of Alzheimer's disease. <i>Brain</i> , 2020, 143, 3793-3804.	3.7	60
533	Are neuropsychiatric symptoms in dementia linked to CSF biomarkers of synaptic and axonal degeneration?. <i>Alzheimer's Research and Therapy</i> , 2020, 12, 153.	3.0	9
534	Admission Levels of Interleukin 10 and Amyloid β^2 1 β^4 Improve the Outcome Prediction Performance of the Helsinki Computed Tomography Score in Traumatic Brain Injury. <i>Frontiers in Neurology</i> , 2020, 11, 549527.	1.1	8
535	Genome-wide association study of Alzheimer's disease CSF biomarkers in the EMIF-AD Multimodal Biomarker Discovery dataset. <i>Translational Psychiatry</i> , 2020, 10, 403.	2.4	42
536	Age and sex impact plasma NFL and t-Tau trajectories in individuals with subjective memory complaints: a 3-year follow-up study. <i>Alzheimer's Research and Therapy</i> , 2020, 12, 147.	3.0	23
537	Multicentre longitudinal study of fluid and neuroimaging Biomarkers of AXonal injury after traumatic brain injury: the BIO-AX-TBI study protocol. <i>BMJ Open</i> , 2020, 10, e042093.	0.8	11
538	Fluid Biomarkers for Chronic Traumatic Encephalopathy. <i>Seminars in Neurology</i> , 2020, 40, 411-419.	0.5	14
539	Association of years to parent's sporadic onset and risk factors with neural integrity and Alzheimer biomarkers. <i>Neurology</i> , 2020, 95, e2065-e2074.	1.5	3
540	Herpes zoster in HIV-1 infection: The role of CSF pleocytosis in secondary CSF escape and discordance. <i>PLoS ONE</i> , 2020, 15, e0236162.	1.1	11

#	ARTICLE	IF	CITATIONS
541	Repeated 5-day cycles of low dose aldesleukin in amyotrophic lateral sclerosis (IMODALS): A phase 2a randomised, double-blind, placebo-controlled trial. <i>EBioMedicine</i> , 2020, 59, 102844.	2.7	41
542	Discriminative Accuracy of Plasma Phospho-tau217 for Alzheimer Disease vs Other Neurodegenerative Disorders. <i>JAMA - Journal of the American Medical Association</i> , 2020, 324, 772.	3.8	640
543	Plasma p-tau181 accurately predicts Alzheimer's disease pathology at least 8 years prior to post-mortem and improves the clinical characterisation of cognitive decline. <i>Acta Neuropathologica</i> , 2020, 140, 267-278.	3.9	209
544	Blood and cerebrospinal fluid neurofilament light differentially detect neurodegeneration in early Alzheimer's disease. <i>Neurobiology of Aging</i> , 2020, 95, 143-153.	1.5	34
545	Models of the blood-brain barrier using iPSC-derived cells. <i>Molecular and Cellular Neurosciences</i> , 2020, 107, 103533.	1.0	44
546	Tracking the potential involvement of metabolic disease in Alzheimer's disease—Biomarkers and beyond. <i>International Review of Neurobiology</i> , 2020, 154, 51-77.	0.9	6
547	Reliability of serum S100B measurement following mild traumatic brain injury: a comparison of assay measurements from two laboratories. <i>Brain Injury</i> , 2020, 34, 1237-1244.	0.6	2
548	Comparing progression biomarkers in clinical trials of early Alzheimer's disease. <i>Annals of Clinical and Translational Neurology</i> , 2020, 7, 1661-1673.	1.7	27
549	NFL and CXCL13 may reveal disease activity in clinically and radiologically stable MS. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 46, 102463.	0.9	20
550	HSV1 VP1-2 deubiquitinates STING to block type I interferon expression and promote brain infection. <i>Journal of Experimental Medicine</i> , 2020, 217, .	4.2	61
551	Cerebrospinal Fluid Metals and the Association with Cerebral Small Vessel Disease. <i>Journal of Alzheimer's Disease</i> , 2020, 78, 1229-1236.	1.2	9
552	Dynamics of cerebrospinal fluid levels of matrix metalloproteinases in human traumatic brain injury. <i>Scientific Reports</i> , 2020, 10, 18075.	1.6	19
553	Tau, S100B and NSE as Blood Biomarkers in Acute Cerebrovascular Events. <i>In Vivo</i> , 2020, 34, 2577-2586.	0.6	17
554	Fatty Acid-Binding Protein 3 in Cerebrospinal Fluid of Hip Fracture Patients with Delirium. <i>Journal of Alzheimer's Disease</i> , 2020, 77, 183-190.	1.2	1
555	Elevated plasma neurofilament light in aging reflects brain white matter alterations but does not predict cognitive decline or Alzheimer's disease. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2020, 12, e12050.	1.2	20
556	Neurofilament light chain in the vitreous humor of the eye. <i>Alzheimer's Research and Therapy</i> , 2020, 12, 111.	3.0	13
557	In the blood: biomarkers for amyloid pathology and neurodegeneration in Alzheimer's disease. <i>Brain Communications</i> , 2020, 2, fcaa054.	1.5	18
558	Serum Glial Fibrillary Acidic Protein (GFAP) Is a Marker of Disease Severity in Frontotemporal Lobar Degeneration. <i>Journal of Alzheimer's Disease</i> , 2020, 77, 1129-1141.	1.2	55

#	ARTICLE	IF	CITATIONS
559	First amyloid β 1 β 42 certified reference material for re β calibrating commercial immunoassays. <i>Alzheimer's and Dementia</i> , 2020, 16, 1493-1503.	0.4	42
560	Dickkopf-1 Overexpression in vitro Nominates Candidate Blood Biomarkers Relating to Alzheimer β ™s Disease Pathology. <i>Journal of Alzheimer's Disease</i> , 2020, 77, 1353-1368.	1.2	7
561	Extensive Plasmid Library to Prepare Tau Protein Variants and Study Their Functional Biochemistry. <i>ACS Chemical Neuroscience</i> , 2020, 11, 3117-3129.	1.7	6
562	Neurofilament light in blood β What more is needed for clinical implementation in multiple sclerosis?. <i>EBioMedicine</i> , 2020, 57, 102826.	2.7	1
563	Fluid Biomarkers for Synaptic Dysfunction and Loss. <i>Biomarker Insights</i> , 2020, 15, 117727192095031.	1.0	74
564	Potential human transmission of amyloid β 2 pathology: surveillance and risks. <i>Lancet Neurology</i> , The, 2020, 19, 872-878.	4.9	46
565	Serum and cerebrospinal fluid neurofilament light chain in patients with central nervous system infections caused by varicella-zoster virus. <i>Journal of NeuroVirology</i> , 2020, 26, 719-726.	1.0	14
566	Validation of Serum Neurofilament Light Chain as a Biomarker of Parkinson's Disease Progression. <i>Movement Disorders</i> , 2020, 35, 1999-2008.	2.2	104
567	Cerebrospinal fluid endo-lysosomal proteins as potential biomarkers for Huntington β ™s disease. <i>PLoS ONE</i> , 2020, 15, e0233820.	1.1	8
568	Age and the association between apolipoprotein E genotype and Alzheimer disease: A cerebrospinal fluid biomarker β based case β control study. <i>PLoS Medicine</i> , 2020, 17, e1003289.	3.9	39
569	Novel tau biomarkers phosphorylated at T181, T217 or T231 rise in the initial stages of the preclinical Alzheimer β ™s <i>continuum</i> when only subtle changes in β pathology are detected. <i>EMBO Molecular Medicine</i> , 2020, 12, e12921.	3.3	202
570	Serum neurofilament light chain withstands delayed freezing and repeated thawing. <i>Scientific Reports</i> , 2020, 10, 19982.	1.6	30
571	Mutant huntingtin and neurofilament light have distinct longitudinal dynamics in Huntington β ™s disease. <i>Science Translational Medicine</i> , 2020, 12, .	5.8	64
572	Full-length and C-terminal neurogranin in Alzheimer β ™s disease cerebrospinal fluid analyzed by novel ultrasensitive immunoassays. <i>Alzheimer's Research and Therapy</i> , 2020, 12, 168.	3.0	7
573	Identification of plasma proteome signatures associated with ATN framework using SOMAscan. <i>Alzheimer's and Dementia</i> , 2020, 16, e036954.	0.4	1
574	CSF levels of the BACE1 substrate Neuregulin1 correlate with cognition and synaptic biomarkers in Alzheimer β ™s disease. <i>Alzheimer's and Dementia</i> , 2020, 16, e037097.	0.4	0
575	Phospho β tau217 and phospho β tau181 in plasma and CSF as biomarkers for Alzheimer β ™s disease. <i>Alzheimer's and Dementia</i> , 2020, 16, e037520.	0.4	2
576	Plasma phospho β tau181 in over 400 cognitively healthy 69 β to 71 β year β olds: Associations with cerebral amyloid, structural imaging and cognition in the Insight 46 study. <i>Alzheimer's and Dementia</i> , 2020, 16, e037848.	0.4	0

#	ARTICLE	IF	CITATIONS
577	Sex differences in CSF biomarkers for neurodegeneration and blood-brain barrier integrity. <i>Alzheimer's and Dementia</i> , 2020, 16, e038588.	0.4	0
578	Fluid-based biomarkers to facilitate clinical trial execution and interpretation. <i>Alzheimer's and Dementia</i> , 2020, 16, e039031.	0.4	0
579	Protective genetic variants in the MS4A gene cluster modulate microglial activity. <i>Alzheimer's and Dementia</i> , 2020, 16, e039431.	0.4	1
580	Premature neuronal differentiation in familial Alzheimer's disease human stem cells in vitro and in postmortem brain tissue. <i>Alzheimer's and Dementia</i> , 2020, 16, e039793.	0.4	0
581	Tracking neurodegeneration in frontotemporal dementia and Alzheimer's disease: A comparative study of plasma tau and neurofilament light chain. <i>Alzheimer's and Dementia</i> , 2020, 16, e040015.	0.4	0
582	Reduction of neurogranin immunostaining in the hippocampus of postmortem brain of Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2020, 16, e040707.	0.4	0
583	AD biomarker stability for stored CSF based on immunoassay results. <i>Alzheimer's and Dementia</i> , 2020, 16, e040747.	0.4	0
584	Associations of dietary patterns and CSF biomarkers for Alzheimer's disease in a population-based sample of 70-year-olds. <i>Alzheimer's and Dementia</i> , 2020, 16, e040800.	0.4	0
585	CSF 7-ketocholesterol is related to amyloid and white matter microstructure in healthy adults. <i>Alzheimer's and Dementia</i> , 2020, 16, e041015.	0.4	0
586	Correlation between cerebrospinal fluid and blood neurofilament light protein: A systematic review and meta-analysis. <i>Alzheimer's and Dementia</i> , 2020, 16, e041018.	0.4	2
587	Selective association of neurogranin gene expression with amyloid and tau pathology in the parahippocampal gyrus in Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2020, 16, e041053.	0.4	0
588	An ultrasensitive immunoassay for detection of p-tau181 in blood. <i>Alzheimer's and Dementia</i> , 2020, 16, e041238.	0.4	1
589	Serum NFL as a predictor of disease progression in dementia with Lewy bodies. <i>Alzheimer's and Dementia</i> , 2020, 16, e041594.	0.4	0
590	Association of plasma YKL40 with brain amyloidosis, memory performance, and sex in subjective memory complainers. <i>Alzheimer's and Dementia</i> , 2020, 16, e041753.	0.4	0
591	Aging and sex impact plasma NFL and tau trajectories in individuals at risk for Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2020, 16, e041792.	0.4	2
592	Ultrasensitive blood biomarkers to predict cognitive decline and diagnose Alzheimer's disease in the absence of AT(N) classification as the reference standard. <i>Alzheimer's and Dementia</i> , 2020, 16, e041808.	0.4	1
593	A polygenic risk score for Alzheimer's disease determines the risk of incident dementia in APOE ε4 negative individuals over the age of 95: A population-based cohort study. <i>Alzheimer's and Dementia</i> , 2020, 16, e042452.	0.4	0
594	Characterization of monomeric and soluble aggregated Aβ in Down's syndrome and Alzheimer's disease brains. <i>Alzheimer's and Dementia</i> , 2020, 16, e042479.	0.4	0

#	ARTICLE	IF	CITATIONS
595	A novel proteomics assay allows parallel quantitation of a panel of synaptic proteins in human cerebrospinal fluid. <i>Alzheimer's and Dementia</i> , 2020, 16, e042578.	0.4	0
596	Association between polygenic risk score of Alzheimer's disease and CSF amyloid beta 42 in a cohort of 70-year-olds from the general population. <i>Alzheimer's and Dementia</i> , 2020, 16, e042616.	0.4	0
597	Neurofilament light and cognitive performance: Associations with amyloid and vascular pathologies in individuals with mild cognitive impairment. <i>Alzheimer's and Dementia</i> , 2020, 16, e042739.	0.4	0
598	Plasma phospho-tau in familial Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2020, 16, e042921.	0.4	0
599	Impact of the APOE gene on amyloid deposition in participants with abnormal soluble amyloid levels. <i>Alzheimer's and Dementia</i> , 2020, 16, e042955.	0.4	0
600	Quantification of tau phosphorylated at threonine 217 using a novel ultrasensitive immunoassay distinguishes Alzheimer's disease from healthy controls. <i>Alzheimer's and Dementia</i> , 2020, 16, e043467.	0.4	1
601	The interaction of amyloid and tau on decreased cortical neurite density in preclinical Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2020, 16, e043979.	0.4	0
602	CSF NFL levels and neuroimaging-derived neurite density index improve prediction of MCI and dementia clinical diagnosis within the Alzheimer's pathologic framework. <i>Alzheimer's and Dementia</i> , 2020, 16, e043987.	0.4	2
603	Amyloid β , tau, synaptic dysfunction, neurodegeneration, glial and vascular biomarkers in the preclinical stage of the Alzheimer's continuum. <i>Alzheimer's and Dementia</i> , 2020, 16, e044444.	0.4	0
604	Emerging beta-amyloid pathology is associated with tau, synaptic, neurodegeneration and gray matter volume differences. <i>Alzheimer's and Dementia</i> , 2020, 16, e044466.	0.4	1
605	Genetically predicted telomere length and Alzheimer's disease endophenotypes: A Mendelian randomization study. <i>Alzheimer's and Dementia</i> , 2020, 16, e044720.	0.4	0
606	The effect of physical activity on CSF biomarkers of Alzheimer's disease differs between men and women. <i>Alzheimer's and Dementia</i> , 2020, 16, e044722.	0.4	0
607	Multiple biological pathways associate with cerebral amyloid load in the early Alzheimer's continuum. <i>Alzheimer's and Dementia</i> , 2020, 16, e044733.	0.4	0
608	Higher frontoparietal metabolism parallels a greater impact of amyloid and anxiety on medial temporal areas in women versus men. <i>Alzheimer's and Dementia</i> , 2020, 16, e044780.	0.4	0
609	Air pollution and biomarkers of Alzheimer's disease in cognitively unimpaired individuals. <i>Alzheimer's and Dementia</i> , 2020, 16, e044802.	0.4	3
610	Multiple pathophysiological biomarkers are associated with gray matter volume and cerebral glucose metabolism in the early preclinical Alzheimer's continuum. <i>Alzheimer's and Dementia</i> , 2020, 16, e044808.	0.4	0
611	APOE ϵ 4 shapes temporo-parietal network properties in middle-aged, cognitively unimpaired individuals: A graph theory analysis. <i>Alzheimer's and Dementia</i> , 2020, 16, e045092.	0.4	0
612	Weight loss predicts Alzheimer's disease biomarker positivity in cognitively unimpaired middle-aged adults. <i>Alzheimer's and Dementia</i> , 2020, 16, e045137.	0.4	0

#	ARTICLE	IF	CITATIONS
613	Proximity to parental age at onset exacerbates amyloid burden while mental conditions exacerbate neural loss during midlife. <i>Alzheimer's and Dementia</i> , 2020, 16, e045171.	0.4	0
614	Incidence of subjective cognitive decline is associated with amyloid β pathology, whereas stability relates to neurodegeneration. <i>Alzheimer's and Dementia</i> , 2020, 16, e045293.	0.4	0
615	CSF phosphorylated tau β 17 is increased in Alzheimer β TMs and Creutzfeldt β Jakob diseases and correlates with amyloid pathology. <i>Alzheimer's and Dementia</i> , 2020, 16, e045296.	0.4	4
616	Amyloid β positive individuals with subjective cognitive decline present increased CSF neurofilament light levels that relate to hippocampal volume. <i>Alzheimer's and Dementia</i> , 2020, 16, e045715.	0.4	0
617	Impact of APOE ϵ 4 on cerebral amyloid deposition in participants with abnormal soluble amyloid levels. <i>Alzheimer's and Dementia</i> , 2020, 16, e045828.	0.4	1
618	DNA methylation differences associated with peripheral biomarkers in the EMIF β AD cohort. <i>Alzheimer's and Dementia</i> , 2020, 16, e045853.	0.4	0
619	Serum neurofilament light and whole brain volume associate with machine β learning derived brain β predicted age in the British 1946 birth cohort. <i>Alzheimer's and Dementia</i> , 2020, 16, e045965.	0.4	1
620	Levels of amyloid β in cerebrospinal fluid predicts cognition five years later: A population β based study of 70 β year β olds. <i>Alzheimer's and Dementia</i> , 2020, 16, e045969.	0.4	0
621	Multimodal genome β wide meta β analysis of brain amyloidosis reveals heterogeneity across CSF, PET, and pathological amyloid measures. <i>Alzheimer's and Dementia</i> , 2020, 16, e046009.	0.4	0
622	Principal components from untargeted CSF metabolomics associated with tau. <i>Alzheimer's and Dementia</i> , 2020, 16, e046065.	0.4	1
623	Baseline cerebrospinal fluid biomarkers of amyloidosis, phosphorylated tau, and total tau relate to greater longitudinal atrophy in regions susceptible to Alzheimer β TMs disease β related neurodegeneration. <i>Alzheimer's and Dementia</i> , 2020, 16, e046095.	0.4	0
624	Synaptic proteins relate to memory scores in preclinical Alzheimer β TMs disease and cognitively healthy controls depending on amyloid. <i>Alzheimer's and Dementia</i> , 2020, 16, e046102.	0.4	0
625	Microglial activation indexed by [11 C]PBR28 is associated with synaptic depletion in the Alzheimer β TMs disease spectrum. <i>Alzheimer's and Dementia</i> , 2020, 16, e046191.	0.4	0
626	Hypertension accentuates reductions in CSF β 42 in elderly depressives. <i>Alzheimer's and Dementia</i> , 2020, 16, e046299.	0.4	0
627	Plasma tau is negatively correlated with frontal lobe CBF in hypertensive adults on the AD spectrum. <i>Alzheimer's and Dementia</i> , 2020, 16, e046355.	0.4	0
628	SNAP25 reflects amyloid β and tau β related synaptic damage: Associations between PET, VBM and cerebrospinal fluid biomarkers of synaptic dysfunction in the Alzheimer β TMs disease spectrum. <i>Alzheimer's and Dementia</i> , 2020, 16, e046358.	0.4	3
629	Exploring genetic contributors to neuroprotection from AD pathologies: A genome β wide association study. <i>Alzheimer's and Dementia</i> , 2020, 16, e046417.	0.4	0
630	Cerebrospinal fluid phosphorylated tau interacts with MMP2 and MMP3: Associations with cognitive performance in older adults. <i>Alzheimer's and Dementia</i> , 2020, 16, e046463.	0.4	0

#	ARTICLE	IF	CITATIONS
631	Plasma-based biomarkers for A β and tau predict longitudinal brain atrophy in cognitively healthy elderly and in patients with Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2020, 16, e046490.	0.4	0
632	Insulin resistance is related to cognitive decline but not biomarkers of Alzheimer's pathology in adults without dementia. <i>Alzheimer's and Dementia</i> , 2020, 16, e047022.	0.4	0
633	Longitudinal changes in established and exploratory cerebrospinal fluid biomarkers by PTAU/A β 42 status in cognitively unimpaired adults. <i>Alzheimer's and Dementia</i> , 2020, 16, e047156.	0.4	0
634	International initiative for harmonization of cerebrospinal fluid diagnostic comments in Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2020, 16, e047209.	0.4	1
635	CSF proteomic profiling of mild cognitive impairment individuals with suspected non-Alzheimer's disease pathophysiology. <i>Alzheimer's and Dementia</i> , 2020, 16, e047247.	0.4	1
636	Improved performance of Elecsys CSF A β measurement achieved using the simple, unified routine-use protocol for CSF collection. <i>Alzheimer's and Dementia</i> , 2020, 16, e047394.	0.4	0
637	Analytical characteristics of the updated elecsys A β 42 Gen 2 assay, including comparisons with the Gen 1 assay. <i>Alzheimer's and Dementia</i> , 2020, 16, e047517.	0.4	0
638	Plasma p-tau181 accurately predicts Alzheimer's disease pathology at least 8 years prior to post-mortem and improves the clinical characterisation of cognitive decline. <i>Alzheimer's and Dementia</i> , 2020, 16, e047539.	0.4	2
639	Alzheimer's pathologic change indexed by CSF β -amyloid42 associates with longitudinal alterations in myelin content. <i>Alzheimer's and Dementia</i> , 2020, 16, e047629.	0.4	0
640	Ultra-performance liquid chromatography-tandem mass spectrometry method for analysis of tau in human cerebrospinal fluid without the need of immunocapture. <i>Alzheimer's and Dementia</i> , 2020, 16, e040373.	0.4	0
641	Concordance of CSF measures of Alzheimer's pathology with amyloid PET status in a preclinical cohort: A comparison of Lumipulse and established immunoassays. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2020, 12, e12097.	1.2	5
642	Steroid-Responsive Encephalitis in Coronavirus Disease 2019. <i>Annals of Neurology</i> , 2020, 88, 423-427.	2.8	230
643	Plasma pyroglutamate-modified amyloid beta differentiates amyloid pathology. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2020, 12, e12029.	1.2	10
644	Intrathecal immunoreactivity in people with or without previous infectious mononucleosis. <i>Acta Neurologica Scandinavica</i> , 2020, 142, 161-168.	1.0	2
645	Tauopathy-Associated Tau Fragment Ending at Amino Acid 224 Is Generated by Calpain-2 Cleavage. <i>Journal of Alzheimer's Disease</i> , 2020, 74, 1143-1156.	1.2	7
646	Cerebrospinal Fluid Biomarkers to Differentiate Idiopathic Normal Pressure Hydrocephalus from Subcortical Ischemic Vascular Disease. <i>Journal of Alzheimer's Disease</i> , 2020, 75, 937-947.	1.2	13
647	Cerebrospinal fluid biomarkers of neurodegeneration, synaptic dysfunction, and axonal injury relate to atrophy in structural brain regions specific to Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2020, 16, 883-895.	0.4	10
648	Losing the identity of a hockey player: the long-term effects of concussions. <i>Concussion</i> , 2020, 5, CNC74.	1.2	4

#	ARTICLE	IF	CITATIONS
649	Validation of Plasma Proteomic Biomarkers Relating to Brain Amyloid Burden in the EMIF-Alzheimer's Disease Multimodal Biomarker Discovery Cohort. <i>Journal of Alzheimer's Disease</i> , 2020, 74, 213-225.	1.2	13
650	A longitudinal examination of plasma neurofilament light and total tau for the clinical detection and monitoring of Alzheimer's disease. <i>Neurobiology of Aging</i> , 2020, 94, 60-70.	1.5	35
651	Relevance of biomarkers across different neurodegenerative diseases. <i>Alzheimer's Research and Therapy</i> , 2020, 12, 56.	3.0	42
652	Neurofilaments: neurobiological foundations for biomarker applications. <i>Brain</i> , 2020, 143, 1975-1998.	3.7	167
653	Plasma neurofilament light chain in the presenilin 1 E280A autosomal dominant Alzheimer's disease kindred: a cross-sectional and longitudinal cohort study. <i>Lancet Neurology</i> , The, 2020, 19, 513-521.	4.9	97
654	Partial reduction of amyloid β production by β -secretase inhibitors does not decrease synaptic transmission. <i>Alzheimer's Research and Therapy</i> , 2020, 12, 63.	3.0	21
655	Biological and clinical characteristics of gene carriers far from predicted onset in the Huntington's disease Young Adult Study (HD-YAS): a cross-sectional analysis. <i>Lancet Neurology</i> , The, 2020, 19, 502-512.	4.9	122
656	Author reply to the Letter to the Editor by Prof. Dr. Dr Mischak: "Analysis of peptidomic analysis of cartilage and subchondral bone in OA patients". <i>European Journal of Clinical Investigation</i> , 2020, 50, e13260.	1.7	0
657	APOE ϵ 4 genotype-dependent cerebrospinal fluid proteomic signatures in Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2020, 12, 65.	3.0	28
658	Human plasma biomarker responses to inhalational general anaesthesia without surgery. <i>British Journal of Anaesthesia</i> , 2020, 125, 282-290.	1.5	27
659	Amyloid beta, tau, synaptic, neurodegeneration, and glial biomarkers in the preclinical stage of the Alzheimer's <i>continuum</i> . <i>Alzheimer's and Dementia</i> , 2020, 16, 1358-1371.	0.4	120
660	Cerebrospinal Fluid YKL-40 and Neurogranin in Familial Alzheimer's Disease: A Pilot Study. <i>Journal of Alzheimer's Disease</i> , 2020, 76, 941-953.	1.2	9
661	Blood Biomarkers: Democratizing Alzheimer's Diagnostics. <i>Neuron</i> , 2020, 106, 881-883.	3.8	38
662	Amyloid precursor protein-b facilitates cell adhesion during early development in zebrafish. <i>Scientific Reports</i> , 2020, 10, 10127.	1.6	18
663	Admission Levels of Total Tau and β -Amyloid Isoforms β 40 and β 42 in Predicting the Outcome of Mild Traumatic Brain Injury. <i>Frontiers in Neurology</i> , 2020, 11, 325.	1.1	11
664	Mild Cognitive Impairment Staging Yields Genetic Susceptibility, Biomarker, and Neuroimaging Differences. <i>Frontiers in Aging Neuroscience</i> , 2020, 12, 139.	1.7	4
665	Dextran- Versus Crystalloid-Based Prime in Cardiac Surgery: A Prospective Randomized Pilot Study. <i>Annals of Thoracic Surgery</i> , 2020, 110, 1541-1547.	0.7	12
666	Neurochemical evidence of astrocytic and neuronal injury commonly found in COVID-19. <i>Neurology</i> , 2020, 95, e1754-e1759.	1.5	304

#	ARTICLE	IF	CITATIONS
667	Cerebrospinal Fluid 7-Ketocholesterol Level is Associated with Amyloid- β 42 and White Matter Microstructure in Cognitively Healthy Adults. <i>Journal of Alzheimer's Disease</i> , 2020, 76, 643-656.	1.2	8
668	A multi-center study of neurofilament assay reliability and inter-laboratory variability. <i>Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration</i> , 2020, 21, 452-458.	1.1	15
669	Haemoglobin causes neuronal damage in vivo which is preventable by haptoglobin. <i>Brain Communications</i> , 2020, 2, fcz053.	1.5	39
670	Interleukin 10 and Heart Fatty Acid-Binding Protein as Early Outcome Predictors in Patients With Traumatic Brain Injury. <i>Frontiers in Neurology</i> , 2020, 11, 376.	1.1	20
671	Cerebrospinal fluid and plasma biomarkers in individuals at risk for genetic prion disease. <i>BMC Medicine</i> , 2020, 18, 140.	2.3	34
672	Increased serum neurofilament light chain concentration indicates poor outcome in Guillain-Barré syndrome. <i>Journal of Neuroinflammation</i> , 2020, 17, 86.	3.1	44
673	APOE- ϵ 4 Shapes the Cerebral Organization in Cognitively Intact Individuals as Reflected by Structural Gray Matter Networks. <i>Cerebral Cortex</i> , 2020, 30, 4110-4120.	1.6	7
674	The clinical promise of biomarkers of synapse damage or loss in Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2020, 12, 21.	3.0	183
675	Cerebrospinal fluid neurofilament light concentration predicts brain atrophy and cognition in Alzheimer's disease. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2020, 12, e12005.	1.2	35
676	Lower Left Ventricular Ejection Fraction Relates to Cerebrospinal Fluid Biomarker Evidence of Neurodegeneration in Older Adults. <i>Journal of Alzheimer's Disease</i> , 2020, 74, 965-974.	1.2	14
677	Dissection of synaptic pathways through the CSF biomarkers for predicting Alzheimer disease. <i>Neurology</i> , 2020, 95, e953-e961.	1.5	50
678	CSF levels of synaptosomal-associated protein 25 and synaptotagmin-1 in first-episode psychosis subjects. <i>IBRO Reports</i> , 2020, 8, 136-142.	0.3	5
679	Diagnostic and prognostic value of serum NfL and p-Tau ₁₈₁ in frontotemporal lobar degeneration. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2020, 91, 960-967.	0.9	93
680	Serum Hepcidin Levels in Cognitively Normal Older Adults with High Neocortical Amyloid- β Load. <i>Journal of Alzheimer's Disease</i> , 2020, 76, 291-301.	1.2	3
681	CXCL13 in patients with facial palsy caused by varicella zoster virus and <i>Borrelia burgdorferi</i> : a comparative study. <i>Diagnostic Microbiology and Infectious Disease</i> , 2020, 98, 115095.	0.8	2
682	Neurofilament light as a biomarker in traumatic brain injury. <i>Neurology</i> , 2020, 95, e610-e622.	1.5	127
683	Time course and diagnostic utility of NfL, tau, GFAP, and UCH-L1 in subacute and chronic TBI. <i>Neurology</i> , 2020, 95, e623-e636.	1.5	136
684	Acute necrotizing encephalopathy with SARS-CoV-2 RNA confirmed in cerebrospinal fluid. <i>Neurology</i> , 2020, 95, 445-449.	1.5	194

#	ARTICLE	IF	CITATIONS
685	Earliest amyloid and tau deposition modulate the influence of limbic networks during closed-loop hippocampal downregulation. <i>Brain</i> , 2020, 143, 976-992.	3.7	16
686	Plasma P-tau181 in Alzheimer's disease: relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer's dementia. <i>Nature Medicine</i> , 2020, 26, 379-386.	15.2	643
687	Diagnostic value of plasma phosphorylated tau181 in Alzheimer's disease and frontotemporal lobar degeneration. <i>Nature Medicine</i> , 2020, 26, 387-397.	15.2	471
688	Evaluating predictive markers for viral rebound and safety assessment in blood and lumbar fluid during HIV-1 treatment interruption. <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 1311-1320.	1.3	15
689	Analytical and Clinical Performance of Amyloid-Beta Peptides Measurements in CSF of ADNI/2 Participants by an LC-MS/MS Reference Method. <i>Clinical Chemistry</i> , 2020, 66, 587-597.	1.5	15
690	Accelerated neuronal and synaptic maturation by BrainPhys medium increases A β 2 secretion and alters A β 2 peptide ratios from iPSC-derived cortical neurons. <i>Scientific Reports</i> , 2020, 10, 601.	1.6	26
691	Perspectives in fluid biomarkers in neurodegeneration from the 2019 biomarkers in neurodegenerative diseases course—a joint PhD student course at University College London and University of Gothenburg. <i>Alzheimer's Research and Therapy</i> , 2020, 12, 20.	3.0	32
692	Quantification of total apolipoprotein E and its isoforms in cerebrospinal fluid from patients with neurodegenerative diseases. <i>Alzheimer's Research and Therapy</i> , 2020, 12, 19.	3.0	29
693	Plasma glial fibrillary acidic protein is raised in progranulin-associated frontotemporal dementia. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2020, 91, 263-270.	0.9	106
694	Contribution of CSF biomarkers to early-onset Alzheimer's disease and frontotemporal dementia neuroimaging signatures. <i>Human Brain Mapping</i> , 2020, 41, 2004-2013.	1.9	22
695	Cerebrospinal Fluid Levels of Interleukin-8 in Delirium, Dementia, and Cognitively Healthy Patients. <i>Journal of Alzheimer's Disease</i> , 2020, 73, 1363-1372.	1.2	18
696	Cerebrospinal Fluid YKL-40 and Chitotriosidase Levels in Frontotemporal Dementia Vary by Clinical, Genetic and Pathological Subtype. <i>Dementia and Geriatric Cognitive Disorders</i> , 2020, 49, 56-76.	0.7	27
697	Neurofilament light chain: a specific serum biomarker of axonal damage severity in rat models of Chemotherapy-Induced Peripheral Neurotoxicity. <i>Archives of Toxicology</i> , 2020, 94, 2517-2522.	1.9	43
698	Neurofilament light in former athletes: a potential biomarker of neurodegeneration and progression. <i>European Journal of Neurology</i> , 2020, 27, 1170-1177.	1.7	12
699	Baseline Results: The Association Between Cardiovascular Risk and Preclinical Alzheimer's Disease Pathology (ASCEND) Study. <i>Journal of Alzheimer's Disease</i> , 2020, 75, 109-117.	1.2	15
700	Cerebrospinal Fluid Biomarkers in Cerebral Amyloid Angiopathy. <i>Journal of Alzheimer's Disease</i> , 2020, 74, 1189-1201.	1.2	38
701	A β 2 deposition is associated with increases in soluble and phosphorylated tau that precede a positive Tau PET in Alzheimer's disease. <i>Science Advances</i> , 2020, 6, eaaz2387.	4.7	202
702	An update on blood-based biomarkers for non-Alzheimer neurodegenerative disorders. <i>Nature Reviews Neurology</i> , 2020, 16, 265-284.	4.9	121

#	ARTICLE	IF	CITATIONS
703	Dissecting the Structural Organization of Multiprotein Amyloid Aggregates Using a Bottom-Up Approach. <i>ACS Chemical Neuroscience</i> , 2020, 11, 1447-1457.	1.7	5
704	Blood phosphorylated tau 181 as a biomarker for Alzheimer's disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts. <i>Lancet Neurology</i> , The, 2020, 19, 422-433.	4.9	668
705	Biomarker profiling beyond amyloid and tau: cerebrospinal fluid markers, hippocampal atrophy, and memory change in cognitively unimpaired older adults. <i>Neurobiology of Aging</i> , 2020, 93, 1-15.	1.5	11
706	Cardiac Surgery is Associated with Biomarker Evidence of Neuronal Damage. <i>Journal of Alzheimer's Disease</i> , 2020, 74, 1211-1220.	1.2	22
707	Clinical Phenotyping and Biomarkers in Spinal and Bulbar Muscular Atrophy. <i>Frontiers in Neurology</i> , 2020, 11, 586610.	1.1	4
708	Alzheimer-like pathology in trisomy 21 cerebral organoids amenable to pharmacological inhibition reveals BACE2 as a gene-dose-sensitive AD-suppressor in human brain. <i>Alzheimer's and Dementia</i> , 2020, 16, e043136.	0.4	6
709	Steroid-Responsive Encephalitis in Coronavirus Disease 2019. , 2020, 88, 423.		1
710	Utility of plasma neurofilament light and total tau for clinical trials in Alzheimer's disease. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2020, 12, e12099.	1.2	16
711	Pre-analytical protocol for measuring Alzheimer's disease biomarkers in fresh CSF. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2020, 12, e12137.	1.2	20
712	Genome-wide study of immune biomarkers in cerebrospinal fluid and serum from patients with bipolar disorder and controls. <i>Translational Psychiatry</i> , 2020, 10, 58.	2.4	8
713	Cerebrospinal fluid lipocalin 2 as a novel biomarker for the differential diagnosis of vascular dementia. <i>Nature Communications</i> , 2020, 11, 619.	5.8	67
714	Cognitive impairment without altered levels of cerebrospinal fluid biomarkers in patients with encephalitis caused by varicella-zoster virus: a pilot study. <i>Scientific Reports</i> , 2020, 10, 22400.	1.6	6
715	Pathophysiological subtypes of Alzheimer's disease based on cerebrospinal fluid proteomics. <i>Brain</i> , 2020, 143, 3776-3792.	3.7	89
716	Cognitive and Neuronal Link With Inflammation: A Longitudinal Study in People With and Without HIV Infection. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2020, 85, 617-625.	0.9	19
717	Analysis of neurodegenerative disease-causing genes in dementia with Lewy bodies. <i>Acta Neuropathologica Communications</i> , 2020, 8, 5.	2.4	27
718	Evaluation of a novel immunoassay to detect p-tau Thr217 in the CSF to distinguish Alzheimer disease from other dementias. <i>Neurology</i> , 2020, 95, e3026-e3035.	1.5	31
719	Plasma neurofilament light protein correlates with diffusion tensor imaging metrics in frontotemporal dementia. <i>PLoS ONE</i> , 2020, 15, e0236384.	1.1	23
720	Proteome profiling in cerebrospinal fluid reveals novel biomarkers of Alzheimer's disease. <i>Molecular Systems Biology</i> , 2020, 16, e9356.	3.2	157

#	ARTICLE	IF	CITATIONS
721	Untangling the roles of amyloid and tau in synaptic and axonal loss in the course of Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2020, 16, e043169.	0.4	1
722	Association of plasma neurofilament light chain (pNfL) with neuroimaging markers of neurodegeneration and cerebrovascular disease. <i>Alzheimer's and Dementia</i> , 2020, 16, e043060.	0.4	0
723	White matter microstructure and cerebrospinal fluid biomarkers of Alzheimer's disease in middle-aged cognitively unimpaired participants (the ALFA study). <i>Alzheimer's and Dementia</i> , 2020, 16, e043027.	0.4	0
724	Cerebrospinal fluid soluble CD30 elevation despite suppressive antiretroviral therapy in individuals living with HIV-1. <i>Journal of Virus Eradication</i> , 2020, 6, 19-26.	0.3	3
725	Title is missing!. , 2020, 17, e1003289.		0
726	Title is missing!. , 2020, 17, e1003289.		0
727	Title is missing!. , 2020, 17, e1003289.		0
728	Title is missing!. , 2020, 17, e1003289.		0
729	Title is missing!. , 2020, 17, e1003289.		0
730	Title is missing!. , 2020, 17, e1003289.		0
731	Title is missing!. , 2020, 17, e1003289.		0
732	Cerebrospinal fluid endo-lysosomal proteins as potential biomarkers for Huntington's disease. , 2020, 15, e0233820.		0
733	Cerebrospinal fluid endo-lysosomal proteins as potential biomarkers for Huntington's disease. , 2020, 15, e0233820.		0
734	Cerebrospinal fluid endo-lysosomal proteins as potential biomarkers for Huntington's disease. , 2020, 15, e0233820.		0
735	Cerebrospinal fluid endo-lysosomal proteins as potential biomarkers for Huntington's disease. , 2020, 15, e0233820.		0
736	Title is missing!. , 2020, 15, e0236384.		0
737	Title is missing!. , 2020, 15, e0236384.		0
738	Title is missing!. , 2020, 15, e0236384.		0

#	ARTICLE	IF	CITATIONS
739	Title is missing!. , 2020, 15, e0236384.		0
740	Molecular imaging mass spectrometry for probing protein dynamics in neurodegenerative disease pathology. <i>Journal of Neurochemistry</i> , 2019, 151, 488-506.	2.1	34
741	Antibody-based methods for the measurement of β -synuclein concentration in human cerebrospinal fluid – method comparison and round robin study. <i>Journal of Neurochemistry</i> , 2019, 149, 126-138.	2.1	44
742	Biomarkers for Antidepressant Efficacy of Electroconvulsive Therapy: An Exploratory Cerebrospinal Fluid Study. <i>Neuropsychobiology</i> , 2019, 77, 13-22.	0.9	20
743	Lumbar drains can affect CSF biomarker levels. <i>Journal of Clinical Pathology</i> , 2019, 72, 91-92.	1.0	0
744	Cerebrospinal fluid neurofilament light is associated with survival in mitochondrial disease patients. <i>Mitochondrion</i> , 2019, 46, 228-235.	1.6	10
745	Gene replacement therapy after neuropathy onset provides therapeutic benefit in a model of CMT1X. <i>Human Molecular Genetics</i> , 2019, 28, 3528-3542.	1.4	29
746	The <i>MS4A</i> gene cluster is a key modulator of soluble TREM2 and Alzheimer's disease risk. <i>Science Translational Medicine</i> , 2019, 11, .	5.8	170
747	Cerebrospinal fluid neurofilament light chain predicts disease activity after the first demyelinating event suggestive of multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2019, 35, 228-232.	0.9	20
748	Screening with a high precision blood-based assay for Alzheimer disease. <i>Neurology</i> , 2019, 93, 10.1212/WNL.0000000000008080.	1.5	2
749	Circulating neurofilament light in ischemic stroke: temporal profile and outcome prediction. <i>Journal of Neurology</i> , 2019, 266, 2796-2806.	1.8	49
750	Plasma neurofilament light chain concentration is increased in anorexia nervosa. <i>Translational Psychiatry</i> , 2019, 9, 180.	2.4	26
751	Ultrasensitive Detection of Plasma Amyloid- β^2 as a Biomarker for Cognitively Normal Elderly Individuals at Risk of Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2019, 71, 775-783.	1.2	38
752	Use of the tau protein-to-peptide ratio in CSF to improve diagnostic classification of Alzheimer's disease. <i>Clinical Mass Spectrometry</i> , 2019, 14, 74-82.	1.9	9
753	Plasma tau complements CSF tau and β -tau in the diagnosis of Alzheimer's disease. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2019, 11, 483-492.	1.2	86
754	Characterization of Cerebrospinal Fluid BACE1 Species. <i>Molecular Neurobiology</i> , 2019, 56, 8603-8616.	1.9	4
755	Sex differences in the genetic predictors of Alzheimer's pathology. <i>Brain</i> , 2019, 142, 2581-2589.	3.7	65
756	Soluble aggregates present in cerebrospinal fluid change in size and mechanism of toxicity during Alzheimer's disease progression. <i>Acta Neuropathologica Communications</i> , 2019, 7, 120.	2.4	64

#	ARTICLE	IF	CITATIONS
757	A tear fluid proteome of Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2019, 63, 1-2.	1.1	1
758	Evolution and clustering of prodromal parkinsonian features in <i>GBA1</i> carriers. <i>Movement Disorders</i> , 2019, 34, 1365-1373.	2.2	33
759	Sex difference in <i>CHI3L1</i> expression levels in human brain aging and in Alzheimer's disease. <i>Brain Research</i> , 2019, 1720, 146305.	1.1	34
760	Comparison of different MRI-based morphometric estimates for defining neurodegeneration across the Alzheimer's disease continuum. <i>NeuroImage: Clinical</i> , 2019, 23, 101895.	1.4	28
761	Correlations between serum and CSF pNfH levels in ALS, FTD and controls: a comparison of three analytical approaches. <i>Clinical Chemistry and Laboratory Medicine</i> , 2019, 57, 1556-1564.	1.4	32
762	Amyloid precursor protein processing in human neurons with an allelic series of the <i>PSEN1</i> intron 4 deletion mutation and total presenilin-1 knockout. <i>Brain Communications</i> , 2019, 1, fcz024.	1.5	13
763	Chemometric Strategies for Sensitive Annotation and Validation of Anatomical Regions of Interest in Complex Imaging Mass Spectrometry Data. <i>Journal of the American Society for Mass Spectrometry</i> , 2019, 30, 2278-2288.	1.2	11
764	Enhanced xeno-free differentiation of hiPSC-derived astroglia applied in a blood-brain barrier model. <i>Fluids and Barriers of the CNS</i> , 2019, 16, 27.	2.4	8
765	Plasma neurofilament light chain and amyloid- β are associated with the kynurenine pathway metabolites in preclinical Alzheimer's disease. <i>Journal of Neuroinflammation</i> , 2019, 16, 186.	3.1	41
766	Autocatalytic amplification of Alzheimer-associated A β 242 peptide aggregation in human cerebrospinal fluid. <i>Communications Biology</i> , 2019, 2, 365.	2.0	46
767	Cerebrospinal Fluid Changes in the Renin-Angiotensin System in Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2019, 72, 525-535.	1.2	16
768	Comparison of variables associated with cerebrospinal fluid neurofilament, total tau, and neurogranin. <i>Alzheimer's and Dementia</i> , 2019, 15, 1437-1447.	0.4	38
769	Cerebrospinal fluid and plasma biomarker trajectories with increasing amyloid deposition in Alzheimer's disease. <i>EMBO Molecular Medicine</i> , 2019, 11, e11170.	3.3	228
770	Detection of early-stage Alzheimer's pathology using blood-based autoantibody biomarkers in elderly hip fracture repair patients. <i>PLoS ONE</i> , 2019, 14, e0225178.	1.1	12
771	Cerebrospinal fluid and plasma neurofilament light relate to abnormal cognition. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2019, 11, 700-709.	1.2	35
772	Plasma neurofilament light chain concentration is increased and correlates with the severity of neuropathy in hereditary transthyretin amyloidosis. <i>Journal of the Peripheral Nervous System</i> , 2019, 24, 314-319.	1.4	46
773	Increased plasma neurofilament light chain concentration correlates with severity of post-mortem neurofibrillary tangle pathology and neurodegeneration. <i>Acta Neuropathologica Communications</i> , 2019, 7, 5.	2.4	125
774	In vivo detection of cerebral tau pathology in long-term survivors of traumatic brain injury. <i>Science Translational Medicine</i> , 2019, 11, .	5.8	56

#	ARTICLE	IF	CITATIONS
775	Growth factors and neurotrophins in patients with stress-related exhaustion disorder. <i>Psychoneuroendocrinology</i> , 2019, 109, 104415.	1.3	15
776	Discovery and validation of plasma proteomic biomarkers relating to brain amyloid burden by SOMAscan assay. <i>Alzheimer's and Dementia</i> , 2019, 15, 1478-1488.	0.4	46
777	Study protocol: ASCRIBED: the impact of Acute Systematic inflammation upon cerebrospinal fluid and blood Biomarkers of brain inflammation and injury in dementia: a study in acute hip fracture patients. <i>BMC Neurology</i> , 2019, 19, 223.	0.8	5
778	Biomarker-guided clustering of Alzheimer's disease clinical syndromes. <i>Neurobiology of Aging</i> , 2019, 83, 42-53.	1.5	48
779	Endo-lysosomal proteins and ubiquitin CSF concentrations in Alzheimer's and Parkinson's disease. <i>Alzheimer's Research and Therapy</i> , 2019, 11, 82.	3.0	51
780	CSF evidence of pericyte damage in Alzheimer's disease is associated with markers of blood-brain barrier dysfunction and disease pathology. <i>Alzheimer's Research and Therapy</i> , 2019, 11, 81.	3.0	72
781	Adverse Vascular Risk Relates to Cerebrospinal Fluid Biomarker Evidence of Axonal Injury in the Presence of Alzheimer's Disease Pathology. <i>Journal of Alzheimer's Disease</i> , 2019, 71, 281-290.	1.2	7
782	Plasma neurofilament light associates with Alzheimer's disease metabolic decline in amyloid-positive individuals. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2019, 11, 679-689.	1.2	48
783	Switching from a regimen containing abacavir/lamivudine or emtricitabine/tenofovir disoproxil fumarate to emtricitabine/tenofovir alafenamide fumarate does not affect central nervous system HIV-1 infection. <i>Infectious Diseases</i> , 2019, 51, 838-846.	1.4	7
784	Leptin deficiency reverses high metabolic state and weight loss without affecting central pathology in the R6/2 mouse model of Huntington's disease. <i>Neurobiology of Disease</i> , 2019, 132, 104560.	2.1	14
785	NFL blood levels are moderated by subconcussive impacts in a cohort of college football players. <i>Brain Injury</i> , 2019, 33, 456-462.	0.6	50
786	The prognostic value of neurofilament levels in patients with sepsis-associated encephalopathy – A prospective, pilot observational study. <i>PLoS ONE</i> , 2019, 14, e0211184.	1.1	64
787	Cerebrospinal fluid levels of glial marker YKL-40 strongly associated with axonal injury in HIV infection. <i>Journal of Neuroinflammation</i> , 2019, 16, 16.	3.1	22
788	Head trauma in sports and risk for dementia. <i>Journal of Internal Medicine</i> , 2019, 285, 591-593.	2.7	3
789	A nonsynonymous mutation in PLCG2 reduces the risk of Alzheimer's disease, dementia with Lewy bodies and frontotemporal dementia, and increases the likelihood of longevity. <i>Acta Neuropathologica</i> , 2019, 138, 237-250.	3.9	87
790	Diagnostic Value of Cerebrospinal Fluid Neurofilament Light Protein in Neurology. <i>JAMA Neurology</i> , 2019, 76, 1035.	4.5	455
791	SILK studies – capturing the turnover of proteins linked to neurodegenerative diseases. <i>Nature Reviews Neurology</i> , 2019, 15, 419-427.	4.9	37
792	Performance of Fully Automated Plasma Assays as Screening Tests for Alzheimer Disease-Related β -Amyloid Status. <i>JAMA Neurology</i> , 2019, 76, 1060.	4.5	282

#	ARTICLE	IF	CITATIONS
793	CSF biomarkers distinguish idiopathic normal pressure hydrocephalus from its mimics. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2019, 90, 1117-1123.	0.9	61
794	NFL is a marker of treatment response in children with SMA treated with nusinersen. <i>Journal of Neurology</i> , 2019, 266, 2129-2136.	1.8	104
795	Cerebrospinal fluid neurofilament light chain tracks cognitive impairment in multiple sclerosis. <i>Journal of Neurology</i> , 2019, 266, 2157-2163.	1.8	41
796	Longstanding psychological stress in relation to biomarkers of neuronal dysfunction in cerebrospinal fluid: a 25-year follow-up study in women. <i>Neurobiology of Aging</i> , 2019, 80, 111-115.	1.5	6
797	Serum Neurofilament Light Chain Concentration Correlates with Infarct Volume but Not Prognosis in Acute Ischemic Stroke. <i>Journal of Stroke and Cerebrovascular Diseases</i> , 2019, 28, 2242-2249.	0.7	40
798	Duration of preclinical, prodromal, and dementia stages of Alzheimer's disease in relation to age, sex, and <i>APOE</i> genotype. <i>Alzheimer's and Dementia</i> , 2019, 15, 888-898.	0.4	290
799	Disease signatures: Biomarkers/indicators of neurodegeneration. <i>Molecular and Cellular Neurosciences</i> , 2019, 97, 1-2.	1.0	1
800	Plasma and CSF neurofilament light. <i>Neurology</i> , 2019, 93, e252-e260.	1.5	160
801	<i>PDXK</i> mutations cause polyneuropathy responsive to pyridoxal 5-phosphate supplementation. <i>Annals of Neurology</i> , 2019, 86, 225-240.	2.8	54
802	Cerebrospinal Fluid Concentrations of Extracellular Matrix Proteins in Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2019, 69, 1213-1220.	1.2	12
803	Breaking the cycle. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2019, 6, e562.	3.1	12
804	Association of Blood and Cerebrospinal Fluid Tau Level and Other Biomarkers With Survival Time in Sporadic Creutzfeldt-Jakob Disease. <i>JAMA Neurology</i> , 2019, 76, 969.	4.5	65
805	Primary fatty amides in plasma associated with brain amyloid burden, hippocampal volume, and memory in the European Medical Information Framework for Alzheimer's Disease biomarker discovery cohort. <i>Alzheimer's and Dementia</i> , 2019, 15, 817-827.	0.4	62
806	Plasma amyloid β 40/42 ratio predicts cerebral amyloidosis in cognitively normal individuals at risk for Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2019, 15, 764-775.	0.4	122
807	Erlangen Score Predicts Cognitive and Neuroimaging Progression in Mild Cognitive Impairment Stage of Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2019, 69, 551-559.	1.2	6
808	Reduced vascular endothelial growth factor levels in the cerebrospinal fluid in patients with treatment resistant major depression and the effects of electroconvulsive therapy – A pilot study. <i>Journal of Affective Disorders</i> , 2019, 253, 449-453.	2.0	17
809	A Serum Protein Biomarker Panel Improves Outcome Prediction in Human Traumatic Brain Injury. <i>Journal of Neurotrauma</i> , 2019, 36, 2850-2862.	1.7	129
810	CSF neurogranin as a neuronal damage marker in CJD: a comparative study with AD. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2019, 90, 846-853.	0.9	46

#	ARTICLE	IF	CITATIONS
811	Differential effects of neurodegeneration biomarkers on subclinical cognitive decline. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2019, 5, 129-138.	1.8	22
812	Advantages and disadvantages of the use of the CSF Amyloid β^2 ($A\beta^2$) 42/40 ratio in the diagnosis of Alzheimer's Disease. <i>Alzheimer's Research and Therapy</i> , 2019, 11, 34.	3.0	325
813	Exercise as a potential modulator of inflammation in patients with Alzheimer's disease measured in cerebrospinal fluid and plasma. <i>Experimental Gerontology</i> , 2019, 121, 91-98.	1.2	72
814	Association Between Longitudinal Plasma Neurofilament Light and Neurodegeneration in Patients With Alzheimer Disease. <i>JAMA Neurology</i> , 2019, 76, 791.	4.5	436
815	Identification of neurotoxic cross-linked amyloid- β^2 dimers in the Alzheimer's brain. <i>Brain</i> , 2019, 142, 1441-1457.	3.7	74
816	Inflammatory biomarkers in Alzheimer's disease plasma. <i>Alzheimer's and Dementia</i> , 2019, 15, 776-787.	0.4	134
817	The Cerebrospinal Fluid in Multiple Sclerosis. <i>Frontiers in Immunology</i> , 2019, 10, 726.	2.2	107
818	Serum tau fragments as predictors of death or poor neurological outcome after out-of-hospital cardiac arrest. <i>Biomarkers</i> , 2019, 24, 584-591.	0.9	3
819	Atrial fibrillation increases the risk of dementia amongst older adults even in the absence of stroke. <i>Journal of Internal Medicine</i> , 2019, 286, 101-110.	2.7	23
820	Centiloid cut-off values for optimal agreement between PET and CSF core AD biomarkers. <i>Alzheimer's Research and Therapy</i> , 2019, 11, 27.	3.0	82
821	Development of parallel reaction monitoring assays for cerebrospinal fluid proteins associated with Alzheimer's disease. <i>Clinica Chimica Acta</i> , 2019, 494, 79-93.	0.5	30
822	Proximity extension assay testing reveals novel diagnostic biomarkers of atypical parkinsonian syndromes. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2019, 90, 768-773.	0.9	29
823	Serum Neurofilament Light Is Elevated Differentially in Older Adults with Uncomplicated Mild Traumatic Brain Injuries. <i>Journal of Neurotrauma</i> , 2019, 36, 2400-2406.	1.7	27
824	Gene replacement therapy in a model of Charcot-Marie-Tooth 4C neuropathy. <i>Brain</i> , 2019, 142, 1227-1241.	3.7	43
825	Plasma biomarkers for amyloid, tau, and cytokines in Down syndrome and sporadic Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2019, 11, 26.	3.0	56
826	Cerebrospinal fluid biomarkers of neurodegeneration, synaptic integrity, and astroglial activation across the clinical Alzheimer's disease spectrum. <i>Alzheimer's and Dementia</i> , 2019, 15, 644-654.	0.4	90
827	Ionized calcium in human cerebrospinal fluid and its influence on intrinsic and synaptic excitability of hippocampal pyramidal neurons in the rat. <i>Journal of Neurochemistry</i> , 2019, 149, 452-470.	2.1	35
828	Cerebrospinal Fluid Spermidine, Glutamine and Putrescine Predict Postoperative Delirium Following Elective Orthopaedic Surgery. <i>Scientific Reports</i> , 2019, 9, 4191.	1.6	17

#	ARTICLE	IF	CITATIONS
829	<i>KLOTHO</i> heterozygosity attenuates <i>APOE4</i>-related amyloid burden in preclinical AD. <i>Neurology</i> , 2019, 92, e1878-e1889.	1.5	40
830	Longitudinal cerebrospinal fluid biomarker trajectories along the Alzheimer's disease continuum in the BIOMARKAPD study. <i>Alzheimer's and Dementia</i> , 2019, 15, 742-753.	0.4	82
831	Correlation between plasma and CSF concentrations of kynurenine pathway metabolites in Alzheimer's disease and relationship to amyloid- β and tau. <i>Neurobiology of Aging</i> , 2019, 80, 11-20.	1.5	80
832	Neurofilament light chain as a biomarker in neurological disorders. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2019, 90, 870-881.	0.9	623
833	Amyloid β 42 and Total Tau Levels in Cerebrospinal Fluid Associate with Survival in an 85-Year-Old Population-Based Cohort Followed until Death. <i>Dementia and Geriatric Cognitive Disorders</i> , 2019, 47, 114-124.	0.7	3
834	Dynamics of extracellular matrix proteins in cerebrospinal fluid and serum and their relation to clinical outcome in human traumatic brain injury. <i>Clinical Chemistry and Laboratory Medicine</i> , 2019, 57, 1565-1573.	1.4	11
835	Searching for novel cerebrospinal fluid biomarkers of tau pathology in frontotemporal dementia: an elusive quest. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2019, 90, 740-746.	0.9	23
836	Cardiorespiratory Fitness Modifies Influence of Sleep Problems on Cerebrospinal Fluid Biomarkers in an At-Risk Cohort. <i>Journal of Alzheimer's Disease</i> , 2019, 69, 111-121.	1.2	8
837	Blood-based molecular biomarkers for Alzheimer's disease. <i>Molecular Brain</i> , 2019, 12, 26.	1.3	180
838	APOE ϵ 4 and the long arm of social inequity: estimated effects of socio-economic status and sex on the timing of dementia onset. <i>Ageing and Society</i> , 2019, 39, 1951-1975.	1.2	6
839	Prion protein quantification in human cerebrospinal fluid as a tool for prion disease drug development. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 7793-7798.	3.3	41
840	Relevance of the interplay between amyloid and tau for cognitive impairment in early Alzheimer's disease. <i>Neurobiology of Aging</i> , 2019, 79, 131-141.	1.5	23
841	Mass Spectrometric Analysis of Lewy Body-Enriched α -Synuclein in Parkinson's Disease. <i>Journal of Proteome Research</i> , 2019, 18, 2109-2120.	1.8	49
842	Heritability and genetic variance of dementia with Lewy bodies. <i>Neurobiology of Disease</i> , 2019, 127, 492-501.	2.1	29
843	Association of IL1RAP-related genetic variation with cerebrospinal fluid concentration of Alzheimer-associated tau protein. <i>Scientific Reports</i> , 2019, 9, 2460.	1.6	7
844	Muscle and not neuronal biomarkers correlate with severity in spinal and bulbar muscular atrophy. <i>Neurology</i> , 2019, 92, e1205-e1211.	1.5	41
845	Biomarkers for Concussion: The Need and the Prospects for the Near Future. , 2019, , 638-645.		0
846	Increased Secondary Nucleation Underlies Accelerated Aggregation of the Four-Residue N-Terminally Truncated A β 42 Species A β 42 ⁵⁴⁻⁴² . <i>ACS Chemical Neuroscience</i> , 2019, 10, 2374-2384.	1.7	16

#	ARTICLE	IF	CITATIONS
847	Longitudinal measurement of serum neurofilament light in presymptomatic familial Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2019, 11, 19.	3.0	65
848	Synaptic vesicle protein 2A as a potential biomarker in synaptopathies. <i>Molecular and Cellular Neurosciences</i> , 2019, 97, 34-42.	1.0	55
849	Sleep oscillation-specific associations with Alzheimer's disease CSF biomarkers: novel roles for sleep spindles and tau. <i>Molecular Neurodegeneration</i> , 2019, 14, 10.	4.4	61
850	Biomarkers for Alzheimer's disease beyond amyloid and tau. <i>Nature Medicine</i> , 2019, 25, 201-203.	15.2	34
851	Cardiomyopathy with lethal arrhythmias associated with inactivation of KLHL24. <i>Human Molecular Genetics</i> , 2019, 28, 1919-1929.	1.4	35
852	A plasma protein classifier for predicting amyloid burden for preclinical Alzheimer's disease. <i>Science Advances</i> , 2019, 5, eaau7220.	4.7	59
853	Neurogranin as a potential synaptic marker in the cerebrospinal fluid of patients with a first episode psychosis. <i>Schizophrenia Research</i> , 2019, 208, 490-492.	1.1	5
854	Cerebrospinal fluid biomarkers for understanding multiple aspects of Alzheimer's disease pathogenesis. <i>Cellular and Molecular Life Sciences</i> , 2019, 76, 1833-1863.	2.4	75
855	Detection of Î±-Synuclein in Biological Samples Using Mass Spectrometry. <i>Methods in Molecular Biology</i> , 2019, 1948, 209-220.	0.4	4
856	Measuring longitudinal cognition: Individual tests versus composites. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2019, 11, 74-84.	1.2	69
857	Sleep deprivation and plasma biomarkers for Alzheimer's disease. <i>Sleep Medicine</i> , 2019, 57, 92-93.	0.8	8
858	Comparison of plasma and cerebrospinal fluid neurofilament light in a multiple sclerosis trial. <i>Acta Neurologica Scandinavica</i> , 2019, 139, 462-468.	1.0	21
859	Peptidomic analysis of cartilage and subchondral bone in OA patients. <i>European Journal of Clinical Investigation</i> , 2019, 49, e13082.	1.7	6
860	A distinct brain beta amyloid signature in cerebral amyloid angiopathy compared to Alzheimer's disease. <i>Neuroscience Letters</i> , 2019, 701, 125-131.	1.0	43
861	Pyroglutamation of amyloid-Î² _{x-42} (AÎ² _{x-42}) followed by AÎ² ₁₋₄₀ deposition underlies plaque polymorphism in progressing Alzheimer's disease pathology. <i>Journal of Biological Chemistry</i> , 2019, 294, 6719-6732.	1.6	49
862	Correlation of Blood Biomarkers and Biomarker Panels with Traumatic Findings on Computed Tomography after Traumatic Brain Injury. <i>Journal of Neurotrauma</i> , 2019, 36, 2178-2189.	1.7	56
863	P4â€¦531: CEREBROSPINAL FLUID APOLIPOPROTEIN E ISOFORM CONCENTRATIONS IN RELATION TO Î²â€¦AMYLOID POSITIVITY. <i>Alzheimer's and Dementia</i> , 2019, 15, P1517.	0.4	0
864	P4â€¦546: THE NEURAL CELL ADHESION PROTEIN NEUROLIGIN 1 IN ALZHEIMER'S DISEASE. <i>Alzheimer's and Dementia</i> , 2019, 15, P1526.	0.4	0

#	ARTICLE	IF	CITATIONS
865	P4â€579: LOWER NEURITE DENSITY AND ORIENTATION DISPERSION WITHIN GRAY AND WHITE MATTER IN THE ALZHEIMER'S DISEASE PATHOLOGIC FRAMEWORK. <i>Alzheimer's and Dementia</i> , 2019, 15, P1542.	0.4	0
866	CSF synaptic protein concentrations are raised in those with atypical Alzheimerâ€™s disease but not frontotemporal dementia. <i>Alzheimer's Research and Therapy</i> , 2019, 11, 105.	3.0	31
867	P4â€573: PROXIMITY TO PARENTAL ONSET AND <i>APOE</i> Î¼4 INDEPENDENTLY CONTRIBUTE TO AMYLOID BURDEN IN MIDDLE-AGED ADULTS WITH A FAMILY HISTORY OF SPORADIC ALZHEIMER'S DISEASE. <i>Alzheimer's and Dementia</i> , 2019, 15, P1539.	0.4	0
868	P4â€525: ASSOCIATION OF CSF TAU WITH HYPERPLASTICITY IN ALZHEIMER'S DISEASE. <i>Alzheimer's and Dementia</i> , 2019, 15, P1515.	0.4	0
869	O3â€02â€01: APOE Î¼4 ALLELIC LOAD MODULATES THE ASSOCIATION BETWEEN CSF BETA-AMYLOID AND GRAY MATTER VOLUME IN COGNITIVELY UNIMPAIRED INDIVIDUALS. <i>Alzheimer's and Dementia</i> , 2019, 15, P877.	0.4	0
870	F4â€05â€01: ASSOCIATIONS BETWEEN PLASMA NFL AND BRAIN PET IN ALZHEIMER'S DISEASE. <i>Alzheimer's and Dementia</i> , 2019, 15, P1224.	0.4	0
871	P4â€473: A NOVEL MASS SPECTROMETRIC METHOD FOR THE ABSOLUTE QUANTIFICATION OF SIX AÎ² PEPTIDES IN HUMAN CEREBROSPINAL FLUID. <i>Alzheimer's and Dementia</i> , 2019, 15, P1492.	0.4	0
872	P4â€535: PRESENTATION OF A ROUTINE-USE PREANALYTICAL PROCEDURE FOR AD CSF BIOMARKERS. <i>Alzheimer's and Dementia</i> , 2019, 15, P1520.	0.4	0
873	O2â€02â€01: DIFFERENT CSF TOTAL AND PHOSPHORYLATED TAU, BUT NOT AÎ², IN OLDER AND YOUNGER AFRICAN AMERICANS AND WHITES. <i>Alzheimer's and Dementia</i> , 2019, 15, P535.	0.4	0
874	P4â€589: COMPARISON OF CEREBROSPINAL FLUID NEUROFILAMENT LIGHT CHAIN PROTEIN AND THREE MRI-BASED MORPHOMETRIC ESTIMATES FOR DEFINING NEURODEGENERATION (N) ACROSS THE ALZHEIMER'S DISEASE CONTINUUM. <i>Alzheimer's and Dementia</i> , 2019, 15, P1547.	0.4	0
875	O2â€05â€01: CEREBROSPINAL FLUID SYNAPTIC VESICLE GLYCOPROTEIN 2A IN ALZHEIMER'S DISEASE. <i>Alzheimer's and Dementia</i> , 2019, 15, P545.	0.4	2
876	ICâ€Pâ€093: PLASMA AMYLOID-BETA AND TAU AND VISUAL CONTRAST SENSITIVITY SYNERGISTICALLY PREDICT CEREBRAL AMYLOID AND TAU DEPOSITION ON PET IN PRECLINICAL AND PRODROMAL AD. <i>Alzheimer's and Dementia</i> , 2019, 15, P82.	0.4	0
877	Complement component 3 levels in the cerebrospinal fluid of cognitively intact elderly individuals with major depressive disorder. <i>Biomarkers in Neuropsychiatry</i> , 2019, 1, 100007.	0.7	10
878	P4â€519: MOLECULAR FORMS OF NEUROGRANIN IN CEREBROSPINAL FLUID. <i>Alzheimer's and Dementia</i> , 2019, 15, P1513.	0.4	0
879	ICâ€Pâ€070: ASSOCIATIONS BETWEEN PLASMA NFL AND BRAIN PET IN THE ALZHEIMER'S DISEASE. <i>Alzheimer's and Dementia</i> , 2019, 15, P64.	0.4	1
880	ICâ€Pâ€071: ASSOCIATIONS BETWEEN PLASMA NFL AND BRAIN ATROPHY IN ALZHEIMER'S DISEASE. <i>Alzheimer's and Dementia</i> , 2019, 15, P65.	0.4	0
881	ICâ€Pâ€072: LONGITUDINAL ASSOCIATIONS BETWEEN PLASMA NFL AND VOXEL-BASED MORPHOMETRY IN ALZHEIMER'S DISEASE. <i>Alzheimer's and Dementia</i> , 2019, 15, P66.	0.4	0
882	A metabolite-based machine learning approach to diagnose Alzheimerâ€™s type dementia in blood: Results from the European Medical Information Framework for Alzheimer disease biomarker discovery cohort. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2019, 5, 933-938.	1.8	70

#	ARTICLE	IF	CITATIONS
883	ICâ€15: VOXELâ€BASED AMYLOID PET STAGING FOR THE WHOLE ALZHEIMER'S DISEASE <i>CONTINUUM</i>. Alzheimer's and Dementia, 2019, 15, P24.	0.4	0
884	Plasma levels of soluble TREM2 and neurofilament light chain in TREM2 rare variant carriers. Alzheimer's Research and Therapy, 2019, 11, 94.	3.0	20
885	Fluid biomarker-based molecular phenotyping of Alzheimer's disease patients in research and clinical settings. Progress in Molecular Biology and Translational Science, 2019, 168, 3-23.	0.9	28
886	Bloodâ€based biomarkers for Alzheimer's disease and related dementias: Keys to success and things to consider. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2019, 11, 784-786.	1.2	1
887	Cerebrospinal fluid growth-associated protein 43 in multiple sclerosis. Scientific Reports, 2019, 9, 17309.	1.6	5
888	Resistance to autosomal dominant Alzheimerâ€™s disease in an APOE3 Christchurch homozygote: a case report. Nature Medicine, 2019, 25, 1680-1683.	15.2	328
889	Neurofilaments in blood is a new promising preclinical biomarker for the screening of natural scrapie in sheep. PLoS ONE, 2019, 14, e0226697.	1.1	17
890	Repeated lumbar punctures within 3â€days may affect CSF biomarker levels. Fluids and Barriers of the CNS, 2019, 16, 37.	2.4	8
891	White matter hyperintensities in progranulin-associated frontotemporal dementia: A longitudinal GENFI study. NeuroImage: Clinical, 2019, 24, 102077.	1.4	27
892	Salivary Biomarkers for Alzheimerâ€™s Disease and Related Disorders. Neurology and Therapy, 2019, 8, 83-94.	1.4	54
893	Plasma concentration of neurofilament light chain protein decreases after switching from tenofovir disoproxil fumarate to tenofovir alafenamide fumarate. PLoS ONE, 2019, 14, e0226276.	1.1	14
894	Fluid and PET biomarkers for amyloid pathology in Alzheimer's disease. Molecular and Cellular Neurosciences, 2019, 97, 3-17.	1.0	82
895	Perspectives on ethnic and racial disparities in Alzheimer's disease and related dementias: Update and areas of immediate need. Alzheimer's and Dementia, 2019, 15, 292-312.	0.4	310
896	Decreased circulating ErbB4 ectodomain fragments as a read-out of impaired signaling function in amyotrophic lateral sclerosis. Neurobiology of Disease, 2019, 124, 428-438.	2.1	11
897	Neurofilament changes in serum and cerebrospinal fluid after acute ischemic stroke. Neuroscience Letters, 2019, 698, 58-63.	1.0	57
898	HOTMAQ: A Multiplexed Absolute Quantification Method for Targeted Proteomics. Analytical Chemistry, 2019, 91, 2112-2119.	3.2	15
899	The Gothenburg H70 Birth cohort study 2014â€16: design, methods and study population. European Journal of Epidemiology, 2019, 34, 191-209.	2.5	89
900	Head trauma in sports â€ clinical characteristics, epidemiology and biomarkers. Journal of Internal Medicine, 2019, 285, 624-634.	2.7	39

#	ARTICLE	IF	CITATIONS
901	Association of Cerebrospinal Fluid Neurofilament Light Protein With Risk of Mild Cognitive Impairment Among Individuals Without Cognitive Impairment. <i>JAMA Neurology</i> , 2019, 76, 187.	4.5	66
902	Learnings about the complexity of extracellular tau aid development of a blood-based screen for Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2019, 15, 487-496.	0.4	94
903	The recency ratio is related to CSF amyloid beta 1-42 levels in MCI-AD. <i>International Journal of Geriatric Psychiatry</i> , 2019, 34, 415-419.	1.3	12
904	Review: Fluid biomarkers for frontotemporal dementias. <i>Neuropathology and Applied Neurobiology</i> , 2019, 45, 81-87.	1.8	35
905	Cerebrospinal Fluid Concentrations of the Synaptic Marker Neurogranin in Neuro-HIV and Other Neurological Disorders. <i>Current HIV/AIDS Reports</i> , 2019, 16, 76-81.	1.1	9
906	Longitudinal tau and metabolic PET imaging in relation to novel CSF tau measures in Alzheimer's disease. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 1152-1163.	3.3	30
907	Functional network resilience to pathology in presymptomatic genetic frontotemporal dementia. <i>Neurobiology of Aging</i> , 2019, 77, 169-177.	1.5	47
908	Serum neurofilament light and prediction of multiple sclerosis in clinically isolated syndrome. <i>Neurology</i> , 2019, 92, 313-314.	1.5	3
909	Improved Differential Diagnosis of Alzheimer's Disease by Integrating ELISA and Mass Spectrometry-Based Cerebrospinal Fluid Biomarkers. <i>Journal of Alzheimer's Disease</i> , 2019, 67, 639-651.	1.2	32
910	Blood-based biomarkers for Alzheimer's disease—An update. <i>Journal of Neuroscience Methods</i> , 2019, 319, 2-6.	1.3	87
911	Accurate risk estimation of β -amyloid positivity to identify prodromal Alzheimer's disease: Cross-validation study of practical algorithms. <i>Alzheimer's and Dementia</i> , 2019, 15, 194-204.	0.4	49
912	A comprehensive screening of copy number variability in dementia with Lewy bodies. <i>Neurobiology of Aging</i> , 2019, 75, 223.e1-223.e10.	1.5	13
913	Serum Neurofilament Light Chain for Prognosis of Outcome After Cardiac Arrest. <i>JAMA Neurology</i> , 2019, 76, 64.	4.5	158
914	Elevated CSF GAP43 is Alzheimer's disease specific and associated with tau and amyloid pathology. <i>Alzheimer's and Dementia</i> , 2019, 15, 55-64.	0.4	97
915	Vitamin D supplementation and neurofilament light chain in multiple sclerosis. <i>Acta Neurologica Scandinavica</i> , 2019, 139, 172-176.	1.0	18
916	Biomarkers for tau pathology. <i>Molecular and Cellular Neurosciences</i> , 2019, 97, 18-33.	1.0	163
917	Cerebrospinal fluid biomarkers of neurofibrillary tangles and synaptic dysfunction are associated with longitudinal decline in white matter connectivity: A multi-resolution graph analysis. <i>NeuroImage: Clinical</i> , 2019, 21, 101586.	1.4	24
918	Novel tau fragments in cerebrospinal fluid: relation to tangle pathology and cognitive decline in Alzheimer's disease. <i>Acta Neuropathologica</i> , 2019, 137, 279-296.	3.9	128

#	ARTICLE	IF	CITATIONS
919	The 12-Word Philadelphia Verbal Learning Test Performances in Older Adults: Brain MRI and Cerebrospinal Fluid Correlates and Regression-Based Normative Data. <i>Dementia and Geriatric Cognitive Disorders Extra</i> , 2019, 8, 476-491.	0.6	7
920	Early Levels of Glial Fibrillary Acidic Protein and Neurofilament Light Protein in Predicting the Outcome of Mild Traumatic Brain Injury. <i>Journal of Neurotrauma</i> , 2019, 36, 1551-1560.	1.7	56
921	CSF concentrations of soluble TREM2 as a marker of microglial activation in HIV-1 infection. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2019, 6, e512.	3.1	50
922	Association of Cerebrospinal Fluid Neurofilament Light Protein Levels With Cognition in Patients With Dementia, Motor Neuron Disease, and Movement Disorders. <i>JAMA Neurology</i> , 2019, 76, 318.	4.5	161
923	A Novel ELISA for the Measurement of Cerebrospinal Fluid SNAP-25 in Patients with Alzheimer's Disease. <i>Neuroscience</i> , 2019, 420, 136-144.	1.1	25
924	Fluid-based proteomics targeted on pathophysiological processes and pathologies in neurodegenerative diseases. <i>Journal of Neurochemistry</i> , 2019, 151, 417-434.	2.1	15
925	The intact postsynaptic protein neurogranin is reduced in brain tissue from patients with familial and sporadic Alzheimer's disease. <i>Acta Neuropathologica</i> , 2019, 137, 89-102.	3.9	64
926	Parkinson's disease: evolution of cognitive impairment and CSF A β 42 profiles in a prospective longitudinal study. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2019, 90, 165-170.	0.9	14
927	GM1 locates to mature amyloid structures implicating a prominent role for glycolipid-protein interactions in Alzheimer pathology. <i>Biochimica Et Biophysica Acta - Proteins and Proteomics</i> , 2019, 1867, 458-467.	1.1	30
928	CSF Beta-amyloid 42 Concentration Predicts Delirium Following Elective Arthroplasty Surgery in an Observational Cohort Study. <i>Annals of Surgery</i> , 2019, 269, 1200-1205.	2.1	56
929	Association of longitudinal white matter degeneration and cerebrospinal fluid biomarkers of neurodegeneration, inflammation and Alzheimer's disease in late-middle-aged adults. <i>Brain Imaging and Behavior</i> , 2019, 13, 41-52.	1.1	32
930	Serum Neurofilament Light, Glial Fibrillary Acidic Protein and Tau Are Possible Serum Biomarkers for Activity of Brain Metastases and Gliomas. <i>World Journal of Oncology</i> , 2019, 10, 169-175.	0.6	28
931	Serum tau concentration after diving – an observational pilot study. <i>Diving and Hyperbaric Medicine</i> , 2019, 49, 88-95.	0.2	5
932	A case series on the value of tau and neurofilament protein levels to predict and detect delirium in cardiac surgery patients. <i>Biomedical Papers of the Medical Faculty of the University Palacky&#x0301;, Olomouc, Czechoslovakia</i> , 2019, 163, 241-246.	0.2	23
933	Title is missing!. , 2019, 14, e0226276.		0
934	Title is missing!. , 2019, 14, e0226276.		0
935	Title is missing!. , 2019, 14, e0226276.		0
936	Title is missing!. , 2019, 14, e0226276.		0

#	ARTICLE	IF	CITATIONS
937	Moderate intensity physical activity associates with CSF biomarkers in a cohort at risk for Alzheimer's disease. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2018, 10, 188-195.	1.2	51
938	Structural Brain Abnormalities in Successfully Treated HIV Infection: Associations With Disease and Cerebrospinal Fluid Biomarkers. <i>Journal of Infectious Diseases</i> , 2018, 217, 69-81.	1.9	40
939	Induction of Amyloid- β 242 Production by Fipronil and Other Pyrazole Insecticides. <i>Journal of Alzheimer's Disease</i> , 2018, 62, 1663-1681.	1.2	23
940	Age-accelerated cognitive decline in asymptomatic adults with CSF β -amyloid. <i>Neurology</i> , 2018, 90, e1306-e1315.	1.5	42
941	Neurogranin as Cerebrospinal Fluid Biomarker for Alzheimer Disease: An Assay Comparison Study. <i>Clinical Chemistry</i> , 2018, 64, 927-937.	1.5	37
942	Neurofilament light chain and tau concentrations are markedly increased in the serum of patients with sporadic Creutzfeldt-Jakob disease, and tau correlates with rate of disease progression. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2018, 89, 955-961.	0.9	68
943	CSF biomarkers of Alzheimer's disease concord with amyloid- β PET and predict clinical progression: A study of fully automated immunoassays in BioFINDER and ADNI cohorts. <i>Alzheimer's and Dementia</i> , 2018, 14, 1470-1481.	0.4	468
944	Sulfatide isoform pattern in cerebrospinal fluid discriminates progressive β -MS from relapsing-remitting β -MS. <i>Journal of Neurochemistry</i> , 2018, 146, 322-332.	2.1	14
945	Low Cerebrospinal Fluid β 242 and β 40 are Related to White Matter Lesions in Cognitively Normal Elderly. <i>Journal of Alzheimer's Disease</i> , 2018, 62, 1877-1886.	1.2	13
946	Neurofilament light and tau as blood biomarkers for sports-related concussion. <i>Neurology</i> , 2018, 90, e1780-e1788.	1.5	147
947	Longitudinal Performance of Plasma Neurofilament Light and Tau in Professional Fighters: The Professional Fighters Brain Health Study. <i>Journal of Neurotrauma</i> , 2018, 35, 2351-2356.	1.7	43
948	Gait in Mild Alzheimer's Disease: Feasibility of Multi-Center Measurement in the Clinic and Home with Body-Worn Sensors: A Pilot Study. <i>Journal of Alzheimer's Disease</i> , 2018, 63, 331-341.	1.2	42
949	Plasma Amyloid- β (A β 242) Correlates with Cerebrospinal Fluid A β 242 in Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2018, 62, 1857-1863.	1.2	100
950	Association of Plasma Neurofilament Light Chain with Neocortical Amyloid- β Load and Cognitive Performance in Cognitively Normal Elderly Participants. <i>Journal of Alzheimer's Disease</i> , 2018, 63, 479-487.	1.2	50
951	Shedding Light on the Molecular Pathology of Amyloid Plaques in Transgenic Alzheimer's Disease Mice Using Multimodal MALDI Imaging Mass Spectrometry. <i>ACS Chemical Neuroscience</i> , 2018, 9, 1802-1817.	1.7	60
952	Neurofilament light protein levels in cerebrospinal fluid predict long-term disability of Guillain-Barré syndrome: A pilot study. <i>Acta Neurologica Scandinavica</i> , 2018, 138, 143-150.	1.0	24
953	The Past and the Future of Alzheimer's Disease Fluid Biomarkers. <i>Journal of Alzheimer's Disease</i> , 2018, 62, 1125-1140.	1.2	106
954	Prevalence of preclinical Alzheimer disease. <i>Neurology</i> , 2018, 90, e1682-e1691.	1.5	82

#	ARTICLE	IF	CITATIONS
955	Human iPS-Derived Astroglia from a Stable Neural Precursor State Show Improved Functionality Compared with Conventional Astrocytic Models. <i>Stem Cell Reports</i> , 2018, 10, 1030-1045.	2.3	81
956	Association of Changes in Plasma Neurofilament Light and Tau Levels With Anesthesia and Surgery. <i>JAMA Neurology</i> , 2018, 75, 542.	4.5	96
957	Cerebrospinal fluid neurofilament light levels in neurodegenerative dementia: Evaluation of diagnostic accuracy in the differential diagnosis of prion diseases. <i>Alzheimer's and Dementia</i> , 2018, 14, 751-763.	0.4	61
958	Neurogranin as a predictor of memory and executive function decline in MCI patients. <i>Neurology</i> , 2018, 90, e887-e895.	1.5	42
959	Traumatic Brain Injury and Alzheimer's Disease: The Cerebrovascular Link. <i>EBioMedicine</i> , 2018, 28, 21-30.	2.7	250
960	Cerebrospinal Fluid and Plasma Levels of Inflammation Differentially Relate to CNS Markers of Alzheimer's Disease Pathology and Neuronal Damage. <i>Journal of Alzheimer's Disease</i> , 2018, 62, 385-397.	1.2	81
961	Cerebrospinal Fluid Biomarkers are Differentially Related to Structural and Functional Changes in Dementia of the Alzheimer's Type. <i>Journal of Alzheimer's Disease</i> , 2018, 62, 417-427.	1.2	5
962	Plasma tau is increased in frontotemporal dementia. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2018, 89, 804-807.	0.9	41
963	Neurofilament light protein in blood predicts regional atrophy in Huntington disease. <i>Neurology</i> , 2018, 90, e717-e723.	1.5	65
964	Sense and antisense RNA are not toxic in Drosophila models of C9orf72-associated ALS/FTD. <i>Acta Neuropathologica</i> , 2018, 135, 445-457.	3.9	59
965	Genetic Variation in FOXO3 is Associated with Self-Rated Health in a Population-Based Sample of Older Individuals. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2018, 73, 1453-1458.	1.7	10
966	Sleep deprivation and cerebrospinal fluid biomarkers for Alzheimer's disease. <i>Sleep</i> , 2018, 41, .	0.6	73
967	Evolution of cerebrospinal fluid total α -synuclein in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2018, 49, 4-8.	1.1	31
968	Cerebrospinal Fluid S100B and Alzheimer's Disease Biomarkers in Hip Fracture Patients with Delirium. <i>Dementia and Geriatric Cognitive Disorders Extra</i> , 2018, 7, 374-385.	0.6	31
969	Comparing ¹⁸ F-AV-1451 with CSF t-tau and p-tau for diagnosis of Alzheimer disease. <i>Neurology</i> , 2018, 90, e388-e395.	1.5	83
970	Plasma neurofilament light chain concentration in the inherited peripheral neuropathies. <i>Neurology</i> , 2018, 90, e518-e524.	1.5	176
971	CSF neurogranin or tau distinguish typical and atypical Alzheimer disease. <i>Annals of Clinical and Translational Neurology</i> , 2018, 5, 162-171.	1.7	30
972	Alzheimer's disease biomarker-guided diagnostic workflow using the added value of six combined cerebrospinal fluid candidates: A β ₄₂ , total tau, phosphorylated tau, NFL, neurogranin, and YKL40. <i>Alzheimer's and Dementia</i> , 2018, 14, 492-501.	0.4	91

#	ARTICLE	IF	CITATIONS
973	Minocycline reduces chronic microglial activation after brain trauma but increases neurodegeneration. <i>Brain</i> , 2018, 141, 459-471.	3.7	143
974	A new enzyme-linked immunosorbent assay for neurofilament light in cerebrospinal fluid: analytical validation and clinical evaluation. <i>Alzheimer's Research and Therapy</i> , 2018, 10, 8.	3.0	111
975	White paper by the Society for CSF Analysis and Clinical Neurochemistry: Overcoming barriers in biomarker development and clinical translation. <i>Alzheimer's Research and Therapy</i> , 2018, 10, 30.	3.0	40
976	Longitudinal Trajectories of Brain Volume and Cortical Thickness in Treated and Untreated Primary Human Immunodeficiency Virus Infection. <i>Clinical Infectious Diseases</i> , 2018, 67, 1697-1704.	2.9	67
977	Amyloid β peptides are differentially vulnerable to preanalytical surface exposure, an effect incompletely mitigated by the use of ratios. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2018, 10, 311-321.	1.2	21
978	Cerebrospinal fluid neurogranin concentration in neurodegeneration: relation to clinical phenotypes and neuropathology. <i>Acta Neuropathologica</i> , 2018, 136, 363-376.	3.9	114
979	Cerebrospinal fluid β -amyloid42 and neurofilament light relate to white matter hyperintensities. <i>Neurobiology of Aging</i> , 2018, 68, 18-25.	1.5	39
980	Prevalence of the apolipoprotein E ϵ 4 allele in amyloid β positive subjects across the spectrum of Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2018, 14, 913-924.	0.4	58
981	Fluid Biomarkers in Alzheimer's Disease and Frontotemporal Dementia. , 2018, , 221-252.		1
982	Tauomics and Kinetics in Human Neurons and Biological Fluids. <i>Neuron</i> , 2018, 97, 1202-1205.	3.8	10
983	Apolipoprotein E genotypes and longevity across dementia disorders. <i>Alzheimer's and Dementia</i> , 2018, 14, 895-901.	0.4	8
984	Cerebrospinal fluid neurogranin and TREM2 in Huntington's disease. <i>Scientific Reports</i> , 2018, 8, 4260.	1.6	25
985	Plasma neurofilament light chain levels in patients with MS switching from injectable therapies to fingolimod. <i>Multiple Sclerosis Journal</i> , 2018, 24, 1046-1054.	1.4	149
986	CSF biomarkers in delirium: a systematic review. <i>International Journal of Geriatric Psychiatry</i> , 2018, 33, 1479-1500.	1.3	51
987	Increase of neuronal injury markers Tau and neurofilament light proteins in umbilical blood after intrapartum asphyxia. <i>Journal of Maternal-Fetal and Neonatal Medicine</i> , 2018, 31, 2468-2472.	0.7	22
988	Neuroinflammation and Tau Interact with Amyloid in Predicting Sleep Problems in Aging Independently of Atrophy. <i>Cerebral Cortex</i> , 2018, 28, 2775-2785.	1.6	40
989	Cerebrospinal fluid and blood biomarkers for neurodegenerative dementias: An update of the Consensus of the Task Force on Biological Markers in Psychiatry of the World Federation of Societies of Biological Psychiatry. <i>World Journal of Biological Psychiatry</i> , 2018, 19, 244-328.	1.3	215
990	A Parallel Reaction Monitoring Mass Spectrometric Method for Analysis of Potential CSF Biomarkers for Alzheimer's Disease. <i>Proteomics - Clinical Applications</i> , 2018, 12, 1700131.	0.8	87

#	ARTICLE	IF	CITATIONS
991	Polymorphisms in dopamine-associated genes and cognitive decline in Parkinson's disease. <i>Acta Neurologica Scandinavica</i> , 2018, 137, 91-98.	1.0	20
992	Association of Cerebral Amyloid- β Aggregation With Cognitive Functioning in Persons Without Dementia. <i>JAMA Psychiatry</i> , 2018, 75, 84.	6.0	133
993	Seizures, CSF neurofilament light and tau in patients with subarachnoid haemorrhage. <i>Acta Neurologica Scandinavica</i> , 2018, 137, 199-203.	1.0	6
994	Chitotriosidase: shucking the role of microglia in amyotrophic lateral sclerosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2018, 89, 228-229.	0.9	2
995	Cerebrospinal fluid in the dementias. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2018, 146, 85-97.	1.0	9
996	Investigating the genetic architecture of dementia with Lewy bodies: a two-stage genome-wide association study. <i>Lancet Neurology</i> , The, 2018, 17, 64-74.	4.9	195
997	CSF neurofilament light concentration is increased in presymptomatic <i>CHMP2B</i> mutation carriers. <i>Neurology</i> , 2018, 90, e157-e163.	1.5	11
998	Increased midlife triglycerides predict brain β -amyloid and tau pathology 20 years later. <i>Neurology</i> , 2018, 90, e73-e81.	1.5	76
999	Central and peripheral leptin and agouti-related protein during and after pregnancy in relation to weight change. <i>Clinical Endocrinology</i> , 2018, 88, 263-271.	1.2	9
1000	C α -quadruplex-binding small molecules ameliorate <i>C9orf72</i> <i>FTD</i> / <i>ALS</i> pathology <i>in vitro</i> and <i>in vivo</i> . <i>EMBO Molecular Medicine</i> , 2018, 10, 22-31.	3.3	178
1001	Obstructive Sleep Apnea Severity Affects Amyloid Burden in Cognitively Normal Elderly. A Longitudinal Study. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2018, 197, 933-943.	2.5	174
1002	O2 α 03 α 05: VERBAL FLUENCY MEASURES ARE ASSOCIATED WITH ALZHEIMER'S DISEASE BIOMARKERS IN CLINICALLY UNIMPAIRED, LATE MIDDLE-AGED ADULTS FROM THE WISCONSIN REGISTRY FOR ALZHEIMER'S PREVENTION. <i>Alzheimer's and Dementia</i> , 2018, 14, P617.	0.4	0
1003	P3 α 495: VERBAL EPISODIC MEMORY IS PREFERENTIALLY RELATED TO WHITE MATTER INTEGRITY IN COGNITIVELY NORMAL OLDER ADULTS: THE VANDERBILT MEMORY & AGING PROJECT. <i>Alzheimer's and Dementia</i> , 2018, 14, P1311.	0.4	0
1004	O5 α 06 α 03: NEW PARADIGMS IN TREATING APOE4-DRIVEN DEMENTIA DISEASES: PROOF OF CONCEPT AND TRANSLATIONAL FINDINGS FROM STUDIES WITH THE ABCA1 AGONIST THERAPEUTIC CS6253. <i>Alzheimer's and Dementia</i> , 2018, 14, P1658.	0.4	0
1005	F5 α 06 α 03: BLOOD-BASED BIOMARKERS FOR CNS INJURY IN MILD TBI: RELATION TO ACUTE INJURY, INJURY HISTORY AND LONG-TERM NEUROBEHAVIORAL OUTCOME. <i>Alzheimer's and Dementia</i> , 2018, 14, P1634.	0.4	0
1006	P3 α 218: NOVEL ALZHEIMER'S DISEASE BIOMARKER-GUIDED DIAGNOSTIC WORKFLOW USING THE ADDED VALUE OF SIX COMBINED CEREBROSPINAL FLUID CANDIDATES: A β ₁₋₄₂ , TOTAL τ , PHOSPHORYLATED τ , NFL, NEUROGRANIN, AND YKL α 40. <i>Alzheimer's and Dementia</i> , 2018, 14, P1154.	0.4	1
1007	P3 α 243: THE ASSOCIATION OF LONGITUDINAL PLASMA NFL WITH POSTMORTEM NEUROPATHOLOGY. <i>Alzheimer's and Dementia</i> , 2018, 14, P1165.	0.4	0
1008	P1 α 318: OBSTRUCTIVE SLEEP APNEA IS ASSOCIATED WITH LOWER MEMORY FUNCTION IN MIDDLE-AGED ADULTS. <i>Alzheimer's and Dementia</i> , 2018, 14, P413.	0.4	0

#	ARTICLE	IF	CITATIONS
1009	P2â€270: INCREASED CSF AMYLOIDâ€12 1â€38 AND 1â€40 CONCENTRATIONS IN INDIVIDUALS WITH MILD COGNITIVE IMPAIRMENT WITH TAU BUT WITHOUT AMYLOID PATHOPHYSIOLOGY. Alzheimer's and Dementia, 2018, 14, P780.	0.4	0
1010	P1â€267: CEREBROSPINAL FLUID/PLASMA ALBUMIN RATIO PREDICTS POSTOPERATIVE DELIRIUM IN AN OLDER ELECTIVE ORTHOPAEDIC POPULATION. Alzheimer's and Dementia, 2018, 14, P384.	0.4	0
1011	P3â€238: LONGITUDINAL ASSOCIATIONS OF PLASMA NEUROFILAMENT LEVELS WITH AMYLOIDâ€PET, FDGâ€PET, AND COGNITION AMONG NONâ€DEMENTED PARTICIPANTS IN THE MAYO CLINIC STUDY ON AGING. Alzheimer's and Dementia, 2018, 14, P1163.	0.4	0
1012	P1â€248: LATENT PROFILES DERIVED FROM ATN RELATED CSF BIOMARKERS. Alzheimer's and Dementia, 2018, 14, P374.	0.4	0
1013	P1â€302: ASSOCIATION OF PLASMA NEUROFILAMENT LIGHT CHAIN WITH COGNITIVE PERFORMANCE IN COGNITIVELY NORMAL ELDERLY PARTICIPANTS. Alzheimer's and Dementia, 2018, 14, P405.	0.4	0
1014	P3â€161: ALTERATIONS IN ALZHEIMERâ€ASSOCIATED SYNAPTIC MARKERS FOLLOWING IRRADIATION OF STEM CELLâ€DERIVED CORTICAL NEURONS. Alzheimer's and Dementia, 2018, 14, P1129.	0.4	0
1015	P3â€270: CEREBROSPINAL FLUID CONCENTRATIONS OF INFLAMMATORY MARKERS IN PARKINSON'S DISEASE AND ATYPICAL PARKINSONIAN DISORDERS. Alzheimer's and Dementia, 2018, 14, P1180.	0.4	0
1016	P4â€071: CELLâ€FREE, SINGLEâ€STRANDED DNA CONCENTRATION IN CSF AS BIOMARKER TO DIAGNOSE ALZHEIMER'S DISEASE STATUS. Alzheimer's and Dementia, 2018, 14, P1460.	0.4	0
1017	O3â€14â€06: DISSECTION OF SYNAPTIC PATHWAYS THROUGH THE ANALYSIS OF BIOMARKERS IN THE CSF: A COMBINING TOOL FOR THE DIAGNOSIS OF ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2018, 14, P1061.	0.4	0
1018	P1â€188: MODELLING AMYLOID BETA PROFILES IN IPSCâ€DERIVED CORTICAL NEURONS OF MULTIPLE FAMILIAL ALZHEIMER'S DISEASE GENOTYPES, INCLUDING A CASE STUDY OF SAME DONOR CULTURE MEDIA, CSF AND BRAIN TISSUE. Alzheimer's and Dementia, 2018, 14, P350.	0.4	0
1019	P2â€273: CEREBROSPINAL FLUID NEUROFILAMENT LIGHT PROTEIN AND RISK OF MILD COGNITIVE IMPAIRMENT IN THE MAYO CLINIC STUDY OF AGING. Alzheimer's and Dementia, 2018, 14, P782.	0.4	0
1020	O2â€04â€04: LONGITUDINAL MEASUREMENT OF SERUM NEUROFILAMENT LIGHT CONCENTRATION IN FAMILIAL ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2018, 14, P623.	0.4	0
1021	P1â€007: POOR SLEEP IS ASSOCIATED WITH CSFâ€MARKERS OF ALZHEIMER'S DISEASE IN 70â€YEARâ€OLDS WITHOUT DEMENTIA. Alzheimer's and Dementia, 2018, 14, P265.	0.4	0
1022	P2â€220: CROSSâ€TALK BETWEEN WNT SIGNALLING AND AMYLOID PRECURSOR PROTEIN IN NEURONS. Alzheimer's and Dementia, 2018, 14, P753.	0.4	0
1023	F2â€02â€01: NEUROFILAMENT LIGHT CHAIN IN AD IN CSF AND BLOOD. Alzheimer's and Dementia, 2018, 14, P603.	0.4	0
1024	O3â€14â€04: THE PROTEINâ€TOâ€PEPTIDE RATIO IMPROVES THE PERFORMANCE OF MICROTUBULEâ€ASSOCIATED PROTEIN TAU IN CSF AS AN ALZHEIMER BIOMARKER. Alzheimer's and Dementia, 2018, 14, P1060.	0.4	0
1025	P1â€286: TRANSFORMATION OF CSF BIOMARKER VALUES BETWEEN MEASUREMENT BATCHES. Alzheimer's and Dementia, 2018, 14, P393.	0.4	3
1026	P1â€217: PROTEOLYTIC PROCESSING OF THE SYNAPTIC ALZHEIMER BIOMARKER NEUROGRANIN BY CALPAIN I AND PROLYL ENDOPEPTIDASE. Alzheimer's and Dementia, 2018, 14, P361.	0.4	0

#	ARTICLE	IF	CITATIONS
1027	P2â€³037: APABETALONE (AN EPIGENETIC BETAâ€³INHIBITOR SMALL MOLECULE) AND EFFECTS ON COGNITION IN DIABETES PATIENTS WITH CARDIOVASCULAR DISEASE. Alzheimer's and Dementia, 2018, 14, P680.	0.4	0
1028	P1â€³139: THE CONTRIBUTION OF SEXâ€³SPECIFIC ASSOCIATIONS IN GENETIC STUDIES OF ALZHEIMER'S DISEASE PATHOLOGY. Alzheimer's and Dementia, 2018, 14, P327.	0.4	0
1029	O3â€³14â€³05: ASSOCIATIONS OF CSF BIOMARKERS OF NEUROINFLAMMATION AND CEREBROVASCULAR DYSFUNCTION WITH ALZHEIMER'S DISEASE PATHOLOGY AND CLINICAL PROGRESSION. Alzheimer's and Dementia, 2018, 14, P1061.	0.4	0
1030	P1â€³279: BIMODAL DISTRIBUTION OF THE CSF AÎ²42/AÎ²40 RATIO IN CLINICAL LABORATORY PRACTICE. Alzheimer's and Dementia, 2018, 14, P389.	0.4	0
1031	Transient increase in CSF GAP-43 concentration after ischemic stroke. BMC Neurology, 2018, 18, 202.	0.8	21
1032	ICâ€³Pâ€³089: OBSTRUCTIVE SLEEP APNEA IS ASSOCIATED WITH LOWER MEMORY FUNCTION IN MIDDLEâ€³AGED ADULTS. Alzheimer's and Dementia, 2018, 14, P74.	0.4	0
1033	D10â€³...Neurofilament light protein in blood predicts regional atrophy in huntingtonâ€³s disease. , 2018, , .		0
1034	D09â€³...Parallel evaluation of mutant huntingtin and neurofilament light as biomarkers for huntingtonâ€³s disease: the hd-csf study. , 2018, , .		0
1035	P2â€³237: ASSOCIATION OF CSF ALPHAâ€³SYNUCLEIN AND TAU CONCENTRATIONS WITH AMYLOID MEAN CORTICAL STANDARD UPTAKE VALUE RATIOS IN PRECLINICAL SUBJECTIVE MEMORY COMPLAINERS STRATIFIED BY ALZHEIMER'S DISEASE BIOMARKERS. Alzheimer's and Dementia, 2018, 14, P762.	0.4	0
1036	O1â€³10â€³02: NEUROGRANIN PREDICTS LONGITUDINAL COGNITIVE DECLINE IN PATIENTS WITH MILD COGNITIVE IMPAIRMENT. Alzheimer's and Dementia, 2018, 14, P243.	0.4	0
1037	P3â€³387: NEURODEGENERATION, AMYLOID, AND LONGITUDINAL VERBAL LEARNING AND MEMORY PERFORMANCE. Alzheimer's and Dementia, 2018, 14, P1243.	0.4	0
1038	P4â€³186: INNOVATIVE BIOMARKERâ€³GUIDED DIAGNOSTIC SYSTEM FROM PRECLINICAL TO ALZHEIMER'S DISEASE DEMENTIA. Alzheimer's and Dementia, 2018, 14, P1510.	0.4	0
1039	P1â€³301: CERTAIN PLASMA Nâ€³TERMINAL TAU FRAGMENTS ARE ELEVATED IN AD AND ADâ€³MCI COMPARED TO CONTROLS. Alzheimer's and Dementia, 2018, 14, P405.	0.4	0
1040	Chronic traumatic encephalopathy: fluid biomarkers. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2018, 158, 323-333.	1.0	14
1041	O2â€³09â€³04: HARMONIZATION OF IMMUNOCHEMICAL METHODS FOR MEASUREMENT OF Î±â€³SYNUCLEIN IN HUMAN CEREBROSPINAL FLUID: A ROUND ROBIN STUDY APPROACH. Alzheimer's and Dementia, 2018, 14, P642.	0.4	0
1042	Barrier Properties and Transcriptome Expression in Human iPSC-Derived Models of the Bloodâ€³Brain Barrier. Stem Cells, 2018, 36, 1816-1827.	1.4	81
1043	O3â€³09â€³03: SERUM NEUROFILAMENT LIGHT LEVELS CORRELATE WITH SEVERITY MEASURES AND NEURODEGENERATION MARKERS IN AUTOSOMAL DOMINANT ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2018, 14, P1037.	0.4	0
1044	CSF sTREM2 in deliriumâ€³relation to Alzheimerâ€³s disease CSF biomarkers AÎ²42, t-tau and p-tau. Journal of Neuroinflammation, 2018, 15, 304.	3.1	36

#	ARTICLE	IF	CITATIONS
1045	Serum neurofilament light levels correlate with severity measures and neurodegeneration markers in autosomal dominant Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2018, 10, 113.	3.0	54
1046	F1â€02â€02: DISCOVERY, REPLICATION AND EXTENSION STUDY OF PLASMA PROTEOMIC BIOMARKERS RELATING TO BRAIN AMYLOID BURDEN AND ALZHEIMER'S DISEASE PROGRESSION. <i>Alzheimer's and Dementia</i> , 2018, 14, P201.	0.4	0
1047	DTâ€02â€04: DETECTING BRAIN AMYLOID STATUS USING FULLY AUTOMATED PLASMA AÎ² BIOMARKER ASSAYS. <i>Alzheimer's and Dementia</i> , 2018, 14, P1670.	0.4	1
1048	P1â€001: CSF CHOLINE ACETYLTRANSFERASE SHOWS DIFFERENTIAL LEVELS AMONG HEALTHY CONTROLS AND PATIENTS WITH AD AND MCI. <i>Alzheimer's and Dementia</i> , 2018, 14, P261.	0.4	0
1049	Persistent central nervous system immune activation following more than 10 years of effective HIV antiretroviral treatment. <i>Aids</i> , 2018, 32, 2171-2178.	1.0	37
1050	Updating Our Definitions of Parkinson's Disease for a Molecular Age. <i>Journal of Parkinson's Disease</i> , 2018, 8, S53-S57.	1.5	7
1051	The gut microbiota-derived metabolite trimethylamine N-oxide is elevated in Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2018, 10, 124.	3.0	273
1052	Alzheimer's disease in Down syndrome: An overlooked population for prevention trials. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2018, 4, 703-713.	1.8	63
1053	Neurofilament Light in Serum and Cerebrospinal Fluid of Hip Fracture Patients with Delirium. <i>Dementia and Geriatric Cognitive Disorders</i> , 2018, 46, 346-357.	0.7	41
1054	Current state of Alzheimer's fluid biomarkers. <i>Acta Neuropathologica</i> , 2018, 136, 821-853.	3.9	370
1055	F1â€02â€01: RELATING CSF MARKERS NEUROGRANIN, NEUROFILAMENTâ€LIGHT AND YKLâ€40 TO AÎ², APOE Îµ4 AND COGNITION: RESULTS FROM THE EMIFâ€AD MULTIMODAL BIOMARKER DISCOVERY STUDY. <i>Alzheimer's and Dementia</i> , 2018, 14, P201.	0.4	0
1056	Blood-based biomarkers for Alzheimer disease: mapping the road to the clinic. <i>Nature Reviews Neurology</i> , 2018, 14, 639-652.	4.9	434
1057	Interlaboratory validation of cerebrospinal fluid Î±â€synuclein quantification in the diagnosis of sporadic Creutzfeldtâ€Jakob disease. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2018, 10, 461-470.	1.2	7
1058	Abnormal CSF amyloid-Î²42 and tau levels in hip fracture patients without dementia. <i>PLoS ONE</i> , 2018, 13, e0204695.	1.1	19
1059	Heading in soccer increases serum neurofilament light protein and SCAT3 symptom metrics. <i>BMJ Open Sport and Exercise Medicine</i> , 2018, 4, e000433.	1.4	58
1060	MRI predictors of amyloid pathology: results from the EMIF-AD Multimodal Biomarker Discovery study. <i>Alzheimer's Research and Therapy</i> , 2018, 10, 100.	3.0	64
1061	Effects of methylprednisolone on blood-brain barrier and cerebral inflammation in cardiac surgeryâ€a randomized trial. <i>Journal of Neuroinflammation</i> , 2018, 15, 283.	3.1	38
1062	Mutated Thyroid Hormone Transporter OATP1C1 Associates with Severe Brain Hypometabolism and Juvenile Neurodegeneration. <i>Thyroid</i> , 2018, 28, 1406-1415.	2.4	57

#	ARTICLE	IF	CITATIONS
1063	Dietary intervention with an Okinawan-based Nordic diet in type 2 diabetes renders decreased interleukin-18 concentrations and increased neurofilament light concentrations in plasma. <i>Nutrition Research</i> , 2018, 60, 13-25.	1.3	12
1064	Early predictors of mortality in parkinsonism and Parkinson disease. <i>Neurology</i> , 2018, 91, e2045-e2056.	1.5	111
1065	Plasma Markers of Neurodegeneration Are Raised in Friedreich's Ataxia. <i>Frontiers in Cellular Neuroscience</i> , 2018, 12, 366.	1.8	28
1066	No change in plasma tau and serum neurofilament light concentrations in adolescent athletes following sport-related concussion. <i>PLoS ONE</i> , 2018, 13, e0206466.	1.1	31
1067	P2-458: PREDICTING COGNITIVE DECLINE THROUGH STRUCTURAL MRI BIOMARKERS: RESULTS FROM THE EMIF AD BIOMARKER DISCOVERY STUDY. <i>Alzheimer's and Dementia</i> , 2018, 14, P895.	0.4	0
1068	F1-02-03: MRI PREDICTORS OF AMYLOID PATHOLOGY: RESULTS FROM THE EMIF AD BIOMARKER DISCOVERY STUDY. <i>Alzheimer's and Dementia</i> , 2018, 14, P202.	0.4	0
1069	Protofibrillar and Fibrillar Amyloid- β Binding Proteins in Cerebrospinal Fluid. <i>Journal of Alzheimer's Disease</i> , 2018, 66, 1053-1064.	1.2	7
1070	P3-166: SUBCELLULAR CO-LOCALIZATION OF APP AND APP-CLEAVING ENZYMES. <i>Alzheimer's and Dementia</i> , 2018, 14, P1131.	0.4	0
1071	Intrathecal treatment trial of rituximab in progressive MS. <i>Neurology</i> , 2018, 91, e1893-e1901.	1.5	32
1072	P2-241: FROM BLOOD-BASED REDOX PROFILE TO THE IDENTIFICATION OF A LEAD BIOMARKER FOR THE TIMELY DIAGNOSIS OF ALZHEIMER'S DISEASE. <i>Alzheimer's and Dementia</i> , 2018, 14, P765.	0.4	0
1073	Expression and secretion of synaptic proteins during stem cell differentiation to cortical neurons. <i>Neurochemistry International</i> , 2018, 121, 38-49.	1.9	20
1074	A β 42/A β 40 and A β 42/A β 38 Ratios Are Associated with Measures of Gait Variability and Activities of Daily Living in Mild Alzheimer's Disease: A Pilot Study. <i>Journal of Alzheimer's Disease</i> , 2018, 65, 1377-1383.	1.2	23
1075	Integration of magnetic resonance imaging and protein and metabolite CSF measurements to enable early diagnosis of secondary progressive multiple sclerosis. <i>Theranostics</i> , 2018, 8, 4477-4490.	4.6	39
1076	CSF pro-orexin and amyloid- β 38 expression in Alzheimer's disease and frontotemporal dementia. <i>Neurobiology of Aging</i> , 2018, 72, 171-176.	1.5	25
1077	Cerebrospinal fluid concentrations of inflammatory markers in Parkinson's disease and atypical parkinsonian disorders. <i>Scientific Reports</i> , 2018, 8, 13276.	1.6	104
1078	Data driven diagnostic classification in Alzheimer's disease based on different reference regions for normalization of PIB-PET images and correlation with CSF concentrations of A β species. <i>NeuroImage: Clinical</i> , 2018, 20, 603-610.	1.4	11
1079	Evaluation of mutant huntingtin and neurofilament proteins as potential markers in Huntington's disease. <i>Science Translational Medicine</i> , 2018, 10, .	5.8	134
1080	Alzheimer-associated cerebrospinal fluid fragments of neurogranin are generated by Calpain-1 and prolyl endopeptidase. <i>Molecular Neurodegeneration</i> , 2018, 13, 47.	4.4	21

#	ARTICLE	IF	CITATIONS
1081	Human Induced Pluripotent Stem Cell-Derived Microglia-Like Cells Harboring TREM2 Missense Mutations Show Specific Deficits in Phagocytosis. <i>Cell Reports</i> , 2018, 24, 2300-2311.	2.9	118
1082	Neurofilaments as biomarkers in neurological disorders. <i>Nature Reviews Neurology</i> , 2018, 14, 577-589.	4.9	1,177
1083	From Cerebrospinal Fluid to Blood: The Third Wave of Fluid Biomarkers for Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2018, 64, S271-S279.	1.2	66
1084	Multimodal Chemical Imaging of Amyloid Plaque Polymorphism Reveals A β 2 Aggregation Dependent Anionic Lipid Accumulations and Metabolism. <i>Analytical Chemistry</i> , 2018, 90, 8130-8138.	3.2	39
1085	Biomarkers in cerebrospinal fluid of patients with bipolar disorder versus healthy individuals: A systematic review. <i>European Neuropsychopharmacology</i> , 2018, 28, 783-794.	0.3	18
1086	A 10-Year Follow-Up of Adiposity and Dementia in Swedish Adults Aged 70 Years and Older. <i>Journal of Alzheimer's Disease</i> , 2018, 63, 1325-1335.	1.2	6
1087	Neurofilament relates to white matter microstructure in older adults. <i>Neurobiology of Aging</i> , 2018, 70, 233-241.	1.5	48
1088	Trisomy of human chromosome 21 enhances amyloid- β 2 deposition independently of an extra copy of <i>APP</i> . <i>Brain</i> , 2018, 141, 2457-2474.	3.7	96
1089	Socioeconomic status, gender and dementia: The influence of work environment exposures and their interactions with APOE ϵ 4. <i>SSM - Population Health</i> , 2018, 5, 171-179.	1.3	24
1090	Sex-specific genetic predictors of Alzheimer's disease biomarkers. <i>Acta Neuropathologica</i> , 2018, 136, 857-872.	3.9	87
1091	Commutability of the certified reference materials for the standardization of β -amyloid 1-42 assay in human cerebrospinal fluid; lessons for tau and β -amyloid 1-40 measurements. <i>Clinical Chemistry and Laboratory Medicine</i> , 2018, 56, 2058-2066.	1.4	27
1092	Neurodegeneration, synaptic dysfunction, and gliosis are phenotypic of Alzheimer dementia. <i>Neurology</i> , 2018, 91, e436-e443.	1.5	38
1093	Neurofilament light chain as disease biomarker in a rodent model of chemotherapy induced peripheral neuropathy. <i>Experimental Neurology</i> , 2018, 307, 129-132.	2.0	51
1094	The impact of preanalytical variables on measuring cerebrospinal fluid biomarkers for Alzheimer's disease diagnosis: A review. <i>Alzheimer's and Dementia</i> , 2018, 14, 1313-1333.	0.4	87
1095	No association of salivary total tau concentration with Alzheimer's disease. <i>Neurobiology of Aging</i> , 2018, 70, 125-127.	1.5	51
1096	Extrinsic Amyloid-Binding Dyes for Detection of Individual Protein Aggregates in Solution. <i>Analytical Chemistry</i> , 2018, 90, 10385-10393.	3.2	20
1097	Searching for neurodegeneration in multiple sclerosis at clinical onset: Diagnostic value of biomarkers. <i>PLoS ONE</i> , 2018, 13, e0194828.	1.1	32
1098	CSF biomarkers of neuroinflammation and cerebrovascular dysfunction in early Alzheimer disease. <i>Neurology</i> , 2018, 91, e867-e877.	1.5	207

#	ARTICLE	IF	CITATIONS
1099	Biomarkers for Alzheimer's disease: current status and prospects for the future. <i>Journal of Internal Medicine</i> , 2018, 284, 643-663.	2.7	550
1100	Levels of ADAM10 are reduced in Alzheimer's disease CSF. <i>Journal of Neuroinflammation</i> , 2018, 15, 213.	3.1	39
1101	Association of cerebrospinal fluid β -synuclein with total and phospho τ ¹⁸¹ protein concentrations and brain amyloid load in cognitively normal subjective memory complainers stratified by Alzheimer's disease biomarkers. <i>Alzheimer's and Dementia</i> , 2018, 14, 1623-1631.	0.4	45
1102	Plasma neurofilament light as a potential biomarker of neurodegeneration in Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2018, 10, 71.	3.0	216
1103	Cerebrospinal fluid tau, $A\beta$, and sTREM2 in Former National Football League Players: Modeling the relationship between repetitive head impacts, microglial activation, and neurodegeneration. <i>Alzheimer's and Dementia</i> , 2018, 14, 1159-1170.	0.4	96
1104	Neuromodulation via the Cerebrospinal Fluid: Insights from Recent in Vitro Studies. <i>Frontiers in Neural Circuits</i> , 2018, 12, 5.	1.4	27
1105	Commentary: Global, regional, and national burden of neurological disorders during 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015. <i>Frontiers in Neurology</i> , 2018, 9, 201.	1.1	31
1106	The EMIF-AD Multimodal Biomarker Discovery study: design, methods and cohort characteristics. <i>Alzheimer's Research and Therapy</i> , 2018, 10, 64.	3.0	62
1107	The anti-asthmatic drug, montelukast, modifies the neurogenic potential in the young healthy and irradiated brain. <i>Cell Death and Disease</i> , 2018, 9, 775.	2.7	10
1108	Low fasting serum insulin and dementia in nondiabetic women followed for 34 years. <i>Neurology</i> , 2018, 91, e427-e435.	1.5	17
1109	Effects of APOE ϵ 4 on neuroimaging, cerebrospinal fluid biomarkers, and cognition in prodromal Alzheimer's disease. <i>Neurobiology of Aging</i> , 2018, 71, 81-90.	1.5	15
1110	Stability of blood-based biomarkers of Alzheimer's disease over multiple freeze-thaw cycles. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2018, 10, 448-451.	1.2	49
1111	Blood-based cerebral biomarkers in preeclampsia: Plasma concentrations of NfL, tau, S100B and NSE during pregnancy in women who later develop preeclampsia - A nested case control study. <i>PLoS ONE</i> , 2018, 13, e0196025.	1.1	29
1112	Neurofilament levels, disease activity and brain volume during follow-up in multiple sclerosis. <i>Journal of Neuroinflammation</i> , 2018, 15, 209.	3.1	94
1113	The presubiculum is preserved from neurodegenerative changes in Alzheimer's disease. <i>Acta Neuropathologica Communications</i> , 2018, 6, 62.	2.4	9
1114	Synaptic proteins in CSF as potential novel biomarkers for prognosis in prodromal Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2018, 10, 5.	3.0	94
1115	Cerebrospinal fluid in the differential diagnosis of Alzheimer's disease: clinical utility of an extended panel of biomarkers in a specialist cognitive clinic. <i>Alzheimer's Research and Therapy</i> , 2018, 10, 32.	3.0	79
1116	Neurofilament light as a blood biomarker for neurodegeneration in Down syndrome. <i>Alzheimer's Research and Therapy</i> , 2018, 10, 39.	3.0	43

#	ARTICLE	IF	CITATIONS
1117	Sex-Specific Association of Apolipoprotein E With Cerebrospinal Fluid Levels of Tau. <i>JAMA Neurology</i> , 2018, 75, 989.	4.5	223
1118	Molecular biomarkers of Alzheimer's disease: progress and prospects. <i>DMM Disease Models and Mechanisms</i> , 2018, 11, .	1.2	163
1119	High Serum Serotonin Predicts Increased Risk for Hip Fracture and Nonvertebral Osteoporotic Fractures: The MrOS Sweden Study. <i>Journal of Bone and Mineral Research</i> , 2018, 33, 1560-1567.	3.1	10
1120	Reduced penetrance of the PSEN1 H163Y autosomal dominant Alzheimer mutation: a 22-year follow-up study. <i>Alzheimer's Research and Therapy</i> , 2018, 10, 45.	3.0	11
1121	Cerebrospinal fluid soluble TREM2 levels in frontotemporal dementia differ by genetic and pathological subgroup. <i>Alzheimer's Research and Therapy</i> , 2018, 10, 79.	3.0	43
1122	Cerebrospinal fluid GAP-43 in early multiple sclerosis. <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , 2018, 4, 205521731879293.	0.5	8
1123	Midlife Stress in Relation to Late-Life Cerebrospinal Fluid Biomarkers of Alzheimer's Disease: A 25-Year Follow-Up Study. <i>Dementia and Geriatric Cognitive Disorders</i> , 2018, 46, 90-99.	0.7	9
1124	Neurofilament light chain in blood is negatively associated with neuropsychological performance in HIV-infected adults and declines with initiation of antiretroviral therapy. <i>Journal of NeuroVirology</i> , 2018, 24, 695-701.	1.0	35
1125	Inflammatory markers of CHMP2B-mediated frontotemporal dementia. <i>Journal of Neuroimmunology</i> , 2018, 324, 136-142.	1.1	10
1126	S-[18F]THK-5117-PET and [11C]PIB-PET Imaging in Idiopathic Normal Pressure Hydrocephalus in Relation to Confirmed Amyloid- β Plaques and Tau in Brain Biopsies. <i>Journal of Alzheimer's Disease</i> , 2018, 64, 171-179.	1.2	14
1127	Serum neurofilament light chain in progressive supranuclear palsy. <i>Parkinsonism and Related Disorders</i> , 2018, 56, 98-101.	1.1	38
1128	Update on biomarkers for amyloid pathology in Alzheimer's disease. <i>Biomarkers in Medicine</i> , 2018, 12, 799-812.	0.6	59
1129	Cerebrospinal fluid sCD27 levels indicate active T cell-mediated inflammation in premanifest Huntington's disease. <i>PLoS ONE</i> , 2018, 13, e0193492.	1.1	21
1130	A comparison of biofluid cytokine markers across platform technologies: Correspondence or divergence?. <i>Cytokine</i> , 2018, 111, 481-489.	1.4	14
1131	Comparative Evaluation of MS-based Metabolomics Software and Its Application to Preclinical Alzheimer's Disease. <i>Scientific Reports</i> , 2018, 8, 9291.	1.6	45
1132	A Strategy for Discovery and Verification of Candidate Biomarkers in Cerebrospinal Fluid of Preclinical Alzheimer's Disease. <i>Frontiers in Molecular Neuroscience</i> , 2018, 11, 483.	1.4	11
1133	The nonlinear relationship between cerebrospinal fluid A β 42 and tau in preclinical Alzheimer's disease. <i>PLoS ONE</i> , 2018, 13, e0191240.	1.1	41
1134	A Selected Reaction Monitoring Protocol for the Measurement of sTREM2 in Cerebrospinal Fluid. <i>Neuromethods</i> , 2018, , 169-177.	0.2	0

#	ARTICLE	IF	CITATIONS
1135	D08â€¦Neurofilament light protein in blood as a potential biomarker of neurodegeneration in huntingtonâ€™s disease: a retrospective cohort analysis. , 2018, , .		0
1136	CSF AÎ²1â€“42 â€“ an excellent but complicated Alzheimer's biomarker â€“ a route to standardisation. Clinica Chimica Acta, 2017, 467, 27-33.	0.5	104
1137	Cerebrospinal fluid biomarkers of inflammation and degeneration as measures of fingolimod efficacy in multiple sclerosis. Multiple Sclerosis Journal, 2017, 23, 62-71.	1.4	81
1138	Genome-wide association study identifies <i>MAPT</i> locus influencing human plasma tau levels. Neurology, 2017, 88, 669-676.	1.5	33
1139	Review: Tau in biofluids â€“ relation to pathology, imaging and clinical features. Neuropathology and Applied Neurobiology, 2017, 43, 194-199.	1.8	117
1140	Plasma concentrations of free amyloid Î²2 cannot predict the development of Alzheimer's disease. Alzheimer's and Dementia, 2017, 13, 778-782.	0.4	70
1141	Neurofilament Protein and Antineurofilament Antibodies Following Traumatic Brain Injuryâ€™Reply. JAMA Neurology, 2017, 74, 363.	4.5	4
1142	Preclinical amyloid pathology biomarker positivity: effects on tau pathology and neurodegeneration. Translational Psychiatry, 2017, 7, e995-e995.	2.4	56
1143	CSF YKLâ€“40 and GAPâ€“43 are related to suicidal ideation in older women. Acta Psychiatrica Scandinavica, 2017, 135, 351-357.	2.2	8
1144	Identification of candidate cerebrospinal fluid biomarkers in parkinsonism using quantitative proteomics. Parkinsonism and Related Disorders, 2017, 37, 65-71.	1.1	34
1145	The effects of different familial Alzheimerâ€™s disease mutations on APP processing in vivo. Alzheimer's Research and Therapy, 2017, 9, 9.	3.0	32
1146	Neurofilament light chain in cerebrospinal fluid and prediction of disease activity in clinically isolated syndrome and relapsingâ€“remitting multiple sclerosis. European Journal of Neurology, 2017, 24, 703-712.	1.7	97
1147	Astroglial activation and altered amyloid metabolism in human repetitive concussion. Neurology, 2017, 88, 1400-1407.	1.5	39
1148	Genome-wide association study identifies four novel loci associated with Alzheimerâ€™s endophenotypes and disease modifiers. Acta Neuropathologica, 2017, 133, 839-856.	3.9	199
1149	Cerebrospinal fluid markers of neuronal and glial cell damage in patients with autoimmune neurologic syndromes with and without underlying malignancies. Journal of Neuroimmunology, 2017, 306, 25-30.	1.1	17
1150	Cerebrospinal fluid microglia and neurodegenerative markers in twins concordant and discordant for psychotic disorders. European Archives of Psychiatry and Clinical Neuroscience, 2017, 267, 391-402.	1.8	16
1151	Cerebrospinal fluid neurofilament light concentration in motor neuron disease and frontotemporal dementia predicts survival. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2017, 18, 397-403.	1.1	58
1152	Blood-based NfL. Neurology, 2017, 88, 930-937.	1.5	369

#	ARTICLE	IF	CITATIONS
1153	The immune response of the human brain to abdominal surgery. <i>Annals of Neurology</i> , 2017, 81, 572-582.	2.8	87
1154	Two-level diagnostic classification using cerebrospinal fluid YKL40 in Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2017, 13, 993-1003.	0.4	39
1155	Serum neurofilament light as a biomarker for mild traumatic brain injury in contact sports. <i>Neurology</i> , 2017, 88, 1788-1794.	1.5	280
1156	Applying fluid biomarkers to Alzheimer's disease. <i>American Journal of Physiology - Cell Physiology</i> , 2017, 313, C3-C10.	2.1	46
1157	Effect of physical exercise on markers of neuronal dysfunction in cerebrospinal fluid in patients with Alzheimer's disease. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2017, 3, 284-290.	1.8	23
1158	Markers of neuroinflammation and neuronal injury in bipolar disorder: Relation to prospective clinical outcomes. <i>Brain, Behavior, and Immunity</i> , 2017, 65, 195-201.	2.0	69
1159	The influence of insulin resistance on cerebrospinal fluid and plasma biomarkers of Alzheimer's pathology. <i>Alzheimer's Research and Therapy</i> , 2017, 9, 31.	3.0	36
1160	A Season of American Football Is Not Associated with Changes in Plasma Tau. <i>Journal of Neurotrauma</i> , 2017, 34, 3295-3300.	1.7	14
1161	Increased levels of ascorbic acid in the cerebrospinal fluid of cognitively intact elderly patients with major depression: a preliminary study. <i>Scientific Reports</i> , 2017, 7, 3485.	1.6	18
1162	Serum Neurofilament light: A biomarker of neuronal damage in multiple sclerosis. <i>Annals of Neurology</i> , 2017, 81, 857-870.	2.8	768
1163	Evolving Relevance of Neuroproteomics in Alzheimer's Disease. <i>Methods in Molecular Biology</i> , 2017, 1598, 101-115.	0.4	14
1164	Inflammation, Amyloid, and Atrophy in The Aging Brain: Relationships with Longitudinal Changes in Cognition. <i>Journal of Alzheimer's Disease</i> , 2017, 58, 829-840.	1.2	31
1165	Serum concentrations of the axonal injury marker neurofilament light protein are not influenced by blood-brain barrier permeability. <i>Brain Research</i> , 2017, 1668, 12-19.	1.1	53
1166	Diagnostic accuracy of CSF neurofilament light chain protein in the biomarker-guided classification system for Alzheimer's disease. <i>Neurochemistry International</i> , 2017, 108, 355-360.	1.9	46
1167	Alzheimer's Disease-Associated Cerebrospinal Fluid (CSF) Biomarkers do not Correlate with CSF Volumes or CSF Production Rate. <i>Journal of Alzheimer's Disease</i> , 2017, 58, 821-828.	1.2	12
1168	C-terminal fragments of the amyloid precursor protein in cerebrospinal fluid as potential biomarkers for Alzheimer disease. <i>Scientific Reports</i> , 2017, 7, 2477.	1.6	28
1169	Plasma Tau Association with Brain Atrophy in Mild Cognitive Impairment and Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2017, 58, 1245-1254.	1.2	54
1170	Neurofilament light chain protein as a marker of neuronal injury: review of its use in HIV-1 infection and reference values for HIV-negative controls. <i>Expert Review of Molecular Diagnostics</i> , 2017, 17, 761-770.	1.5	114

#	ARTICLE	IF	CITATIONS
1171	Tracking and predicting disease progression in progressive supranuclear palsy: CSF and blood biomarkers. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2017, 88, 883-888.	0.9	26
1172	Neurofilament light protein in blood as a potential biomarker of neurodegeneration in Huntington's disease: a retrospective cohort analysis. <i>Lancet Neurology</i> , The, 2017, 16, 601-609.	4.9	272
1173	Consensus guidelines for lumbar puncture in patients with neurological diseases. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2017, 8, 111-126.	1.2	197
1174	The use of cerebrospinal fluid biomarkers to measure change in neurodegeneration in Alzheimer's disease clinical trials. <i>Expert Review of Neurotherapeutics</i> , 2017, 17, 767-775.	1.4	4
1175	Blood-Brain Barrier Disruption Is Initiated During Primary HIV Infection and Not Rapidly Altered by Antiretroviral Therapy. <i>Journal of Infectious Diseases</i> , 2017, 215, 1132-1140.	1.9	50
1176	Specific patterns of whole-brain structural covariance of the anterior and posterior hippocampus in young APOE ϵ 4 carriers. <i>Behavioural Brain Research</i> , 2017, 326, 256-264.	1.2	12
1177	The recency ratio is associated with reduced CSF glutamate in late-life depression. <i>Neurobiology of Learning and Memory</i> , 2017, 141, 14-18.	1.0	10
1178	Cardiorespiratory fitness alters the influence of a polygenic risk score on biomarkers of AD. <i>Neurology</i> , 2017, 88, 1650-1658.	1.5	35
1179	Tau oligomers in cerebrospinal fluid in Alzheimer's disease. <i>Annals of Clinical and Translational Neurology</i> , 2017, 4, 226-235.	1.7	72
1180	Alterations in the Balance of Amyloid- β 2 Protein Precursor Species in the Cerebrospinal Fluid of Alzheimer's Disease Patients. <i>Journal of Alzheimer's Disease</i> , 2017, 57, 1281-1291.	1.2	4
1181	Association of Plasma Neurofilament Light With Neurodegeneration in Patients With Alzheimer Disease. <i>JAMA Neurology</i> , 2017, 74, 557.	4.5	664
1182	Phenotypic Screening Identifies Modulators of Amyloid Precursor Protein Processing in Human Stem Cell Models of Alzheimer's Disease. <i>Stem Cell Reports</i> , 2017, 8, 870-882.	2.3	53
1183	Histology-Compatible MALDI Mass Spectrometry Based Imaging of Neuronal Lipids for Subsequent Immunofluorescent Staining. <i>Analytical Chemistry</i> , 2017, 89, 4685-4694.	3.2	60
1184	Psychosis and biological markers. <i>Lancet Psychiatry</i> , the, 2017, 4, 3-5.	3.7	4
1185	Recommendations for CSF AD biomarkers in the diagnostic evaluation of dementia. <i>Alzheimer's and Dementia</i> , 2017, 13, 274-284.	0.4	113
1186	Recommendations for cerebrospinal fluid Alzheimer's disease biomarkers in the diagnostic evaluation of mild cognitive impairment. <i>Alzheimer's and Dementia</i> , 2017, 13, 285-295.	0.4	108
1187	Increased blood-brain barrier permeability is associated with dementia and diabetes but not amyloid pathology or APOE genotype. <i>Neurobiology of Aging</i> , 2017, 51, 104-112.	1.5	154
1188	Expanding the cerebrospinal fluid endopeptidome. <i>Proteomics</i> , 2017, 17, 1600384.	1.3	28

#	ARTICLE	IF	CITATIONS
1189	Delineating Amyloid Plaque Associated Neuronal Sphingolipids in Transgenic Alzheimer's Disease Mice (tgArcSwe) Using MALDI Imaging Mass Spectrometry. <i>ACS Chemical Neuroscience</i> , 2017, 8, 347-355.	1.7	66
1190	Serum neurofilament light in familial Alzheimer disease. <i>Neurology</i> , 2017, 89, 2167-2175.	1.5	204
1191	Monitoring disease activity in multiple sclerosis using serum neurofilament light protein. <i>Neurology</i> , 2017, 89, 2230-2237.	1.5	307
1192	Fluid biomarkers for microglial activation and axonal injury in multiple sclerosis. <i>Acta Neurologica Scandinavica</i> , 2017, 136, 15-17.	1.0	15
1193	Mass Spectrometric Analysis of Cerebrospinal Fluid Ubiquitin in Alzheimer's Disease and Parkinsonian Disorders. <i>Proteomics - Clinical Applications</i> , 2017, 11, 1700100.	0.8	28
1194	Earliest accumulation of β -amyloid occurs within the default-mode network and concurrently affects brain connectivity. <i>Nature Communications</i> , 2017, 8, 1214.	5.8	596
1195	Cognitive impairment in Glucocerebrosidase (GBA) associated PD: Not primarily associated with cerebrospinal fluid Abeta and Tau profiles. <i>Movement Disorders</i> , 2017, 32, 1780-1783.	2.2	19
1196	Neurofilament light protein in CSF and blood is associated with neurodegeneration and disease severity in Huntington's disease R6/2 mice. <i>Scientific Reports</i> , 2017, 7, 14114.	1.6	49
1197	The role of blood and CSF biomarkers in the evaluation of new treatments against multiple sclerosis. <i>Expert Review of Clinical Immunology</i> , 2017, 13, 1143-1153.	1.3	20
1198	Serum tau and neurological outcome in cardiac arrest. <i>Annals of Neurology</i> , 2017, 82, 665-675.	2.8	86
1199	Proteomic studies of cerebrospinal fluid biomarkers of Alzheimer's disease: an update. <i>Expert Review of Proteomics</i> , 2017, 14, 1007-1020.	1.3	21
1200	Cerebrospinal Fluid Neurogranin as a Biomarker of Neurodegenerative Diseases: A Cross-Sectional Study. <i>Journal of Alzheimer's Disease</i> , 2017, 59, 1327-1334.	1.2	35
1201	A novel quantification-driven proteomic strategy identifies an endogenous peptide of pleiotrophin as a new biomarker of Alzheimer's disease. <i>Scientific Reports</i> , 2017, 7, 13333.	1.6	45
1202	Gut microbiome alterations in Alzheimer's disease. <i>Scientific Reports</i> , 2017, 7, 13537.	1.6	1,256
1203	[O2 ⁺ 05 ⁻ 06]: GUT MICROBIOME ALTERATIONS IN ALZHEIMER'S DISEASE AND THE RELATIONSHIP WITH CSF BIOMARKERS. <i>Alzheimer's and Dementia</i> , 2017, 13, P563.	0.4	3
1204	Successful combined targeting of B- and plasma cells in treatment refractory anti-NMDAR encephalitis. <i>Journal of Neuroimmunology</i> , 2017, 312, 15-18.	1.1	46
1205	Novel Trimodal MALDI Imaging Mass Spectrometry (IMS3) at 10 μ m Reveals Spatial Lipid and Peptide Correlates Implicated in $A\beta$ Plaque Pathology in Alzheimer's Disease. <i>ACS Chemical Neuroscience</i> , 2017, 8, 2778-2790.	1.7	84
1206	Neurogranin, a synaptic protein, is associated with memory independent of Alzheimer biomarkers. <i>Neurology</i> , 2017, 89, 1782-1788.	1.5	76

#	ARTICLE	IF	CITATIONS
1207	Impaired synaptic function is linked to cognition in Parkinson's disease. <i>Annals of Clinical and Translational Neurology</i> , 2017, 4, 700-713.	1.7	23
1208	A user's guide for α -synuclein biomarker studies in biological fluids: Perianalytical considerations. <i>Movement Disorders</i> , 2017, 32, 1117-1130.	2.2	54
1209	Alzheimer's disease markers in the aged sheep (<i>Ovis aries</i>). <i>Neurobiology of Aging</i> , 2017, 58, 112-119.	1.5	30
1210	CSF/serum albumin ratio in dementias: a cross-sectional study on 1861 patients. <i>Neurobiology of Aging</i> , 2017, 59, 1-9.	1.5	84
1211	β -amyloid ₁₋₄₅₁ and CSF τ and τ as biomarkers in Alzheimer's disease. <i>EMBO Molecular Medicine</i> , 2017, 9, 1212-1223.	3.3	156
1212	Absolute Quantification of β -amyloid ₁₋₄₂ in CSF Using a Mass Spectrometric Reference Measurement Procedure. <i>Journal of Visualized Experiments</i> , 2017, , .	0.2	3
1213	Immediate initiation of cART is associated with lower levels of cerebrospinal fluid YKL-40, a marker of microglial activation, in HIV-1 infection. <i>Aids</i> , 2017, 31, 247-252.	1.0	21
1214	Plasma and cerebrospinal fluid tau and neurofilament concentrations in rapidly progressive neurological syndromes: a neuropathology-based cohort. <i>European Journal of Neurology</i> , 2017, 24, 1326.	1.7	71
1215	Inhibiting the Ca ²⁺ Influx Induced by Human CSF. <i>Cell Reports</i> , 2017, 21, 3310-3316.	2.9	20
1216	[P3-297]: SUBJECTIVE COGNITIVE DECLINE AND NEUROIMAGING AND CEREBROSPINAL FLUID MARKERS OF CEREBROVASCULAR HEALTH: THE VANDERBILT MEMORY AND AGING PROJECT. <i>Alzheimer's and Dementia</i> , 2017, 13, P1057.	0.4	0
1217	Low-dose β -secretase inhibition increases secretion of β -peptides and intracellular oligomeric β . <i>Molecular and Cellular Neurosciences</i> , 2017, 85, 211-219.	1.0	6
1218	[P2-141]: TRISOMY 21 CAUSES A DEFICIT IN LYSOSOMAL CATHEPSINS AND ALTERS APP/ β PROCESSING, INDEPENDENTLY OF AN EXTRA COPY OF <i>APP</i> . <i>Alzheimer's and Dementia</i> , 2017, 13, P661.	0.4	0
1219	Reduced Cerebrospinal Fluid Concentration of Apolipoprotein A-I in Patients with Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2017, 59, 1017-1026.	1.2	24
1220	The predictive value of T-tau and AB1-42 levels in idiopathic normal pressure hydrocephalus. <i>Acta Neurochirurgica</i> , 2017, 159, 2293-2300.	0.9	19
1221	Electroconvulsive therapy does not alter the synaptic protein neurogranin in the cerebrospinal fluid of patients with major depression. <i>Journal of Neural Transmission</i> , 2017, 124, 1641-1645.	1.4	3
1222	[P4-182]: A NEUROBIOLOGICAL MODEL OF MEMORY IMPAIRMENT IN LATE-LIFE MAJOR DEPRESSIVE DISORDER. <i>Alzheimer's and Dementia</i> , 2017, 13, P1332.	0.4	1
1223	[O1-04-03]: NEIGHBORHOOD SOCIOECONOMIC CONTEXTUAL DISADVANTAGE, BASELINE COGNITION AND ALZHEIMER'S DISEASE BIOMARKERS IN THE WISCONSIN REGISTRY FOR ALZHEIMER'S PREVENTION (WRAP) STUDY. <i>Alzheimer's and Dementia</i> , 2017, 13, P195.	0.4	2
1224	Low vitamin D status in relation to cardiovascular disease and mortality in Swedish women - Effect of extended follow-up. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2017, 27, 1143-1151.	1.1	20

#	ARTICLE	IF	CITATIONS
1225	Poor sleep is associated with CSF biomarkers of amyloid pathology in cognitively normal adults. <i>Neurology</i> , 2017, 89, 445-453.	1.5	166
1226	Study protocol: Insight 46 – a neuroscience sub-study of the MRC National Survey of Health and Development. <i>BMC Neurology</i> , 2017, 17, 75.	0.8	64
1227	Ex vivo 18O-labeling mass spectrometry identifies a peripheral amyloid β clearance pathway. <i>Molecular Neurodegeneration</i> , 2017, 12, 18.	4.4	17
1228	Cerebrospinal fluid monoamine metabolite profiles in bipolar disorder, ADHD, and controls. <i>Journal of Neural Transmission</i> , 2017, 124, 1135-1143.	1.4	19
1229	The chitinases expression is related to Simian Immunodeficiency Virus Encephalitis (SIVE) and in HIV encephalitis (HIVE). <i>Virus Research</i> , 2017, 227, 220-230.	1.1	24
1230	Association of Amyloid Pathology With Myelin Alteration in Preclinical Alzheimer Disease. <i>JAMA Neurology</i> , 2017, 74, 41.	4.5	147
1231	Cerebrospinal fluid biomarkers as a measure of disease activity and treatment efficacy in relapsing-remitting multiple sclerosis. <i>Journal of Neurochemistry</i> , 2017, 141, 296-304.	2.1	124
1232	Blood Biomarkers for Alzheimer's Disease: Much Promise, Cautious Progress. <i>Molecular Diagnosis and Therapy</i> , 2017, 21, 13-22.	1.6	29
1233	Blood-based biomarkers in Alzheimer disease: Current state of the science and a novel collaborative paradigm for advancing from discovery to clinic. <i>Alzheimer's and Dementia</i> , 2017, 13, 45-58.	0.4	227
1234	Combined tissue and fluid proteomics with Tandem Mass Tags to identify low-abundance protein biomarkers of disease in peripheral body fluid: An Alzheimer's Disease case study. <i>Rapid Communications in Mass Spectrometry</i> , 2017, 31, 153-159.	0.7	35
1235	Serum Neurofilament Light Protein as a Marker for Diffuse Axonal Injury: Results from a Case Series Study. <i>Journal of Neurotrauma</i> , 2017, 34, 1124-1127.	1.7	104
1236	No support for premature central nervous system aging in HIV-1 when measured by cerebrospinal fluid phosphorylated tau (p-tau). <i>Virulence</i> , 2017, 8, 599-604.	1.8	12
1237	Analysis of C9orf72 repeat expansions in a large international cohort of dementia with Lewy bodies. <i>Neurobiology of Aging</i> , 2017, 49, 214.e13-214.e15.	1.5	12
1238	CSF neurofilament light levels predict hippocampal atrophy in cognitively healthy older adults. <i>Neurobiology of Aging</i> , 2017, 49, 138-144.	1.5	60
1239	A common challenge in older adults: Classification, overlap, and therapy of depression and dementia. <i>Alzheimer's and Dementia</i> , 2017, 13, 59-71.	0.4	112
1240	Validation of a new assay for β -synuclein detection in cerebrospinal fluid. <i>Clinical Chemistry and Laboratory Medicine</i> , 2017, 55, 254-260.	1.4	6
1241	Cerebrospinal Fluid Stanniocalcin-1 as a Biomarker for Alzheimer's Disease and Other Neurodegenerative Disorders. <i>NeuroMolecular Medicine</i> , 2017, 19, 154-160.	1.8	18
1242	Cerebrospinal fluid interferon alpha levels correlate with neurocognitive impairment in ambulatory HIV-Infected individuals. <i>Journal of NeuroVirology</i> , 2017, 23, 106-112.	1.0	22

#	ARTICLE	IF	CITATIONS
1243	The ACE Gene Is Associated with Late-Life Major Depression and Age at Dementia Onset in a Population-Based Cohort. <i>American Journal of Geriatric Psychiatry</i> , 2017, 25, 170-177.	0.6	13
1244	Concordance Between Different Amyloid Immunoassays and Visual Amyloid Positron Emission Tomographic Assessment. <i>JAMA Neurology</i> , 2017, 74, 1492.	4.5	97
1245	Effect of Spinal Manometers on Cerebrospinal Fluid Amyloid- β Concentration. <i>Journal of Alzheimer's Disease</i> , 2017, 56, 885-891.	1.2	6
1246	BRain health and healthy AgeIng in retired rugby union players, the BRAIN Study: study protocol for an observational study in the UK. <i>BMJ Open</i> , 2017, 7, e017990.	0.8	9
1247	[P1â€“219]: PROBING DEVELOPMENTAL CONSEQUENCES OF PSEN1 MUTATIONS IN IPSC DIFFERENTIATION IN 2D AND 3D. <i>Alzheimer's and Dementia</i> , 2017, 13, P327.	0.4	0
1248	[P1â€“025]: PROBING DEVELOPMENTAL CONSEQUENCES OF PSEN1 MUTATIONS IN IPSC DIFFERENTIATION IN 2D AND 3D. <i>Alzheimer's and Dementia</i> , 2017, 13, P242.	0.4	0
1249	[P1â€“027]: PET TAU AND AMYLOIDâ€“BETA DIFFER IN THEIR RELATIONSHIP TO AGE, COGNITION AND CSF BIOMARKERS IN MILD ALZHEIMER'S DISEASE: AN OBSERVATIONAL STUDY. <i>Alzheimer's and Dementia</i> , 2017, 13, P243.	0.4	0
1250	[P1â€“028]: DIAGNOSTIC ACCURACY OF CSF NEUROFILAMENT LIGHT CHAIN PROTEIN IN THE UNBIASED BIOMARKERâ€“GUIDED CLASSIFICATION SYSTEM FOR ALZHEIMER'S DISEASE. <i>Alzheimer's and Dementia</i> , 2017, 13, P243.	0.4	0
1251	[P2â€“536]: THE PREVALENCE OF PRECLINICAL ALZHEIMER'S DISEASE IN A POPULATION STUDY OF 70â€“YEARâ€“OLDS. <i>Alzheimer's and Dementia</i> , 2017, 13, P848.	0.4	2
1252	[P3â€“084]: Nâ€“TERMINAL FRAGMENT OF TAU: ASSAY DEVELOPMENT WITH INâ€“HOUSE CLEAVAGEâ€“SPECIFIC ANTIBODY. <i>Alzheimer's and Dementia</i> , 2017, 13, P964.	0.4	0
1253	[P3â€“171]: ACUTE, TRANSIENT INCREASE IN SECRETION OF NEURODEGENERATION BIOMARKERS AFTER IRRADIATION OF HUMAN CORTICAL NEURONS. <i>Alzheimer's and Dementia</i> , 2017, 13, P1000.	0.4	0
1254	[P3â€“174]: EFFECT OF PHYSICAL EXERCISE ON MARKERS OF NEURONAL DYSFUNCTION IN CEREBROSPINAL FLUID IN PATIENTS WITH ALZHEIMER'S DISEASE. <i>Alzheimer's and Dementia</i> , 2017, 13, P1000.	0.4	0
1255	[P3â€“198]: PREDICTION PERFORMANCE OF ALPHAâ€“SYNUCLEIN PROTEIN IN PRECLINICAL SUBJECTIVE MEMORY COMPLAINERS STRATIFIED BY AD BIOMARKERS: THE INSIGHTâ€“PRE AD STUDY. <i>Alzheimer's and Dementia</i> , 2017, 13, P1011.	0.4	0
1256	[P3â€“423]: REGIONAL DEFICIT IN SLEEPING BRAIN ACTIVITY ASSOCIATED WITH TAU AND AMYLOID PATHOLOGY IN COGNITIVELY HEALTHY MIDDLEâ€“AGED ADULTS. <i>Alzheimer's and Dementia</i> , 2017, 13, P1128.	0.4	0
1257	[P3â€“425]: ELEVATED CSF LEVELS OF NEUROFILAMENT LIGHT CHAIN IS ASSOCIATED WITH GRAY MATTER NEURODEGENERATION IN BOTH HUMANS AND TRANSGENIC RAT MODEL OF ALZHEIMER'S DISEASE. <i>Alzheimer's and Dementia</i> , 2017, 13, P1130.	0.4	0
1258	[P4â€“143]: UTILITY OF THE ATN DEFINITION OF BIOMARKER STATUS IN THE ALZHEIMER'S DISEASE NEUROIMAGING INITIATIVE. <i>Alzheimer's and Dementia</i> , 2017, 13, P1312.	0.4	0
1259	[P4â€“163]: STATISTICAL ALGORITHMS FOR HARMONIZING BIOMARKER DISTRIBUTIONS ACROSS DIFFERENT COHORTS, SITES AND ASSAYS: APPLICATIONS TO CSF MEASUREMENTS. <i>Alzheimer's and Dementia</i> , 2017, 13, P1322.	0.4	0
1260	[P1â€“150]: INVESTIGATION OF THE ASSOCIATION BETWEEN GENETIC VARIATION IN <i>IL1RAP</i> AND ALZHEIMER'Sâ€“RELATED CSFâ€“BIOMARKERS. <i>Alzheimer's and Dementia</i> , 2017, 13, P300.	0.4	0

#	ARTICLE	IF	CITATIONS
1261	[P1â€“048]: ELEVATED CSF LEVELS OF NEUROFILAMENT LIGHT CHAIN IS ASSOCIATED WITH GRAY MATTER NEURODEGENERATION IN BOTH HUMANS AND TRANSGENIC RAT MODEL OF ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2017, 13, P41.	0.4	0
1262	[P1â€“049]: REGIONAL DEFICIT IN SLEEPING BRAIN ACTIVITY ASSOCIATED WITH TAU AND AMYLOID PATHOLOGY IN COGNITIVELY HEALTHY MIDDLE-AGED ADULTS. Alzheimer's and Dementia, 2017, 13, P41.	0.4	0
1263	[P1â€“180]: DISTINCT A β PRODUCTION IN STEM CELL-DERIVED CORTICAL NEURONS FROM PATIENTS WITH FAD MUTATION. Alzheimer's and Dementia, 2017, 13, P311.	0.4	0
1264	[P1â€“187]: NOVEL METHOD FOR OLIGOMERIC A β DETECTION REVEALS INTRACELLULAR ACCUMULATION OF A β UPON LOW-DOSE TREATMENT WITH A GAMMA-SECRETASE INHIBITOR. Alzheimer's and Dementia, 2017, 13, P314.	0.4	0
1265	[P1â€“268]: ANALYSIS OF NEW POTENTIAL CSF BIOMARKERS FOR ALZHEIMER'S DISEASE BY PARALLEL REACTION MONITORING MASS SPECTROMETRY. Alzheimer's and Dementia, 2017, 13, P352.	0.4	0
1266	[P1â€“281]: DIAGNOSTIC PERFORMANCE USING CSF YKL40 IN ALZHEIMER'S DISEASE AND FRONTOTEMPORAL DEMENTIA. Alzheimer's and Dementia, 2017, 13, P357.	0.4	0
1267	[P1â€“282]: DIAGNOSTIC ACCURACY OF CSF A β 42, P-TAU, T-TAU, NEUROFILAMENT LIGHT CHAIN, NEUROGRANIN, YKL40 COMBINED BIOMARKERS IN A MULTICENTER COHORT OF COGNITIVELY IMPAIRED PATIENTS. Alzheimer's and Dementia, 2017, 13, P358.	0.4	0
1268	[P1â€“287]: DIAGNOSTIC ACCURACY OF CSF NEUROFILAMENT LIGHT CHAIN PROTEIN IN THE UNBIASED BIOMARKER-GUIDED CLASSIFICATION SYSTEM FOR ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2017, 13, P361.	0.4	0
1269	[P1â€“348]: CSF A β 42 CONCENTRATION INDEPENDENTLY PREDICTS POSTOPERATIVE DELIRIUM IN AN ELDERLY ELECTIVE ARTHROPLASTY POPULATION. Alzheimer's and Dementia, 2017, 13, P390.	0.4	0
1270	[P1â€“448]: PET TAU AND AMYLOID-BETA DIFFER IN THEIR RELATIONSHIP TO AGE, COGNITION AND CSF BIOMARKERS IN MILD ALZHEIMER'S DISEASE: AN OBSERVATIONAL STUDY. Alzheimer's and Dementia, 2017, 13, P456.	0.4	0
1271	[P1â€“611]: LIFETIME PHYSICAL ACTIVITY IS ASSOCIATED WITH CSF AMYLOID IN COGNITIVELY ASYMPTOMATIC APOE E4+ ADULTS. Alzheimer's and Dementia, 2017, 13, P530.	0.4	0
1272	[P2â€“158]: IS THE PRESUBICULUM PROTECTED FROM NEURODEGENERATIVE CHANGES? A PATHOLOGICAL AND BIOCHEMICAL INVESTIGATION. Alzheimer's and Dementia, 2017, 13, P668.	0.4	0
1273	[P2â€“208]: CSF AND PLASMA LEVELS OF INFLAMMATION DIFFERENTIALLY RELATE TO CNS MARKERS OF ALZHEIMER'S DISEASE PATHOLOGY AND NEURONAL DAMAGE. Alzheimer's and Dementia, 2017, 13, P689.	0.4	1
1274	[P2â€“211]: AMYLOID- β 42 (A β 42) DIFFERENTIALLY CORRELATES WITH CSF TOTAL AND HYPERPHOSPHORYLATED TAU IN AN AMYLOID-POSITIVE VERSUS AMYLOID-NEGATIVE EARLY PRODROMAL AND ASYMPTOMATIC AT-RISK4 FOR AD POPULATION. Alzheimer's and Dementia, 2017, 13, P690.	0.4	0
1275	[P2â€“212]: EUROPEAN MEDICAL INFORMATION FRAMEWORK FOR ALZHEIMER'S DISEASE (EMIF-AD): THE BIOMARKER DISCOVERY STUDY. Alzheimer's and Dementia, 2017, 13, P691.	0.4	1
1276	[P2â€“241]: CSF NEUROGRANIN IS INCREASED IN FAMILIAL ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2017, 13, P703.	0.4	0
1277	[P2â€“246]: NOVEL CSF FRAGMENTS OF TAU: CANDIDATE BIOMARKERS OF ALZHEIMER'S DISEASE AND TAUOPATHIES. Alzheimer's and Dementia, 2017, 13, P706.	0.4	0
1278	[P2â€“254]: SERUM FERRITIN IS INCREASED IN A SUBSET OF PATIENTS WITH FRONTOTEMPORAL DEMENTIA. Alzheimer's and Dementia, 2017, 13, P710.	0.4	0

#	ARTICLE	IF	CITATIONS
1279	[P2â€“260]: TWOâ€“LEVEL DIAGNOSTIC CLASSIFICATION USING CEREBROSPINAL FLUID NEUROGRANIN IN ALZHEIMER'S DISEASE. <i>Alzheimer's and Dementia</i> , 2017, 13, P712.	0.4	0
1280	[P2â€“262]: ASSOCIATION OF PLASMA NEUROFILAMENT LIGHT CHAIN PROTEIN WITH BRAIN AMYLOID STATUS IN A PRECLINICAL COHORT OF SUBJECTIVE MEMORY COMPLAINERS: THE INSIGHTâ€“READ STUDY. <i>Alzheimer's and Dementia</i> , 2017, 13, P713.	0.4	0
1281	[F1â€“02â€“03]: VALIDATING PLASMA NEUROFILAMENT LIGHT AS A BLOOD BIOMARKER FOR NEURODEGENERATION USING NEUROIMAGING. <i>Alzheimer's and Dementia</i> , 2017, 13, P175.	0.4	0
1282	[O1â€“05â€“04]: CLINICAL PERFORMANCE OF NEUROGRANIN AS A CEREBROSPINAL FLUID BIOMARKER FOR ALZHEIMER'S DISEASE: AN ASSAY COMPARISON STUDY. <i>Alzheimer's and Dementia</i> , 2017, 13, P199.	0.4	0
1283	[O1â€“08â€“02]: ELEVATED CEREBROSPINAL FLUID NEUROFILAMENT LIGHT LEVELS ARE ASSOCIATED WITH COMPROMISED WHITE MATTER INTEGRITY AMONG OLDER ADULTS. <i>Alzheimer's and Dementia</i> , 2017, 13, P207.	0.4	0
1284	[O1â€“10â€“01]: EVIDENCE FOR EARLY DETECTION OF CSF BETAâ€“AMYLOID AND TAU AND EFFECT ON LONGITUDINAL COGNITIVE PERFORMANCE IN INDIVIDUALS AT RISK FOR ALZHEIMER'S DISEASE. <i>Alzheimer's and Dementia</i> , 2017, 13, P213.	0.4	0
1285	[O1â€“10â€“03]: BIOMARKERS OF INFLAMMATION IN ALZHEIMER'S DISEASE. <i>Alzheimer's and Dementia</i> , 2017, 13, P215.	0.4	1
1286	[O1â€“10â€“06]: ASTROGLIAL ACTIVATION AND ALTERED AMYLOID METABOLISM IN HUMAN REPETITIVE CONCUSSIVE TRAUMATIC BRAIN INJURY. <i>Alzheimer's and Dementia</i> , 2017, 13, P216.	0.4	0
1287	[O1â€“11â€“03]: CEREBROSPINAL FLUID ENDOPHENOTYPES PROVIDE INSIGHT INTO BIOLOGY UNDERLYING ALZHEIMER'S DISEASE. <i>Alzheimer's and Dementia</i> , 2017, 13, P218.	0.4	0
1288	[O3â€“10â€“02]: LONGITUDINAL CSF BIOMARKER CHANGES IN MIDDLEâ€“AGED ADULTS AT RISK FOR AD: THE WISCONSIN REGISTRY FOR ALZHEIMER'S PREVENTION (WRAP) AND WISCONSIN ADRC COHORTS. <i>Alzheimer's and Dementia</i> , 2017, 13, P923.	0.4	1
1289	[O3â€“10â€“03]: LONGITUDINAL CEREBROSPINAL FLUID BIOMARKER TRAJECTORIES ALONG THE ALZHEIMER'S DISEASE CONTINUUM: A MULTICENTRE EUROPEAN STUDY. <i>Alzheimer's and Dementia</i> , 2017, 13, P924.	0.4	3
1290	[O3â€“11â€“03]: MODERATE INTENSITY PHYSICAL ACTIVITY IS ASSOCIATED WITH CSF BIOMARKERS IN PRECLINICAL ALZHEIMER'S DISEASE. <i>Alzheimer's and Dementia</i> , 2017, 13, P927.	0.4	0
1291	[O4â€“02â€“01]: PLASMA AND CSF LEVELS OF NEUROFILAMENT LIGHT CHAIN CORRELATE IN ATYPICAL PARKINSONIAN SYNDROMES AND DISTINGUISH THEM FROM PARKINSON'S AND ALZHEIMER'S DISEASE. <i>Alzheimer's and Dementia</i> , 2017, 13, P1228.	0.4	0
1292	[O4â€“02â€“04]: SERUM NEUROFILAMENT LIGHT CONCENTRATION IN FAMILIAL ALZHEIMER'S DISEASE AND ASSOCIATION WITH MARKERS OF DISEASE STAGE AND SEVERITY. <i>Alzheimer's and Dementia</i> , 2017, 13, P1230.	0.4	0
1293	[P4â€“392]: NOVEL ASSAYS TO MONITOR AÎ² PEPTIDES GENERATED BY THE ASPARAGATE ENDOPEPTIDASE AFTER INHIBITION OF BACE. <i>Alzheimer's and Dementia</i> , 2017, 13, P1478.	0.4	0
1294	[P4â€“470]: PRESYNAPTIC DEGRADATION IN ALZHEIMER'S DISEASE MEASURED BY NOVEL GAPâ€“43 ELISA IN CSF. <i>Alzheimer's and Dementia</i> , 2017, 13, P1513.	0.4	0
1295	[ICâ€“Pâ€“171]: MODERATE INTENSITY PHYSICAL ACTIVITY ASSOCIATES WITH CSF BIOMARKERS IN PRECLINICAL ALZHEIMER'S DISEASE. <i>Alzheimer's and Dementia</i> , 2017, 13, P128.	0.4	0
1296	Sample Preparation for Endopeptidomic Analysis in Human Cerebrospinal Fluid. <i>Journal of Visualized Experiments</i> , 2017, , .	0.2	1

#	ARTICLE	IF	CITATIONS
1297	Mild traumatic brain injury is associated with increased levels of axonal injury biomarkers in blood. <i>British Journal of Sports Medicine</i> , 2017, 51, A6.3-A7.	3.1	1
1298	[P4â€“382]: PROTEOMIC CHANGES IN ZEBRAFISH LACKING THE AMYLOID PRECURSOR HOMOLOG, APPB, USING A HIGHâ€“THROUGHPUT DIFFERENTIAL PROTEOMIC APPROACH. <i>Alzheimer's and Dementia</i> , 2017, 13, P1439.	0.4	0
1299	PET Tau and Amyloid- β^2 Burden in Mild Alzheimerâ€™s Disease: Divergent Relationship with Age, Cognition, and Cerebrospinal Fluid Biomarkers. <i>Journal of Alzheimer's Disease</i> , 2017, 60, 283-293.	1.2	67
1300	[P3â€“075]: PLEIOTROPHIN, A NEW BIOMARKER FOR AD, IDENTIFIED USING A NOVEL STRATEGY IN CLINICAL PROTEOMICS. <i>Alzheimer's and Dementia</i> , 2017, 13, P960.	0.4	0
1301	High Interferon- β^3 Uniquely in V β^1 T Cells Correlates with Markers of Inflammation and Axonal Damage in Early Multiple Sclerosis. <i>Frontiers in Immunology</i> , 2017, 8, 260.	2.2	19
1302	Microstructural white matter alterations in preclinical Alzheimerâ€™s disease detected using free water elimination diffusion tensor imaging. <i>PLoS ONE</i> , 2017, 12, e0173982.	1.1	104
1303	Cognitive function in very old men does not correlate to biomarkers of Alzheimerâ€™s disease. <i>BMC Geriatrics</i> , 2017, 17, 208.	1.1	9
1304	Neurogranin and tau in cerebrospinal fluid and plasma of patients with acute ischemic stroke. <i>BMC Neurology</i> , 2017, 17, 170.	0.8	70
1305	Effects of surgery and propofol-remifentanyl total intravenous anesthesia on cerebrospinal fluid biomarkers of inflammation, Alzheimerâ€™s disease, and neuronal injury in humans: a cohort study. <i>Journal of Neuroinflammation</i> , 2017, 14, 193.	3.1	15
1306	Preclinical effects of APOE ϵ^4 on cerebrospinal fluid A β^242 concentrations. <i>Alzheimer's Research and Therapy</i> , 2017, 9, 87.	3.0	22
1307	Intracranial Arterial 4D Flow in Individuals with Mild Cognitive Impairment is Associated with Cognitive Performance and Amyloid Positivity. <i>Journal of Alzheimer's Disease</i> , 2017, 60, 243-252.	1.2	15
1308	Fluid biomarkers for disease activity in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2017, 23, 1660-1661.	1.4	4
1309	High-throughput analysis of sulfatides in cerebrospinal fluid using automated extraction and UPLC-MS/MS. <i>Journal of Lipid Research</i> , 2017, 58, 1482-1489.	2.0	14
1310	Reduced cerebrospinal fluid concentration of interleukin-12/23 subunit p40 in patients with cognitive impairment. <i>PLoS ONE</i> , 2017, 12, e0176760.	1.1	18
1311	Insulin Resistance is Associated with Increased Levels of Cerebrospinal Fluid Biomarkers of Alzheimerâ€™s Disease and Reduced Memory Function in At-Risk Healthy Middle-Aged Adults. <i>Journal of Alzheimer's Disease</i> , 2016, 52, 1373-1383.	1.2	51
1312	A Genetic Variant of the Sortilin 1 Gene is Associated with Reduced Risk of Alzheimerâ€™s Disease. <i>Journal of Alzheimer's Disease</i> , 2016, 53, 1353-1363.	1.2	28
1313	Association between APOE Genotype and Change in Physical Function in a Population-Based Swedish Cohort of Older Individuals Followed Over Four Years. <i>Frontiers in Aging Neuroscience</i> , 2016, 8, 225.	1.7	18
1314	Increased Intrathecal Immune Activation in Virologically Suppressed HIV-1 Infected Patients with Neurocognitive Impairment. <i>PLoS ONE</i> , 2016, 11, e0157160.	1.1	93

#	ARTICLE	IF	CITATIONS
1315	Association between Plasma Homocysteine Levels and Neuronal Injury in HIV Infection. PLoS ONE, 2016, 11, e0158973.	1.1	7
1316	The APOE Genotype in Idiopathic Normal Pressure Hydrocephalus. PLoS ONE, 2016, 11, e0158985.	1.1	6
1317	Effect of Docosahexaenoic Acid on a Biomarker of Head Trauma in American Football. Medicine and Science in Sports and Exercise, 2016, 48, 974-982.	0.2	68
1318	Blood biomarkers indicate mild neuroaxonal injury and increased amyloid β production after transient hypoxia during breath-hold diving. Brain Injury, 2016, 30, 1226-1230.	0.6	23
1319	Alzheimer's disease cerebrospinal fluid biomarkers predict cognitive decline in lewy body dementia. Movement Disorders, 2016, 31, 1203-1208.	2.2	70
1320	Update on fluid biomarkers for concussion. Concussion, 2016, 1, CNC12.	1.2	11
1321	Apolipoprotein E polymorphism in aneurysmal subarachnoid haemorrhage in West Sweden. Acta Neurologica Scandinavica, 2016, 133, 466-474.	1.0	12
1322	Î²-Synuclein in Neurodegeneration: A Good Protein that may go Bad. Brain Pathology, 2016, 26, 387-388.	2.1	0
1323	Neurofilament Light: A Dynamic Cross-Disease Fluid Biomarker for Neurodegeneration. Neuron, 2016, 91, 1-3.	3.8	178
1324	Cerebrospinal fluid levels of insulin, leptin, and agouti-related protein in relation to BMI in pregnant women. Obesity, 2016, 24, 1299-1304.	1.5	10
1325	Cerebral white matter lesions: associations with A β isoforms and amyloid PET. Scientific Reports, 2016, 6, 20709.	1.6	52
1326	Pathway-Specific Polygenic Risk Scores as Predictors of Amyloid- β Deposition and Cognitive Function in a Sample at Increased Risk for Alzheimer's Disease. Journal of Alzheimer's Disease, 2016, 55, 473-484.	1.2	93
1327	Associations between Performance on Abbreviated CogState Battery, Other Measures of Cognitive Function, and Biomarkers in People at Risk for Alzheimer's Disease. Journal of Alzheimer's Disease, 2016, 54, 1395-1408.	1.2	40
1328	Cerebrospinal fluid tau, neurogranin, and neurofilament light in Alzheimer's disease. EMBO Molecular Medicine, 2016, 8, 1184-1196.	3.3	219
1329	Non-Phosphorylated Tau as a Potential Biomarker of Alzheimer's Disease: Analytical and Diagnostic Characterization. Journal of Alzheimer's Disease, 2016, 55, 159-170.	1.2	23
1330	Serum erythropoietin and outcome after ischaemic stroke: a prospective study. BMJ Open, 2016, 6, e009827.	0.8	9
1331	sTREM 2 cerebrospinal fluid levels are a potential biomarker for microglia activity in early-stage Alzheimer's disease and associate with neuronal injury markers. EMBO Molecular Medicine, 2016, 8, 466-476.	3.3	392
1332	Comprehensive Quantitative Profiling of Tau and Phosphorylated Tau Peptides in Cerebrospinal Fluid by Mass Spectrometry Provides New Biomarker Candidates. Journal of Alzheimer's Disease, 2016, 55, 303-313.	1.2	44

#	ARTICLE	IF	CITATIONS
1333	The pre-synaptic vesicle protein synaptotagmin is a novel biomarker for Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2016, 8, 41.	3.0	121
1334	Diagnosing Dementia in the Clinical Setting: Can Amyloid PET Provide Additional Value Over Cerebrospinal Fluid?. <i>Journal of Alzheimer's Disease</i> , 2016, 54, 1297-1302.	1.2	21
1335	Specific Triazine Herbicides Induce Amyloid- β 42 Production. <i>Journal of Alzheimer's Disease</i> , 2016, 54, 1593-1605.	1.2	14
1336	Preclinical Amyloid- β 2 and Axonal Degeneration Pathology in Delirium. <i>Journal of Alzheimer's Disease</i> , 2016, 55, 371-379.	1.2	35
1337	P3-129: Psychological Stress in Midlife Associated with Higher Levels of CSF T-TAU and AB40 in Late-Life: A 25-YEAR Longitudinal Population Study of Women. , 2016, 12, P869-P869.		0
1338	O1-05-01: Increased Amyloidogenic app Processing in ApoE E4-Negative Individuals with Cerebral β -Amyloidosis. <i>Alzheimer's and Dementia</i> , 2016, 12, P182.	0.4	0
1339	O5-01-02: Stress is Associated with Greater Insulin Resistance, Higher CSF Phosphorylated TAU, and Decreased Glucose Metabolism in the Medial Temporal Lobe in apoe β 4 Carriers. , 2016, 12, P375-P376.		0
1340	P1-172: Combined Added Value of Cerebrospinal Fluid Neurogranin and Neurofilament Light Chain Protein in the Diagnosis and Classification Of Prodromal and Alzheimer's Disease Dementia. <i>Alzheimer's and Dementia</i> , 2016, 12, P468.	0.4	0
1341	IC-050: MCI Status, Amyloid and TAU Biomarkers, and Composite Cognitive Impairment Scores are Associated with Cogstate Performance in The Wisconsin Registry For Alzheimer's Prevention. <i>Alzheimer's and Dementia</i> , 2016, 12, P41.	0.4	0
1342	P1-322: Four-Dimensional Arterial Blood Flow Metrics in The Internal Carotid Artery Predict Cognitive Performance and are Associated with CSF Biomarkers in Patients with MCI. <i>Alzheimer's and Dementia</i> , 2016, 12, P548.	0.4	0
1343	P1-344: Poor Sleep Quality is Associated with CSF Markers of Amyloid Deposition in Cognitively Healthy Adults at Risk for Alzheimer's Disease. <i>Alzheimer's and Dementia</i> , 2016, 12, P561.	0.4	0
1344	P1-410: Lifetime Recreational Physical Activity is Associated with CSF Amyloid in Cognitively Asymptomatic Adults. <i>Alzheimer's and Dementia</i> , 2016, 12, P591.	0.4	0
1345	P2-151: Cerebrospinal Fluid Biomarker Profile of Amyloid, TAU, Synaptic, Microglial, and Lysosomal Pathophysiology in Cognitively Normal Preclinical Individuals Stratified by Amyloid-Pet Status. <i>Alzheimer's and Dementia</i> , 2016, 12, P672.	0.4	0
1346	P2-152: Characterization of the Postsynaptic Protein Neurogranin in Different Brain Regions in Patients with Familial Alzheimer's Disease, Alzheimer's Disease, Pathological Aging And Healthy Controls. <i>Alzheimer's and Dementia</i> , 2016, 12, P672.	0.4	0
1347	P2-137: The CSF AB42/40 Ratio does not Mitigate Misinterpretation of AB Loss Upon Serial Tube Transfers. <i>Alzheimer's and Dementia</i> , 2016, 12, P664.	0.4	0
1348	P2-142: Comparison of T-tau, Neurogranin and NFL as CSF Neurodegeneration Markers in Alzheimer's Disease. <i>Alzheimer's and Dementia</i> , 2016, 12, P667.	0.4	0
1349	IC-123: Four Dimensional Arterial Blood Flow Metrics in The Internal Carotid Artery Predict Cognitive Performance and Are Associated With CSF Biomarkers in Patients With MCI. <i>Alzheimer's and Dementia</i> , 2016, 12, P91.	0.4	0
1350	P2-430: The Prevalence of Pathological CSF Abeta β 42 and ITS Relation to Education in a Population Sample of Older People from Sweden. <i>Alzheimer's and Dementia</i> , 2016, 12, P810.	0.4	0

#	ARTICLE	IF	CITATIONS
1351	P3-162: Diagnostic Value of Cerebrospinal Fluid Neurofilament Light Chain Protein in the Classification of Prodromal and Alzheimer's Disease Dementia. , 2016, 12, P881-P881.		1
1352	P3-165: Plasma Biomarker Profile of Amyloid, TAU, and Neuronal Pathophysiology in Cognitively Normal Preclinical Individuals Stratified by Amyloid-Pet Status. , 2016, 12, P882-P883.		0
1353	P3-193: Serum Neurofilament Light Protein Predicts Clinical Outcome in Traumatic Brain Injury. , 2016, 12, P896-P897.		0
1354	P4-114: Cerebrospinal Fluid Biomarkers of Neuronal Injury in Chronic Traumatic Brain Injury. , 2016, 12, P1056-P1056.		0
1355	F1-03-02: How ad-specific are ad CSF Biomarkers?. Alzheimer's and Dementia, 2016, 12, P166.	0.4	0
1356	O1-05-06: Stability of Amyloid-Beta (1-42) in Fresh Versus Frozen Human Cerebrospinal Fluid Samples as Measured with the Elecsys [®] Amyloid(1-42) Immunoassay. Alzheimer's and Dementia, 2016, 12, P185.	0.4	0
1357	O1-11-05: CSF In the Differential Diagnosis of Alzheimer's Disease: Clinical Utility of an Extended Panel Of Biomarkers in a Specialist Cognitive Clinic. Alzheimer's and Dementia, 2016, 12, P203.	0.4	1
1358	O3-03-02: MCI STATUS, AMYLOID AND TAU BIOMARKERS, AND COMPOSITE COGNITIVE IMPAIRMENT SCORES ARE ASSOCIATED WITH COGSTATE PERFORMANCE IN THE WISCONSIN REGISTRY FOR ALZHEIMER'S PREVENTION. , 2016, 12, P285-P286.		0
1359	O3-09-01: Distinct Cognitive Trajectories in Late Middle-Age and their Associations with Brain Structure and Alzheimer's Disease Biomarkers: Findings from the Wisconsin Registry for Alzheimer's Prevention. Alzheimer's and Dementia, 2016, 12, P306.	0.4	0
1360	O4-10-01: PLASMA NFL: A NEW BIOMARKER FOR DIFFERENTIAL DIAGNOSIS OF PARKINSONIAN DISORDERS. Alzheimer's and Dementia, 2016, 12, P357.	0.4	0
1361	P1-012: A Population-Based Study on the Relation Between Sleep Disturbance and Beta-Amyloid 42 in Cerebrospinal Fluid in 70-Year-Olds. , 2016, 12, P404-P404.		0
1362	P1-028: Does Calcium Supplementation Increase the Risk of Dementia in Women With Cerebrovascular Disease? A Five Year Follow-Up of Older Swedish Women. , 2016, 12, P412-P412.		0
1363	P1-171: Added Diagnostic Value of Cerebrospinal Fluid Neurogranin in the Classification of Prodromal and Alzheimer's Disease Dementia. Alzheimer's and Dementia, 2016, 12, P468.	0.4	0
1364	P1-177: How Accurate are Cerebrospinal Fluid Biomarkers for the Diagnosis of Alzheimer Disease? A Systematic Review. , 2016, 12, P471-P472.		0
1365	P1-181: State-Dependent Alterations in CSF A β 42 Levels in Cognitively-Intact Elderly With Late Life Major Depression. Alzheimer's and Dementia, 2016, 12, P473.	0.4	0
1366	P1-204: Neurogranin: a Specific Synaptic Biomarker for Amnesic Alzheimer's Disease?. Alzheimer's and Dementia, 2016, 12, P483.	0.4	0
1367	P4-312: Progress on the Development of Certified Reference Materials for AB1-42. Alzheimer's and Dementia, 2016, 12, P1153.	0.4	0
1368	P4-313: Commutability of the Candidate Certified Reference Materials for the Standardization of A β 1-42 Measurements in Human Cerebrospinal Fluid. Alzheimer's and Dementia, 2016, 12, P1153.	0.4	0

#	ARTICLE	IF	CITATIONS
1369	P4â€³24: Plasma Neurofilament Light Concentration Predicts Longâ€³Term Outcome an Acute Stroke. <i>Alzheimer's and Dementia</i> , 2016, 12, P1158.	0.4	0
1370	Cerebrospinal Fluid Markers of Alzheimerâ€™s Disease Pathology and Microglial Activation are Associated with Altered White Matter Microstructure in Asymptomatic Adults at Risk for Alzheimerâ€™s Disease. <i>Journal of Alzheimer's Disease</i> , 2016, 50, 873-886.	1.2	101
1371	Neurofilaments in blood and CSF for diagnosis and prediction of onset in Creutzfeldt-Jakob disease. <i>Scientific Reports</i> , 2016, 6, 38737.	1.6	81
1372	Comparing biological markers of Alzheimer's disease across blood fraction and platforms: Comparing apples to oranges. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2016, 3, 27-34.	1.2	44
1373	Serum 25-hydroxy vitamin D levels in middle-aged women in relationship to adiposity and height trajectories over three decades. <i>European Journal of Clinical Nutrition</i> , 2016, 70, 709-714.	1.3	8
1374	Abnormality in glutamineâ€“glutamate cycle in the cerebrospinal fluid of cognitively intact elderly individuals with major depressive disorder: a 3-year follow-up study. <i>Translational Psychiatry</i> , 2016, 6, e744-e744.	2.4	69
1375	Serum Neurofilament Light in American Football Athletes over the Course of a Season. <i>Journal of Neurotrauma</i> , 2016, 33, 1784-1789.	1.7	110
1376	Myo-inositol changes precede amyloid pathology and relate to <i>APOE</i> genotype in Alzheimer disease. <i>Neurology</i> , 2016, 86, 1754-1761.	1.5	66
1377	CSF and blood biomarkers for the diagnosis of Alzheimer's disease: a systematic review and meta-analysis. <i>Lancet Neurology</i> , The, 2016, 15, 673-684.	4.9	1,413
1378	Cerebrospinal Fluid Biomarkers in Alzheimerâ€™s Disease. <i>Methods in Pharmacology and Toxicology</i> , 2016, , 153-179.	0.1	0
1379	Monitoring of 30 marker candidates in early Parkinson disease as progression markers. <i>Neurology</i> , 2016, 87, 168-177.	1.5	133
1380	Comparison of three analytical platforms for quantification of the neurofilament light chain in blood samples: ELISA, electrochemiluminescence immunoassay and Simoa. <i>Clinical Chemistry and Laboratory Medicine</i> , 2016, 54, 1655-1661.	1.4	517
1381	Glial and neuronal markers in cerebrospinal fluid in different types of multiple sclerosis. <i>Journal of Neuroimmunology</i> , 2016, 299, 112-117.	1.1	43
1382	CSF profiling of the human brain enriched proteome reveals associations of neuromodulin and neurogranin to Alzheimer's disease. <i>Proteomics - Clinical Applications</i> , 2016, 10, 1242-1253.	0.8	64
1383	Pittsburgh compound B imaging and cerebrospinal fluid amyloid-Î² in a multicentre European memory clinic study. <i>Brain</i> , 2016, 139, 2540-2553.	3.7	107
1384	Neurochemical Aftermath of Repetitive Mild Traumatic Brain Injury. <i>JAMA Neurology</i> , 2016, 73, 1308.	4.5	96
1385	Asymptomatic Cerebrospinal Fluid HIV-1 Viral Blips and Viral Escape During Antiretroviral Therapy: A Longitudinal Study. <i>Journal of Infectious Diseases</i> , 2016, 214, 1822-1825.	1.9	53
1386	Plasma tau in Alzheimer disease. <i>Neurology</i> , 2016, 87, 1827-1835.	1.5	371

#	ARTICLE	IF	CITATIONS
1387	Multicenter immunoassay validation of cerebrospinal fluid neurofilament light: a biomarker for neurodegeneration. <i>Bioanalysis</i> , 2016, 8, 2243-2254.	0.6	14
1388	Cerebrospinal fluid-induced retardation of amyloid β aggregation correlates with Alzheimer's disease and the APOE ϵ 4 allele. <i>Brain Research</i> , 2016, 1651, 11-16.	1.1	25
1389	Cerebrospinal fluid neurogranin and τ 40 as biomarkers of Alzheimer's disease. <i>Annals of Clinical and Translational Neurology</i> , 2016, 3, 12-20.	1.7	137
1390	Plasma neurofilament light chain predicts progression in progressive supranuclear palsy. <i>Annals of Clinical and Translational Neurology</i> , 2016, 3, 216-225.	1.7	163
1391	Longitudinal measurements of cerebrospinal fluid biomarkers in Parkinson's disease. <i>Movement Disorders</i> , 2016, 31, 898-905.	2.2	136
1392	Cerebrospinal fluid total tau concentration predicts clinical phenotype in Huntington's disease. <i>Journal of Neurochemistry</i> , 2016, 139, 22-25.	2.1	58
1393	Amyloid mis-metabolism in idiopathic normal pressure hydrocephalus. <i>Fluids and Barriers of the CNS</i> , 2016, 13, 13.	2.4	38
1394	Beneficial effects of increased lysozyme levels in Alzheimer's disease modelled in <i>Drosophila melanogaster</i> . <i>FEBS Journal</i> , 2016, 283, 3508-3522.	2.2	15
1395	Reference measurement procedure for CSF amyloid beta $A\beta_{42}$ and the CSF $A\beta_{42}/A\beta_{40}$ ratio – a cross-validation study against amyloid PET. <i>Journal of Neurochemistry</i> , 2016, 139, 651-658.	2.1	78
1396	Calcium supplementation and risk of dementia in women with cerebrovascular disease. <i>Neurology</i> , 2016, 87, 1674-1680.	1.5	35
1397	Increased neurogranin concentrations in cerebrospinal fluid of Alzheimer's disease and in mild cognitive impairment due to AD. <i>Journal of Neural Transmission</i> , 2016, 123, 1443-1447.	1.4	39
1398	Plasma β -amyloid in Alzheimer's disease and vascular disease. <i>Scientific Reports</i> , 2016, 6, 26801.	1.6	442
1399	Blood-brain barrier integrity, intrathecal immunoactivation, and neuronal injury in HIV. <i>Neurology: Neuroimmunology and Neuroinflammation</i> , 2016, 3, e300.	3.1	36
1400	Neurofilament light in CSF and serum is a sensitive marker for axonal white matter injury in MS. <i>Neurology: Neuroimmunology and Neuroinflammation</i> , 2016, 3, e271.	3.1	118
1401	Comparison of Different Matrices as Potential Quality Control Samples for Neurochemical Dementia Diagnostics. <i>Journal of Alzheimer's Disease</i> , 2016, 52, 51-64.	1.2	18
1402	Update on ultrasensitive technologies to facilitate research on blood biomarkers for central nervous system disorders. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2016, 3, 98-102.	1.2	62
1403	Fluid biomarkers for mild traumatic brain injury and related conditions. <i>Nature Reviews Neurology</i> , 2016, 12, 563-574.	4.9	215
1404	Serum neurofilament light chain protein is a measure of disease intensity in frontotemporal dementia. <i>Neurology</i> , 2016, 87, 1329-1336.	1.5	354

#	ARTICLE	IF	CITATIONS
1405	Cerebrospinal fluid viral load and biomarkers of neuronal and glial cells in Ramsay Hunt syndrome. <i>European Journal of Neuroscience</i> , 2016, 44, 2944-2949.	1.2	9
1406	Cerebrospinal Fluid Amyloid Beta and Tau Concentrations Are Not Modulated by 16 Weeks of Moderate- to High-Intensity Physical Exercise in Patients with Alzheimer Disease. <i>Dementia and Geriatric Cognitive Disorders</i> , 2016, 42, 146-158.	0.7	40
1407	The clinical value of fluid biomarkers for dementia diagnosis – Authors' reply. <i>Lancet Neurology</i> , The, 2016, 15, 1204-1205.	4.9	7
1408	O2â€10â€05: Cerebrospinal Fluid Levels of Amyloid Beta and Tau as Endophenotypes Reveal Novel Variants Potentially Informative for Alzheimer's Disease. <i>Alzheimer's and Dementia</i> , 2016, 12, P252.	0.4	0
1409	Label-free quantitative comparison of cerebrospinal fluid glycoproteins and endogenous peptides in subjects with Alzheimer's disease, mild cognitive impairment, and healthy individuals. <i>Proteomics - Clinical Applications</i> , 2016, 10, 1225-1241.	0.8	30
1410	A targeted proteomic multiplex CSF assay identifies increased malate dehydrogenase and other neurodegenerative biomarkers in individuals with Alzheimer's disease pathology. <i>Translational Psychiatry</i> , 2016, 6, e952-e952.	2.4	46
1411	Traumatic brain injuries. <i>Nature Reviews Disease Primers</i> , 2016, 2, 16084.	18.1	380
1412	Neuromodulation of fast-spiking and non-fast-spiking hippocampal CA1 interneurons by human cerebrospinal fluid. <i>Journal of Physiology</i> , 2016, 594, 937-952.	1.3	16
1413	Increased amyloidogenic APP processing in APOE 4-negative individuals with cerebral 2-amyloidosis. <i>Nature Communications</i> , 2016, 7, 10918.	5.8	48
1414	Amyloid precursor protein expression and processing are differentially regulated during cortical neuron differentiation. <i>Scientific Reports</i> , 2016, 6, 29200.	1.6	65
1415	Serum neurofilament light protein predicts clinical outcome in traumatic brain injury. <i>Scientific Reports</i> , 2016, 6, 36791.	1.6	281
1416	Orexin-A is Associated with Increases in Cerebrospinal Fluid Phosphorylated-Tau in Cognitively Normal Elderly Subjects. <i>Sleep</i> , 2016, 39, 1253-1260.	0.6	44
1417	The Vanderbilt Memory & Aging Project: Study Design and Baseline Cohort Overview. <i>Journal of Alzheimer's Disease</i> , 2016, 52, 539-559.	1.2	44
1418	Increased Cerebrospinal Fluid Levels of Ubiquitin Carboxyl-Terminal Hydrolase L1 in Patients with Alzheimer's Disease. <i>Dementia and Geriatric Cognitive Disorders Extra</i> , 2016, 6, 283-294.	0.6	33
1419	D4â€...Prediction of huntingtonâ€™s disease phenotype by cerebrospinal fluid biomarkers of inflammation and cell death. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2016, 87, A35.1-A35.	0.9	0
1420	Reduced Slow-Wave Sleep Is Associated with High Cerebrospinal Fluid AÎ242 Levels in Cognitively Normal Elderly. <i>Sleep</i> , 2016, 39, 2041-2048.	0.6	140
1421	No diurnal variation of classical and candidate biomarkers of Alzheimer's disease in CSF. <i>Molecular Neurodegeneration</i> , 2016, 11, 65.	4.4	16
1422	Cerebrospinal fluid markers of neuronal and glial cell damage to monitor disease activity and predict long-term outcome in patients with autoimmune encephalitis. <i>European Journal of Neurology</i> , 2016, 23, 796-806.	1.7	46

#	ARTICLE	IF	CITATIONS
1423	Soluble CD14 in cerebrospinal fluid is associated with markers of inflammation and axonal damage in untreated HIV-infected patients: a retrospective cross-sectional study. <i>BMC Infectious Diseases</i> , 2016, 16, 176.	1.3	23
1424	<i>APOE</i> ϵ 4 carriers may undergo synaptic damage conferring risk of Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2016, 12, 1159-1166.	0.4	29
1425	Biomarker clusters are differentially associated with longitudinal cognitive decline in late midlife. <i>Brain</i> , 2016, 139, 2261-2274.	3.7	41
1426	Cerebrospinal fluid ratios with $A\beta_{42}$ predict preclinical brain β -amyloid accumulation. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2016, 2, 27-38.	1.2	44
1427	β -Amyloid precursor protein-b is essential for Mauthner cell development in the zebrafish in a Notch-dependent manner. <i>Developmental Biology</i> , 2016, 413, 26-38.	0.9	19
1428	Targeting LAMP2 in human cerebrospinal fluid with a combination of immunopurification and high resolution parallel reaction monitoring mass spectrometry. <i>Clinical Proteomics</i> , 2016, 13, 4.	1.1	22
1429	Low Circulating Acute Brain-Derived Neurotrophic Factor Levels Are Associated With Poor Long-Term Functional Outcome After Ischemic Stroke. <i>Stroke</i> , 2016, 47, 1943-1945.	1.0	98
1430	Increased cerebrospinal fluid soluble TREM2 concentration in Alzheimer's disease. <i>Molecular Neurodegeneration</i> , 2016, 11, 3.	4.4	236
1431	Cerebral amyloid burden and Alzheimer's disease subtypes – does localization information matter?. <i>European Journal of Neurology</i> , 2016, 23, 233-234.	1.7	2
1432	Serum Tau Fragments Predict Return to Play in Concussed Professional Ice Hockey Players. <i>Journal of Neurotrauma</i> , 2016, 33, 1995-1999.	1.7	71
1433	Single-Molecule Imaging of Individual Amyloid Protein Aggregates in Human Biofluids. <i>ACS Chemical Neuroscience</i> , 2016, 7, 399-406.	1.7	99
1434	Increased CSF neurogranin concentration is specific to Alzheimer disease. <i>Neurology</i> , 2016, 86, 829-835.	1.5	170
1435	Soluble TREM-2 in cerebrospinal fluid from patients with multiple sclerosis treated with natalizumab or mitoxantrone. <i>Multiple Sclerosis Journal</i> , 2016, 22, 1587-1595.	1.4	73
1436	Genome-wide analysis of genetic correlation in dementia with Lewy bodies, Parkinson's and Alzheimer's diseases. <i>Neurobiology of Aging</i> , 2016, 38, 214.e7-214.e10.	1.5	78
1437	CSF $A\beta_{42}/A\beta_{40}$ and $A\beta_{42}/A\beta_{38}$ ratios: better diagnostic markers of Alzheimer disease. <i>Annals of Clinical and Translational Neurology</i> , 2016, 3, 154-165.	1.7	329
1438	<i>CACNA1C</i> polymorphism and altered phosphorylation of tau in bipolar disorder. <i>British Journal of Psychiatry</i> , 2016, 208, 195-196.	1.7	19
1439	Defeating Alzheimer's disease and other dementias: a priority for European science and society. <i>Lancet Neurology</i> , The, 2016, 15, 455-532.	4.9	1,242
1440	Identification of tissue-specific cell death using methylation patterns of circulating DNA. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, E1826-34.	3.3	492

#	ARTICLE	IF	CITATIONS
1441	A single dose of the β -secretase inhibitor semagacestat alters the cerebrospinal fluid peptidome in humans. <i>Alzheimer's Research and Therapy</i> , 2016, 8, 11.	3.0	15
1442	YKL-40 is a CSF biomarker of intrathecal inflammation in secondary progressive multiple sclerosis. <i>Journal of Neuroimmunology</i> , 2016, 292, 52-57.	1.1	64
1443	Total-tau and neurofilament light in CSF reflect spinal cord ischaemia after endovascular aortic repair. <i>Neurochemistry International</i> , 2016, 93, 1-5.	1.9	17
1444	Plasma Concentration of the Neurofilament Light Protein (NFL) is a Biomarker of CNS Injury in HIV Infection: A Cross-Sectional Study. <i>EBioMedicine</i> , 2016, 3, 135-140.	2.7	360
1445	Selective vulnerability in neurodegeneration: insights from clinical variants of Alzheimer's disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2016, 87, 1000-1004.	0.9	62
1446	Pro-inflammatory S100A9 Protein as a Robust Biomarker Differentiating Early Stages of Cognitive Impairment in Alzheimer's Disease. <i>ACS Chemical Neuroscience</i> , 2016, 7, 34-39.	1.7	60
1447	Technical performance of a novel, fully automated electrochemiluminescence immunoassay for the quantitation of $A\beta_{1-42}$ in human cerebrospinal fluid. <i>Alzheimer's and Dementia</i> , 2016, 12, 517-526. ^{0.4}		254
1448	Apolipoprotein E ϵ 4 is positively related to spatial performance but unrelated to hippocampal volume in healthy young adults. <i>Behavioural Brain Research</i> , 2016, 299, 11-18.	1.2	14
1449	Round robin test on quantification of amyloid $A\beta_{1-42}$ in cerebrospinal fluid by mass spectrometry. <i>Alzheimer's and Dementia</i> , 2016, 12, 55-59.	0.4	46
1450	Association of Cerebrospinal Fluid Neurofilament Light Concentration With Alzheimer Disease Progression. <i>JAMA Neurology</i> , 2016, 73, 60.	4.5	354
1451	Assessing the commutability of reference material formats for the harmonization of amyloid- β measurements. <i>Clinical Chemistry and Laboratory Medicine</i> , 2016, 54, 1177-1191.	1.4	49
1452	The Gothenburg MCI study: Design and distribution of Alzheimer's disease and subcortical vascular disease diagnoses from baseline to 6-year follow-up. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2016, 36, 114-131.	2.4	67
1453	Performance and complications of lumbar puncture in memory clinics: Results of the multicenter lumbar puncture feasibility study. <i>Alzheimer's and Dementia</i> , 2016, 12, 154-163.	0.4	179
1454	Alzheimer's disease and subcortical vascular disease spectrum in a hospital-based setting: Overview of results from the Gothenburg MCI and dementia studies. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2016, 36, 95-113.	2.4	42
1455	Cerebrospinal Fluid Inflammatory Biomarkers Reflect Clinical Severity in Huntington's Disease. <i>PLoS ONE</i> , 2016, 11, e0163479.	1.1	58
1456	C3 deficiency ameliorates the negative effects of irradiation of the young brain on hippocampal development and learning. <i>Oncotarget</i> , 2016, 7, 19382-19394.	0.8	21
1457	A High Throughput, Multiplexed and Targeted Proteomic CSF Assay to Quantify Neurodegenerative Biomarkers and Apolipoprotein E Isoforms Status. <i>Journal of Visualized Experiments</i> , 2016, , .	0.2	2
1458	Cardiorespiratory Fitness Attenuates the Influence of Amyloid on Cognition. <i>Journal of the International Neuropsychological Society</i> , 2015, 21, 841-850.	1.2	49

#	ARTICLE	IF	CITATIONS
1459	P4-004: Cardiorespiratory capacity modifies the association between a polygenic risk score and CSF biomarkers in preclinical Alzheimer's disease. , 2015, 11, P766-P766.		1
1460	P2-063: A β 40 and A β 42 levels in plasma: Comparison of enzyme-linked immunosorbent assay (ELISA) with multiplex technology. , 2015, 11, P507-P507.		0
1461	Intracranial arterial four-dimensional flow is associated with metrics of brain health and Alzheimer's disease. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2015, 1, 420-428.	1.2	28
1462	IC-P-063: Alzheimer's disease biomarker-based clusters predict amyloid accumulation and cognitive decline in a preclinical cohort: Findings from the wisconsin registry for Alzheimer's prevention (WRAP). , 2015, 11, P47-P49.		1
1463	P1-316: The role of lysozyme in Alzheimer's disease. , 2015, 11, P477-P478.		6
1464	P3-075: Development of a targeted proteomic multiplex CSF assay for neurodegenerative markers. , 2015, 11, P645-P646.		0
1465	IC-P-096: Insulin resistance is associated with altered microstructure in the medial temporal lobe and fornix of cognitively healthy APOE4 carriers. , 2015, 11, P66-P67.		0
1466	P1-069: Moderate-to-high intensity physical training does not alter cerebrospinal amyloid- β 1-42 levels in patients with Alzheimer's disease. , 2015, 11, P364-P365.		0
1467	P1-204: Insulin resistance is associated with altered microstructure in the medial temporal lobe and fornix of cognitively healthy ApoE ϵ 4 carriers. , 2015, 11, P427-P428.		0
1468	P4-264: Amyloid pathology is associated with extensive myelin alteration in preclinical Alzheimer's disease: New insights into disease process with novel brain imaging. , 2015, 11, P885-P885.		0
1469	O1-01-03: Alzheimer's disease biomarker-based clusters predict amyloid accumulation and cognitive decline in a preclinical cohort: Findings from the wisconsin registry for Alzheimer's prevention (WRAP). Alzheimer's and Dementia, 2015, 11, P123.	0.4	2
1470	Quantification of total apolipoprotein E and its specific isoforms in cerebrospinal fluid and blood in Alzheimer's disease and other neurodegenerative diseases. EuPA Open Proteomics, 2015, 8, 137-143.	2.5	34
1471	The Expression of Transthyretin and Amyloid- β 2 Protein Precursor is Altered in the Brain of Idiopathic Normal Pressure Hydrocephalus Patients. Journal of Alzheimer's Disease, 2015, 48, 959-968.	1.2	19
1472	Amyloid- β and Tau Dynamics in Human Brain Interstitial Fluid in Patients with Suspected Normal Pressure Hydrocephalus. Journal of Alzheimer's Disease, 2015, 46, 261-269.	1.2	39
1473	Genetic Variants of GSK3B are Associated with Biomarkers for Alzheimer's Disease and Cognitive Function. Journal of Alzheimer's Disease, 2015, 44, 1313-1322.	1.2	26
1474	Greater Specificity for Cerebrospinal Fluid P-tau231 over P-tau181 in the Differentiation of Healthy Controls from Alzheimer's Disease. Journal of Alzheimer's Disease, 2015, 49, 93-100.	1.2	35
1475	Cerebrospinal Fluid Fatty Acid-Binding Protein 3 is Related to Dementia Development in a Population-Based Sample of Older Adult Women Followed for 8 Years. Journal of Alzheimer's Disease, 2015, 49, 733-741.	1.2	18
1476	Evolving Evidence for the Value of Neuroimaging Methods and Biological Markers in Subjects Categorized with Subjective Cognitive Decline. Journal of Alzheimer's Disease, 2015, 48, S171-S191.	1.2	34

#	ARTICLE	IF	CITATIONS
1477	Does Caffeine Consumption Modify Cerebrospinal Fluid Amyloid- β Levels in Patients with Alzheimer's Disease?. <i>Journal of Alzheimer's Disease</i> , 2015, 47, 1069-1078.	1.2	28
1478	Biomarkers in Sporadic and Familial Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2015, 47, 291-317.	1.2	75
1479	Increased Cerebrospinal Fluid Level of Insulin-like Growth Factor-II in Male Patients with Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2015, 48, 637-646.	1.2	40
1480	Longitudinal cerebrospinal fluid biomarker measurements in preclinical sporadic Alzheimer's disease: A prospective 9-year study. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2015, 1, 403-411.	1.2	26
1481	IC-P-131: The relationship between intracranial vascular health and metrics of Alzheimer's disease. , 2015, 11, P88-P90.		0
1482	Do cerebrospinal fluid transfer methods affect measured amyloid β ₄₂ , total tau, and phosphorylated tau in clinical practice?. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2015, 1, 380-384.	1.2	5
1483	Serum IGF-1 is higher in patients with idiopathic normal pressure hydrocephalus than in the population. <i>Growth Hormone and IGF Research</i> , 2015, 25, 269-273.	0.5	2
1484	Using florbetapir positron emission tomography to explore cerebrospinal fluid cut points and gray zones in small sample sizes. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2015, 1, 440-446.	1.2	16
1485	P1-099: White matter lesions but not lacunes are associated with the CSF levels of β ₃₈ and β ₄₀ , and to a lesser degree with CSF β ₄₂ . , 2015, 11, P376-P377.		0
1486	P4-204: LAMP-2 changes β generation, uptake, and degradation. , 2015, 11, P859-P859.		0
1487	P2-062: Are cerebrospinal fluid levels of neurogranin associated with hippocampal atrophy and brain white matter volume decrease?. , 2015, 11, P506-P507.		0
1488	O3-14-01: Dissecting IWG-2 typical and atypical Alzheimer's disease: Insights from cerebrospinal fluid analysis. , 2015, 11, P254-P254.		0
1489	O4-11-04: Performance and complications of lumbar puncture in memory clinics: Results of the multicenter lp feasibility study. , 2015, 11, P297-P297.		1
1490	APLP1 as a cerebrospinal fluid biomarker for β -secretase modulator treatment. <i>Alzheimer's Research and Therapy</i> , 2015, 7, 77.	3.0	9
1491	Impact of cerebrospinal fluid matrix on the detection of Alzheimer's disease with β ₄₂ and influence of disease on the total β ₄₂ / β ₄₀ ratio. <i>Journal of Neurochemistry</i> , 2015, 135, 1049-1058.	2.1	18
1492	The cerebrospinal fluid biomarker profile in an HIV-infected subject with Alzheimer's disease. <i>AIDS Research and Therapy</i> , 2015, 12, 23.	0.7	17
1493	Neurogranin and YKL-40: independent markers of synaptic degeneration and neuroinflammation in Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2015, 7, 74.	3.0	109
1494	Insulin Resistance is Associated with Higher Cerebrospinal Fluid Tau Levels in Asymptomatic APOE ϵ ₄ Carriers. <i>Journal of Alzheimer's Disease</i> , 2015, 46, 525-533.	1.2	65

#	ARTICLE	IF	CITATIONS
1495	Case Report of Complex Amyotrophic Lateral Sclerosis with Cognitive Impairment and Cortical Amyloid Deposition. <i>Journal of Alzheimer's Disease</i> , 2015, 47, 661-667.	1.2	14
1496	Cerebrospinal fluid biomarkers for Alzheimer's disease. <i>Current Opinion in Psychiatry</i> , 2015, 28, 402-409.	3.1	39
1497	Increased Levels of Inflammatory Immune Mediators in Vitreous From Pseudophakic Eyes. , 2015, 56, 3407.		24
1498	A Practical Guide to Immunoassay Method Validation. <i>Frontiers in Neurology</i> , 2015, 6, 179.	1.1	348
1499	The Central Biobank and Virtual Biobank of BIOMARKAPD: A Resource for Studies on Neurodegenerative Diseases. <i>Frontiers in Neurology</i> , 2015, 6, 216.	1.1	36
1500	The past and the future of Alzheimer's disease CSF biomarkers—a journey toward validated biochemical tests covering the whole spectrum of molecular events. <i>Frontiers in Neuroscience</i> , 2015, 9, 345.	1.4	66
1501	First Administration of the Fc-Attenuated Anti- β 2 Amyloid Antibody GSK933776 to Patients with Mild Alzheimer's Disease: A Randomized, Placebo-Controlled Study. <i>PLoS ONE</i> , 2015, 10, e0098153.	1.1	27
1502	Cognitive Performance and Cerebrospinal Fluid Biomarkers of Neurodegeneration: A Study of Patients with Bipolar Disorder and Healthy Controls. <i>PLoS ONE</i> , 2015, 10, e0127100.	1.1	38
1503	Levels and Age Dependency of Neurofilament Light and Glial Fibrillary Acidic Protein in Healthy Individuals and Their Relation to the Brain Parenchymal Fraction. <i>PLoS ONE</i> , 2015, 10, e0135886.	1.1	97
1504	Quality Assessment of 25(OH)D, Insulin, Total Cholesterol, Triglycerides, and Potassium in 40-Year-Old Frozen Serum. <i>Epidemiology Research International</i> , 2015, 2015, 1-8.	0.2	4
1505	Neural and Nonneural Contributions to Wrist Rigidity in Parkinson's Disease: An Explorative Study Using the NeuroFlexor. <i>BioMed Research International</i> , 2015, 2015, 1-8.	0.9	15
1506	Monocyte and microglial activation in patients with mood-stabilized bipolar disorder. <i>Journal of Psychiatry and Neuroscience</i> , 2015, 40, 250-258.	1.4	75
1507	Cerebrospinal Fluid Total Prion Protein. <i>JAMA Neurology</i> , 2015, 72, 261.	4.5	1
1508	First effects of rising amyloid- β in transgenic mouse brain: synaptic transmission and gene expression. <i>Brain</i> , 2015, 138, 1992-2004.	3.7	67
1509	Rarity of the Alzheimer Disease "Protective" A673T Variant in the United States. <i>JAMA Neurology</i> , 2015, 72, 209.	4.5	41
1510	Absence of Cerebrospinal Fluid Signs of Neuronal Injury Before and After Immediate Antiretroviral Therapy in Acute HIV Infection. <i>Journal of Infectious Diseases</i> , 2015, 212, 1759-1767.	1.9	34
1511	CSF neuroinflammatory biomarkers in bipolar disorder are associated with cognitive impairment. <i>European Neuropsychopharmacology</i> , 2015, 25, 1091-1098.	0.3	47
1512	O4-11-01: Multicentre performance evaluation of a novel, fully automated electrochemiluminescence immunoassay for the quantitation of A β (1-42) in human cerebrospinal fluid. , 2015, 11, P295-P296.		0

#	ARTICLE	IF	CITATIONS
1513	Identification of novel CSF biomarkers for neurodegeneration and their validation by a high-throughput multiplexed targeted proteomic assay. <i>Molecular Neurodegeneration</i> , 2015, 10, 64.	4.4	121
1514	P4-066: The relationship between intracranial vascular health and metrics of Alzheimer's disease. , 2015, 11, P793-P794.		0
1515	P1-010: Quantification of the synaptic protein neurogranin in cerebrospinal fluid across different neurodegenerative diseases: A selective Alzheimer's disease biomarker?. , 2015, 11, P340-P340.		0
1516	P1-110: Predictors of cognitive decline in elderly depressives. , 2015, 11, P381-P382.		0
1517	P1-115: Consensus guidelines to perform lumbar puncture for CSF sampling in patients with neurological conditions. , 2015, 11, P384-P384.		1
1518	P2-074: Differences in the TREM2 levels in the CSF of Alzheimer's disease cases and controls. , 2015, 11, P511-P511.		0
1519	O1-02-01: Microglial-derived proteins in CSF are candidate biomarkers for early diagnosis of Alzheimer's disease. , 2015, 11, P126-P126.		0
1520	O5-05-02: Characterization of the postsynaptic protein neurogranin in brain tissue of Alzheimer's disease patients and healthy controls. , 2015, 11, P325-P325.		0
1521	P4-036: CSF Alzheimer's disease-related biomarkers are higher in subjects with periodontal disease. , 2015, 11, P779-P779.		0
1522	P1-033: A candidate reference method for analysis of amyloid beta 1-42 (A β 1-42) peptide in human CSF using 2D-HPLC with a xevo t q-s mass spectrometer. , 2015, 11, P349-P349.		0
1523	Independent information from cerebrospinal fluid amyloid- β 2 and florbetapir imaging in Alzheimer's disease. <i>Brain</i> , 2015, 138, 772-783.	3.7	200
1524	Alzheimer's disease â€” Recent biomarker developments in relation to updated diagnostic criteria. <i>Clinica Chimica Acta</i> , 2015, 449, 3-8.	0.5	25
1525	CSF biomarkers and clinical progression of Parkinson disease. <i>Neurology</i> , 2015, 84, 57-63.	1.5	178
1526	Fluid markers of traumatic brain injury. <i>Molecular and Cellular Neurosciences</i> , 2015, 66, 99-102.	1.0	43
1527	An Integrated Workflow for Multiplex CSF Proteomics and Peptidomicsâ€™ Identification of Candidate Cerebrospinal Fluid Biomarkers of Alzheimerâ€™s Disease. <i>Journal of Proteome Research</i> , 2015, 14, 654-663.	1.8	84
1528	Evolving brain structural changes in PSEN1 mutation carriers. <i>Neurobiology of Aging</i> , 2015, 36, 1261-1270.	1.5	30
1529	A study on the specificity of the association between hippocampal volume and delayed primacy performance in cognitively intact elderly individuals. <i>Neuropsychologia</i> , 2015, 69, 1-8.	0.7	25
1530	Brain Amyloid-Beta Fragment Signatures in Pathological Ageing and Alzheimer's Disease by Hybrid Immunoprecipitation Mass Spectrometry. <i>Neurodegenerative Diseases</i> , 2015, 15, 50-57.	0.8	41

#	ARTICLE	IF	CITATIONS
1531	Explorative and targeted neuroproteomics in Alzheimer's disease. <i>Biochimica Et Biophysica Acta - Proteins and Proteomics</i> , 2015, 1854, 769-778.	1.1	41
1532	A panel of nine cerebrospinal fluid biomarkers may identify patients with atypical parkinsonian syndromes. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2015, 86, 1240-1247.	0.9	196
1533	The Distribution of Apolipoprotein E Genotype Over The Adult Lifespan and in Relation to Country of Birth. <i>American Journal of Epidemiology</i> , 2015, 181, 214-217.	1.6	27
1534	Understanding Biomarkers of Neurodegeneration: Ultrasensitive detection techniques pave the way for mechanistic understanding. <i>Nature Medicine</i> , 2015, 21, 217-219.	15.2	68
1535	Cerebrospinal fluid levels of the synaptic protein neurogranin correlates with cognitive decline in prodromal Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2015, 11, 1180-1190.	0.4	254
1536	Plasma amyloid β "quo vadis?". <i>Neurobiology of Aging</i> , 2015, 36, 2671-2673.	1.5	17
1537	The Alzheimer's Disease Neuroimaging Initiative 2 Biomarker Core: A review of progress and plans. <i>Alzheimer's and Dementia</i> , 2015, 11, 772-791.	0.4	79
1538	Alzheimer's disease cerebrospinal fluid biomarker in cognitively normal subjects. <i>Brain</i> , 2015, 138, 2701-2715.	3.7	109
1539	Repetitive concussions " How dangerous are they?. <i>Molecular and Cellular Neurosciences</i> , 2015, 66, 73-74.	1.0	0
1540	Cerebrospinal fluid tau and amyloid- β_{1-42} in patients with dementia. <i>Brain</i> , 2015, 138, 2716-2731.	3.7	152
1541	Validation of a quantitative cerebrospinal fluid alpha-synuclein assay in a European-wide interlaboratory study. <i>Neurobiology of Aging</i> , 2015, 36, 2587-2596.	1.5	30
1542	Pre-analytical and analytical factors influencing Alzheimer's disease cerebrospinal fluid biomarker variability. <i>Clinica Chimica Acta</i> , 2015, 449, 9-15.	0.5	66
1543	Benchmarking biomarker-based criteria for Alzheimer's disease: Data from the Swedish Dementia Registry, SveDem. <i>Alzheimer's and Dementia</i> , 2015, 11, 1470-1479.	0.4	17
1544	Clearance systems in the brain "implications for Alzheimer disease. <i>Nature Reviews Neurology</i> , 2015, 11, 457-470.	4.9	1,127
1545	Antiviral activity and CSF concentrations of 600/100 mg of darunavir/ritonavir once daily in HIV-1 patients with plasma viral suppression. <i>Journal of Antimicrobial Chemotherapy</i> , 2015, 70, 1513-1516.	1.3	9
1546	Genetic Variants and Related Biomarkers in Sporadic Alzheimer's Disease. <i>Current Genetic Medicine Reports</i> , 2015, 3, 19-25.	1.9	3
1547	A highly sensitive novel immunoassay specifically detects low levels of soluble $A\beta$ oligomers in human cerebrospinal fluid. <i>Alzheimer's Research and Therapy</i> , 2015, 7, 14.	3.0	78
1548	APP Metabolism Regulates Tau Proteostasis in Human Cerebral Cortex Neurons. <i>Cell Reports</i> , 2015, 11, 689-696.	2.9	158

#	ARTICLE	IF	CITATIONS
1549	Prevalence of Cerebral Amyloid Pathology in Persons Without Dementia. JAMA - Journal of the American Medical Association, 2015, 313, 1924.	3.8	1,166
1550	Laboratory Testing for Lyme Neuroborreliosis. JAMA Neurology, 2015, 72, 125.	4.5	1
1551	Neurological consequences of traumatic brain injuries in sports. Molecular and Cellular Neurosciences, 2015, 66, 114-122.	1.0	141
1552	Effect of Cognitive Reserve on Age-Related Changes in Cerebrospinal Fluid Biomarkers of Alzheimer Disease. JAMA Neurology, 2015, 72, 699.	4.5	75
1553	Quantification of mutant huntingtin protein in cerebrospinal fluid from Huntington's disease patients. Journal of Clinical Investigation, 2015, 125, 1979-1986.	3.9	209
1554	Glial and neuronal markers in cerebrospinal fluid predict progression in multiple sclerosis. Multiple Sclerosis Journal, 2015, 21, 550-561.	1.4	126
1555	Amyloid biomarkers in Alzheimer's disease. Trends in Pharmacological Sciences, 2015, 36, 297-309.	4.0	404
1556	Dissecting IWG-2 typical and atypical Alzheimer's disease: insights from cerebrospinal fluid analysis. Journal of Neurology, 2015, 262, 2722-2730.	1.8	39
1557	Protective properties of lysozyme on A β -amyloid pathology: implications for Alzheimer disease. Neurobiology of Disease, 2015, 83, 122-133.	2.1	58
1558	Reduced cerebrospinal fluid concentrations of oxysterols in response to natalizumab treatment of relapsing remitting multiple sclerosis. Journal of the Neurological Sciences, 2015, 358, 201-206.	0.3	22
1559	Increased CSF biomarkers of angiogenesis in Parkinson disease. Neurology, 2015, 85, 1834-1842.	1.5	109
1560	Serum visinin-like protein-1 in concussed professional ice hockey players. Brain Injury, 2015, 29, 872-876.	0.6	25
1561	Cerebrospinal Fluid Patterns and the Risk of Future Dementia in Early, Incident Parkinson Disease. JAMA Neurology, 2015, 72, 1175.	4.5	148
1562	Hereditary diffuse leukoencephalopathy with spheroids with phenotype of primary progressive multiple sclerosis. European Journal of Neurology, 2015, 22, 328-333.	1.7	40
1563	Human cerebrospinal fluid increases the excitability of pyramidal neurons in the <i>in vitro</i> brain slice. Journal of Physiology, 2015, 593, 231-243.	1.3	29
1564	The relationship between cerebrospinal fluid tau markers, hippocampal volume, and delayed primacy performance in cognitively intact elderly individuals. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2015, 1, 81-86.	1.2	7
1565	Characterization of the postsynaptic protein neurogranin in paired cerebrospinal fluid and plasma samples from Alzheimer's disease patients and healthy controls. Alzheimer's Research and Therapy, 2015, 7, 40.	3.0	104
1566	Cerebrospinal fluid biomarkers in Alzheimer's disease: Diagnostic accuracy and prediction of dementia. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2015, 1, 455-463.	1.2	77

#	ARTICLE	IF	CITATIONS
1567	USING FLORBETAPIR PET TO INCREASE DIAGNOSTIC CERTAINTY IN ATYPICAL DEMENTIAS. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2015, 86, e4.112-e4.	0.9	0
1568	Câ€terminal neurogranin is increased in cerebrospinal fluid but unchanged in plasma in Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2015, 11, 1461-1469.	0.4	117
1569	Detailed comparison of amyloid PET and CSF biomarkers for identifying early Alzheimer disease. <i>Neurology</i> , 2015, 85, 1240-1249.	1.5	288
1570	Neurogranin Levels in Cerebrospinal Fluid. <i>JAMA Neurology</i> , 2015, 72, 1237.	4.5	19
1571	The impact of Tween 20 on repeatability of amyloid β^2 and tau measurements in cerebrospinal fluid. <i>Clinical Chemistry and Laboratory Medicine</i> , 2015, 53, e329-32.	1.4	4
1572	Cerebrospinal fluid neurogranin: relation to cognition and neurodegeneration in Alzheimer's disease. <i>Brain</i> , 2015, 138, 3373-3385.	3.7	200
1573	Cerebrospinal fluid substance P concentrations are elevated in patients with Alzheimer's disease. <i>Neuroscience Letters</i> , 2015, 609, 58-62.	1.0	20
1574	A 9-Year Prospective Population-Based Study on the Association Between the APOE*E4 Allele and Late-Life Depression in Sweden. <i>Biological Psychiatry</i> , 2015, 78, 730-736.	0.7	70
1575	Cerebrospinal fluid biomarkers in trials for Alzheimer and Parkinson diseases. <i>Nature Reviews Neurology</i> , 2015, 11, 41-55.	4.9	144
1576	Increased cerebrospinal fluid interleukin-8 in bipolar disorder patients associated with lithium and antipsychotic treatment. <i>Brain, Behavior, and Immunity</i> , 2015, 43, 198-204.	2.0	51
1577	Binding of Human Proteins to Amyloid- β^2 Protofibrils. <i>ACS Chemical Biology</i> , 2015, 10, 766-774.	1.6	26
1578	Serum SNTF Increases in Concussed Professional Ice Hockey Players and Relates to the Severity of Postconcussion Symptoms. <i>Journal of Neurotrauma</i> , 2015, 32, 1294-1300.	1.7	99
1579	Monitoring concussion in a knocked-out boxer by CSF biomarker analysis. <i>Knee Surgery, Sports Traumatology, Arthroscopy</i> , 2015, 23, 2536-2539.	2.3	21
1580	Correlations between Alzheimer's Disease Cerebrospinal Fluid Biomarkers and Cerebral Glucose Metabolism after 12 Months of Phenserine Treatment. <i>Journal of Alzheimer's Disease</i> , 2015, 47, 691-704.	1.2	7
1581	RIPOSTE: a framework for improving the design and analysis of laboratory-based research. <i>ELife</i> , 2015, 4, .	2.8	24
1582	Cerebrospinal fluid markers of central nervous system injury in decompression illness - a case-controlled pilot study. <i>Diving and Hyperbaric Medicine</i> , 2015, 45, 240-3.	0.2	4
1583	Biomarker Evidence of Axonal Injury in Neuroasymptomatic HIV-1 Patients. <i>PLoS ONE</i> , 2014, 9, e88591.	1.1	128
1584	Neurological Assessment and Its Relationship to CSF Biomarkers in Amateur Boxers. <i>PLoS ONE</i> , 2014, 9, e99870.	1.1	30

#	ARTICLE	IF	CITATIONS
1585	Cerebrospinal Fluid (CSF) Neuronal Biomarkers across the Spectrum of HIV Infection: Hierarchy of Injury and Detection. <i>PLoS ONE</i> , 2014, 9, e116081.	1.1	95
1586	Cerebrovascular Biomarker Profile Is Related to White Matter Disease and Ventricular Dilation in a LADIS Substudy. <i>Dementia and Geriatric Cognitive Disorders Extra</i> , 2014, 4, 385-394.	0.6	33
1587	Targeting Synaptic Pathology with a Novel Affinity Mass Spectrometry Approach. <i>Molecular and Cellular Proteomics</i> , 2014, 13, 2584-2592.	2.5	26
1588	β -site amyloid precursor protein-cleaving enzyme 1 (BACE1) inhibitor treatment induces $A\beta_{25-X}$ peptides through alternative amyloid precursor protein cleavage. <i>Alzheimer's Research and Therapy</i> , 2014, 6, 75.	3.0	31
1589	Cerebrospinal fluid markers including trefoil factor 3 are associated with neurodegeneration in amyloid-positive individuals. <i>Translational Psychiatry</i> , 2014, 4, e419-e419.	2.4	39
1590	The Role of Clusterin in Amyloid- β -Associated Neurodegeneration. <i>JAMA Neurology</i> , 2014, 71, 180.	4.5	66
1591	Genetic analysis implicates APOE, SNCA and suggests lysosomal dysfunction in the etiology of dementia with Lewy bodies. <i>Human Molecular Genetics</i> , 2014, 23, 6139-6146.	1.4	178
1592	Evolving Character of Chronic Central Nervous System HIV Infection. <i>Seminars in Neurology</i> , 2014, 34, 007-013.	0.5	29
1593	Cerebrospinal fluid biomarkers in parkinsonian conditions: an update and future directions. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2014, 85, 1065-1075.	0.9	83
1594	Comment on "An antidepressant decreases CSF $A\beta_{25}$ production in healthy individuals and in transgenic AD mice". <i>Science Translational Medicine</i> , 2014, 6, 268le5.	5.8	8
1595	Increased Levels of Chitotriosidase and YKL-40 in Cerebrospinal Fluid from Patients with Alzheimer's Disease. <i>Dementia and Geriatric Cognitive Disorders Extra</i> , 2014, 4, 297-304.	0.6	82
1596	Unresolved questions in Alzheimer's research: will biomarkers help?. <i>Biomarkers in Medicine</i> , 2014, 8, 61-63.	0.6	2
1597	The cerebrospinal fluid cytokine signature of multiple sclerosis: A homogenous response that does not conform to the Th1/Th2/Th17 convention. <i>Journal of Neuroimmunology</i> , 2014, 277, 153-159.	1.1	26
1598	Diagnostic accuracy of CSF Ab42 and florbetapir PET for Alzheimer's disease. <i>Annals of Clinical and Translational Neurology</i> , 2014, 1, 534-543.	1.7	96
1599	Cerebrospinal Fluid Biomarker and Brain Biopsy Findings in Idiopathic Normal Pressure Hydrocephalus. <i>PLoS ONE</i> , 2014, 9, e91974.	1.1	91
1600	SNAP-25 is a promising novel cerebrospinal fluid biomarker for synapse degeneration in Alzheimer's disease. <i>Molecular Neurodegeneration</i> , 2014, 9, 53.	4.4	216
1601	Amyloid-beta 42 adsorption following serial tube transfer. <i>Alzheimer's Research and Therapy</i> , 2014, 6, 5.	3.0	39
1602	Modulation of β -amyloid by a single dose of GSK933776 in patients with mild Alzheimer's disease: a phase I study. <i>Alzheimer's Research and Therapy</i> , 2014, 6, 19.	3.0	29

#	ARTICLE	IF	CITATIONS
1603	TREM2 mutations implicated in neurodegeneration impair cell surface transport and phagocytosis. <i>Science Translational Medicine</i> , 2014, 6, 243ra86.	5.8	600
1604	Immunosuppressive therapy reduces axonal damage in progressive multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2014, 20, 43-50.	1.4	101
1605	Metabolite and Peptide Levels in Plasma and CSF Differentiating Healthy Controls from Patients with Newly Diagnosed Parkinson's Disease. <i>Journal of Parkinson's Disease</i> , 2014, 4, 549-560.	1.5	99
1606	Accuracy of Brain Amyloid Detection in Clinical Practice Using Cerebrospinal Fluid β -Amyloid 42. <i>JAMA Neurology</i> , 2014, 71, 1282.	4.5	300
1607	Apolipoprotein E Genotype and the Diagnostic Accuracy of Cerebrospinal Fluid Biomarkers for Alzheimer Disease. <i>JAMA Psychiatry</i> , 2014, 71, 1183.	6.0	85
1608	Diagnostic Performance of Cerebrospinal Fluid Total Tau and Phosphorylated Tau in Creutzfeldt-Jakob Disease. <i>JAMA Neurology</i> , 2014, 71, 476.	4.5	164
1609	Tau, S-100 Calcium-Binding Protein B, and Neuron-Specific Enolase as Biomarkers of Concussion—Reply. <i>JAMA Neurology</i> , 2014, 71, 926.	4.5	8
1610	CSF neurofilament light differs in neurodegenerative diseases and predicts severity and survival. <i>Neurology</i> , 2014, 83, 1945-1953.	1.5	213
1611	Blood Biomarkers for Brain Injury in Concussed Professional Ice Hockey Players. <i>JAMA Neurology</i> , 2014, 71, 684.	4.5	336
1612	Monitoring of β -Amyloid Dynamics after Human Traumatic Brain Injury. <i>Journal of Neurotrauma</i> , 2014, 31, 42-55.	1.7	54
1613	CSF levels of YKL-40 are increased in MS and decrease with immunosuppressive treatment. <i>Journal of Neuroimmunology</i> , 2014, 269, 87-89.	1.1	51
1614	Neurochemical Evidence of Potential Neurotoxicity After Prophylactic Cranial Irradiation. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014, 89, 607-614.	0.4	16
1615	The amyloid- β degradation pattern in plasma—A possible tool for clinical trials in Alzheimer's disease. <i>Neuroscience Letters</i> , 2014, 573, 7-12.	1.0	62
1616	Biomarkers in Amyloid- β Immunotherapy Trials in Alzheimer's Disease. <i>Neuropsychopharmacology</i> , 2014, 39, 189-201.	2.8	66
1617	Non-neurological surgery and cerebrospinal fluid biomarkers for neuronal and astroglial integrity. <i>Journal of Neural Transmission</i> , 2014, 121, 649-653.	1.4	18
1618	Biomarker Modelling of Early Molecular Changes in Alzheimer's Disease. <i>Molecular Diagnosis and Therapy</i> , 2014, 18, 213-227.	1.6	4
1619	Cerebrospinal fluid biomarkers in cardiac arrest survivors. <i>Resuscitation</i> , 2014, 85, 227-232.	1.3	25
1620	EPHA2 polymorphisms in Estonian patients with age-related cataract. <i>Ophthalmic Genetics</i> , 2014, 37, 1-5.	0.5	13

#	ARTICLE	IF	CITATIONS
1621	Understanding the cause of sporadic Alzheimer's disease. Expert Review of Neurotherapeutics, 2014, 14, 621-630.	1.4	47
1622	Cerebrospinal fluid analysis in Alzheimer's disease: technical issues and future developments. Journal of Neurology, 2014, 261, 1234-1243.	1.8	30
1623	Cerebrospinal fluid α -synuclein levels in Parkinson's disease " changed or unchanged?. European Journal of Neurology, 2014, 21, 365-367.	1.7	14
1624	Altered cognitive performance and synaptic function in the hippocampus of mice lacking C3. Experimental Neurology, 2014, 253, 154-164.	2.0	59
1625	Lysosomal Network Proteins as Potential Novel CSF Biomarkers for Alzheimer's Disease. NeuroMolecular Medicine, 2014, 16, 150-160.	1.8	89
1626	CSF $A\beta_{1-42}$ combined with neuroimaging biomarkers in the early detection, diagnosis and prediction of Alzheimer's disease. , 2014, 10, 381-392.		64
1627	Biomarker time out. Multiple Sclerosis Journal, 2014, 20, 1560-1563.	1.4	4
1628	Post-cardiac arrest serum levels of glial fibrillary acidic protein for predicting neurological outcome. Resuscitation, 2014, 85, 1654-1661.	1.3	32
1629	Highly potent soluble amyloid- β seeds in human Alzheimer brain but not cerebrospinal fluid. Brain, 2014, 137, 2909-2915.	3.7	61
1630	Elevated Concentrations of Neurofilament Light Chain in the Cerebrospinal Fluid of Bipolar Disorder Patients. Neuropsychopharmacology, 2014, 39, 2349-2356.	2.8	68
1631	CSF $A\beta_{42}$ predicts early-onset dementia in Parkinson disease. Neurology, 2014, 82, 1784-1790.	1.5	135
1632	Mass Spectrometry-Based Candidate Reference Measurement Procedure for Quantification of Amyloid- β in Cerebrospinal Fluid. Clinical Chemistry, 2014, 60, 987-994.	1.5	132
1633	CSF in Alzheimer's Disease. Advances in Clinical Chemistry, 2014, 65, 143-172.	1.8	19
1634	Biomarkers in dementia: clinical utility and new directions. Journal of Neurology, Neurosurgery and Psychiatry, 2014, 85, 1426-1434.	0.9	119
1635	CSF α -synuclein and UCH-L1 levels in Parkinson's disease and atypical parkinsonian disorders. Parkinsonism and Related Disorders, 2014, 20, 382-387.	1.1	68
1636	Altered Cerebrospinal Fluid Levels of Amyloid β and Amyloid Precursor-Like Protein 1 Peptides in Down's Syndrome. NeuroMolecular Medicine, 2014, 16, 510-516.	1.8	28
1637	The cerebrospinal fluid "Alzheimer profile" Easily said, but what does it mean?. Alzheimer's and Dementia, 2014, 10, 713.	0.4	249
1638	Automated cerebrospinal fluid cell count " New reference ranges and evaluation of its clinical use in central nervous system infections. Clinical Biochemistry, 2014, 47, 25-30.	0.8	22

#	ARTICLE	IF	CITATIONS
1639	The interaction between sleep-disordered breathing and apolipoprotein E genotype on cerebrospinal fluid biomarkers for Alzheimer's disease in cognitively normal elderly individuals. <i>Neurobiology of Aging</i> , 2014, 35, 1318-1324.	1.5	109
1640	Imatinib treatment and A β 42 in humans. <i>Alzheimer's and Dementia</i> , 2014, 10, S374-80.	0.4	15
1641	Perspective on future role of biological markers in clinical therapy trials of Alzheimer's disease: A long-range point of view beyond 2020. <i>Biochemical Pharmacology</i> , 2014, 88, 426-449.	2.0	105
1642	Levels of cerebrospinal fluid α -synuclein oligomers are increased in Parkinson's disease with dementia and dementia with Lewy bodies compared to Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2014, 6, 25.	3.0	169
1643	Higher CSF interleukin-6 and CSF interleukin-8 in current depression in older women. Results from a population-based sample. <i>Brain, Behavior, and Immunity</i> , 2014, 41, 55-58.	2.0	75
1644	Bidirectional links between Alzheimer's disease and Niemann-Pick type C disease. <i>Neurobiology of Disease</i> , 2014, 72, 37-47.	2.1	68
1645	Blood-cerebrospinal fluid barrier dysfunction in patients with bipolar disorder in relation to antipsychotic treatment. <i>Psychiatry Research</i> , 2014, 217, 143-146.	1.7	36
1646	Cerebrospinal fluid sphingolipids, β -amyloid, and tau in adults at risk for Alzheimer's disease. <i>Neurobiology of Aging</i> , 2014, 35, 2486-2494.	1.5	57
1647	CSF biomarkers for Alzheimer's pathology and the effect size of APOE ϵ 4. <i>Molecular Psychiatry</i> , 2014, 19, 148-149.	4.1	30
1648	Acute Sleep Deprivation Increases Serum Levels of Neuron-Specific Enolase (NSE) and S100 Calcium Binding Protein B (S-100B) in Healthy Young Men. <i>Sleep</i> , 2014, 37, 195-198.	0.6	60
1649	Neuronal and Glia-Related Biomarkers in Cerebrospinal Fluid of Patients with Acute Ischemic Stroke. <i>Journal of Central Nervous System Disease</i> , 2014, 6, JCNDS.S13821.	0.7	82
1650	Preclinical Cerebrospinal Fluid and Volumetric Magnetic Resonance Imaging Biomarkers in Swedish Familial Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2014, 43, 1393-1402.	1.2	26
1651	P2-087: PATTERNS OF [C-11]PIB AMYLOID BURDEN THAT ARE ASSOCIATED WITH CEREBROSPINAL FLUID AD BIOMARKERS IN PEOPLE AT RISK FOR ALZHEIMER'S DISEASE: FINDINGS FROM THE WRAP STUDY. , 2014, 10, P502-P503.		0
1652	P1-051: THE DISTRIBUTION OF APOLIPOPROTEIN E GENOTYPE OVER THE ADULT LIFESPAN AND IN RELATION TO BIRTH ORIGIN. , 2014, 10, P322-P322.		0
1653	P4-049: IMPACT OF READY TO USE CALIBRATORS AND THE USE OF UNIFIED STANDARD OPERATING PROCEDURES ON THE VARIABILITY IN ASSAY PERFORMANCE. , 2014, 10, P800-P800.		0
1654	P2-110: ELEVATED CEREBROSPINAL FLUID LEVELS OF NEUROGRANIN IN ALZHEIMER'S DISEASE. , 2014, 10, P511-P511.		0
1655	P2-122: ULTRASENSITIVE DETECTION OF NEURODEGENERATIVE BIOMARKERS IN BLOOD WITH THE FULLY AUTOMATED SIMOA ANALYZER: CLINICAL APPLICATIONS. , 2014, 10, P515-P516.		1
1656	IC-P-007: PATTERNS OF [C-11]PIB AMYLOID BURDEN THAT ARE ASSOCIATED WITH CEREBROSPINAL FLUID AD BIOMARKERS IN PEOPLE AT RISK FOR ALZHEIMER'S DISEASE: FINDINGS FROM THE WRAP STUDY. , 2014, 10, P10-P10.		0

#	ARTICLE	IF	CITATIONS
1657	P3-103: INCREASED LEVELS OF CEREBROSPINAL FLUID FATTY ACID BINDING PROTEIN 3 ARE RELATED TO DEMENTIA DEVELOPMENT IN A POPULATION-BASED SAMPLE OF ELDERLY WOMEN FOLLOWED FOR 8 YEARS. , 2014, 10, P666-P666.		0
1658	THE ROAD AHEAD TO CURE ALZHEIMER'S DISEASE: DEVELOPMENT OF BIOLOGICAL MARKERS AND NEUROIMAGING METHODS FOR PREVENTION TRIALS ACROSS ALL STAGES AND TARGET POPULATIONS. Journal of prevention of Alzheimer's disease, The, 2014, 1, 1-22.	1.5	48
1659	Cerebrospinal Fluid Biomarkers in Alzheimer's Disease and Frontotemporal Dementia. , 2014, , 131-157.		0
1660	Fluid biomarkers in Alzheimer's disease – current concepts. Molecular Neurodegeneration, 2013, 8, 20.	4.4	180
1661	Plasma tau levels in Alzheimer's disease. Alzheimer's Research and Therapy, 2013, 5, 9.	3.0	328
1662	Cerebrospinal fluid neurofilament light chain protein levels in subtypes of frontotemporal dementia. BMC Neurology, 2013, 13, 54.	0.8	111
1663	The zebrafish amyloid precursor protein-b is required for motor neuron guidance and synapse formation. Developmental Biology, 2013, 381, 377-388.	0.9	31
1664	Cerebrospinal fluid biomarkers in patients with varicella-zoster virus CNS infections. Journal of Neurology, 2013, 260, 1813-1821.	1.8	49
1665	Evaluation of the Cerebrospinal Fluid Amyloid- β_{1-42} /Amyloid- β_{1-40} Ratio Measured by Alpha-LISA to Distinguish Alzheimer's Disease from Other Dementia Disorders. Dementia and Geriatric Cognitive Disorders, 2013, 36, 99-110.	0.7	45
1666	Analysis of Amino-Terminal Variants of Amyloid- β Peptides by Capillary Isoelectric Focusing Immunoassay. Analytical Chemistry, 2013, 85, 8142-8149.	3.2	34
1667	The influence of disease duration, clinical course, and immunosuppressive therapy on the synthesis of intrathecal oligoclonal IgG bands in multiple sclerosis. Journal of Neuroimmunology, 2013, 264, 100-105.	1.1	30
1668	Soluble amyloid precursor protein β_1 and β_2 in CSF in Alzheimer's disease. Brain Research, 2013, 1513, 117-126.	1.1	43
1669	Altered Concentrations of Amyloid Precursor Protein Metabolites in the Cerebrospinal Fluid of Patients with Bipolar Disorder. Neuropsychopharmacology, 2013, 38, 664-672.	2.8	74
1670	Heart fatty acid binding protein and β -associated Alzheimer's neurodegeneration. Molecular Neurodegeneration, 2013, 8, 39.	4.4	49
1671	Approach to Cerebrospinal Fluid (CSF) Biomarker Discovery and Evaluation in HIV Infection. Journal of NeuroImmune Pharmacology, 2013, 8, 1147-1158.	2.1	37
1672	$\beta_{1-15/16}$ as a Potential Diagnostic Marker in Neurodegenerative Diseases. NeuroMolecular Medicine, 2013, 15, 169-179.	1.8	13
1673	Biomarkers of mild traumatic brain injury in cerebrospinal fluid and blood. Nature Reviews Neurology, 2013, 9, 201-210.	4.9	509
1674	CSF biomarker variability in the Alzheimer's Association quality control program. Alzheimer's and Dementia, 2013, 9, 251-261.	0.4	344

#	ARTICLE	IF	CITATIONS
1675	Serum but not cerebrospinal fluid levels of insulin-like growth factor-I (IGF-I) and IGF-binding protein-3 (IGFBP-3) are increased in Alzheimer's disease. <i>Psychoneuroendocrinology</i> , 2013, 38, 1729-1737.	1.3	66
1676	Biomarker evidence for uncoupling of amyloid build-up and toxicity in Alzheimer's disease. , 2013, 9, 459-462.		13
1677	The ELISA-Measured Increase in Cerebrospinal Fluid Tau that Discriminates Alzheimer's Disease from other Neurodegenerative Disorders is not Attributable to Differential Recognition of Tau Assembly Forms. <i>Journal of Alzheimer's Disease</i> , 2013, 33, 923-928.	1.2	10
1678	Cerebrospinal fluid biomarkers in neurological diseases in children. <i>European Journal of Paediatric Neurology</i> , 2013, 17, 7-13.	0.7	18
1679	Cerebrospinal Fluid Brain Injury Biomarkers in Children: A Multicenter Study. <i>Pediatric Neurology</i> , 2013, 49, 31-39.e2.	1.0	33
1680	Reduced cerebrospinal fluid level of thyroxine in patients with Alzheimer's disease. <i>Psychoneuroendocrinology</i> , 2013, 38, 1058-1066.	1.3	38
1681	Tau proteins in serum predict neurological outcome after hypoxic brain injury from cardiac arrest: Results of a pilot study. <i>Resuscitation</i> , 2013, 84, 351-356.	1.3	199
1682	Global standardization measurement of cerebral spinal fluid for Alzheimer's disease: An update from the Alzheimer's Association Global Biomarkers Consortium. <i>Alzheimer's and Dementia</i> , 2013, 9, 137-140.	0.4	105
1683	Intraneuronal tau aggregation precedes diffuse plaque deposition, but amyloid- β^2 changes occur before increases of tau in cerebrospinal fluid. <i>Acta Neuropathologica</i> , 2013, 126, 631-641.	3.9	125
1684	The Application of Cerebrospinal Fluid Biomarkers in Early Diagnosis of Alzheimer Disease. <i>Medical Clinics of North America</i> , 2013, 97, 369-376.	1.1	53
1685	Cerebrospinal fluid Alzheimer's biomarker profiles in CNS infections. <i>Journal of Neurology</i> , 2013, 260, 620-626.	1.8	87
1686	Single Lipid Vesicle Assay for Characterizing Single-Enzyme Kinetics of Phospholipid Hydrolysis in a Complex Biological Fluid. <i>Journal of the American Chemical Society</i> , 2013, 135, 14151-14158.	6.6	30
1687	Reduced expression of hsa-miR-27a-3p in CSF of patients with Alzheimer disease. <i>Neurology</i> , 2013, 81, 2103-2106.	1.5	139
1688	Complement Gene Single Nucleotide Polymorphisms and Biomarker Endophenotypes of Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2013, 35, 51-57.	1.2	6
1689	A Selected Reaction Monitoring (SRM)-Based Method for Absolute Quantification of $A\beta^{38}$, $A\beta^{40}$, and $A\beta^{42}$ in Cerebrospinal Fluid of Alzheimer's Disease Patients and Healthy Controls. <i>Journal of Alzheimer's Disease</i> , 2013, 33, 1021-1032.	1.2	100
1690	Cerebrospinal fluid biomarkers of β^2 -amyloid metabolism in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2013, 19, 543-552.	1.4	43
1691	Correlations of CSF tau and amyloid levels with Alzheimer pathology in neuropathologically verified dementia with Lewy bodies. <i>International Journal of Geriatric Psychiatry</i> , 2013, 28, 738-744.	1.3	22
1692	Olympic boxing is associated with elevated levels of the neuronal protein tau in plasma. <i>Brain Injury</i> , 2013, 27, 425-433.	0.6	127

#	ARTICLE	IF	CITATIONS
1693	Cerebrospinal Fluid and Neuroimaging Biomarker Abnormalities Suggest Early Neurological Injury in a Subset of Individuals During Primary HIV Infection. <i>Journal of Infectious Diseases</i> , 2013, 207, 1703-1712.	1.9	142
1694	Neurodegenerative and inflammatory biomarkers in cerebrospinal fluid in patients with Cushing's syndrome in remission. <i>European Journal of Endocrinology</i> , 2013, 169, 211-215.	1.9	7
1695	Cerebrospinal fluid biomarkers for pathological processes in Alzheimer's disease. <i>Current Opinion in Psychiatry</i> , 2013, 26, 276-282.	3.1	20
1696	Identification of an important potential confound in CSF AD studies: aliquot volume. <i>Clinical Chemistry and Laboratory Medicine</i> , 2013, 51, 2311-7.	1.4	37
1697	Idiopathic normal-pressure hydrocephalus. <i>Neurology</i> , 2013, 80, 1385-1392.	1.5	140
1698	Semagacestat's fall: where next for AD therapies?. <i>Nature Medicine</i> , 2013, 19, 1214-1215.	15.2	18
1699	Cerebrospinal Fluid Biomarkers Mirror Rate of Cognitive Decline. <i>Journal of Alzheimer's Disease</i> , 2013, 34, 949-956.	1.2	32
1700	Cerebrospinal fluid biomarkers for Alzheimer disease and subcortical axonal damage in 5,542 clinical samples. <i>Alzheimer's Research and Therapy</i> , 2013, 5, 47.	3.0	37
1701	Plasma Amyloid- β^2 in Patients with Tangier Disease. <i>Journal of Alzheimer's Disease</i> , 2013, 35, 307-312.	1.2	3
1702	Characterization of Novel CSF Tau and ptau Biomarkers for Alzheimer's Disease. <i>PLoS ONE</i> , 2013, 8, e76523.	1.1	173
1703	Evaluating Amyloid- β^2 Oligomers in Cerebrospinal Fluid as a Biomarker for Alzheimer's Disease. <i>PLoS ONE</i> , 2013, 8, e66381.	1.1	119
1704	Increased CSF Levels of Phosphorylated Neurofilament Heavy Protein following Bout in Amateur Boxers. <i>PLoS ONE</i> , 2013, 8, e81249.	1.1	54
1705	Pyroglutamate Amyloid β^2 ($A\beta^2$) Aggravates Behavioral Deficits in Transgenic Amyloid Mouse Model for Alzheimer Disease. <i>Journal of Biological Chemistry</i> , 2012, 287, 8154-8162.	1.6	71
1706	What is a certified reference material?. <i>Biomarkers in Medicine</i> , 2012, 6, 369-370.	0.6	11
1707	Microglial Markers are Elevated in the Prodromal Phase of Alzheimer's Disease and Vascular Dementia. <i>Journal of Alzheimer's Disease</i> , 2012, 33, 45-53.	1.2	106
1708	Cerebrospinal Fluid Levels of β^2 -Amyloid 1-42, but Not of Tau, Are Fully Changed Already 5 to 10 Years Before the Onset of Alzheimer Dementia. <i>Archives of General Psychiatry</i> , 2012, 69, 98.	13.8	554
1709	Low Cerebrospinal Fluid Sulfatide Predicts Progression of White Matter Lesions – The LADIS Study. <i>Dementia and Geriatric Cognitive Disorders</i> , 2012, 34, 61-67.	0.7	19
1710	Effect of Immunotherapy With Bapineuzumab on Cerebrospinal Fluid Biomarker Levels in Patients With Mild to Moderate Alzheimer Disease. <i>Archives of Neurology</i> , 2012, 69, 1002.	4.9	215

#	ARTICLE	IF	CITATIONS
1711	Evaluation of the Performance of Novel A β Isoforms as Theragnostic Markers in Alzheimer's Disease: From the Cell to the Patient. <i>Neurodegenerative Diseases</i> , 2012, 10, 138-140.	0.8	19
1712	Lower CSF Amyloid Beta Peptides and Higher F2-Isoprostanes in Cognitively Intact Elderly Individuals With Major Depressive Disorder. <i>American Journal of Psychiatry</i> , 2012, 169, 523-530.	4.0	121
1713	Diagnostic Tools: Fluid Biomarkers for Alzheimer's Disease. <i>Advances in Biological Psychiatry</i> , 2012, , 71-79.	0.2	0
1714	Amyloid- β 1-15/16 as a Marker for β -Secretase Inhibition in Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2012, 31, 335-341.	1.2	39
1715	Longitudinal Cerebrospinal Fluid Biomarkers over Four Years in Mild Cognitive Impairment. <i>Journal of Alzheimer's Disease</i> , 2012, 30, 767-778.	1.2	76
1716	Evaluation of Plasma A β as Predictor of Alzheimer's Disease in Older Individuals Without Dementia: A Population-Based Study. <i>Journal of Alzheimer's Disease</i> , 2012, 28, 231-238.	1.2	48
1717	Development and assessment of sensitive immuno-PCR assays for the quantification of cerebrospinal fluid three- and four-repeat tau isoforms in tauopathies. <i>Journal of Neurochemistry</i> , 2012, 123, 396-405.	2.1	64
1718	The Neuropathology and Neurobiology of Traumatic Brain Injury. <i>Neuron</i> , 2012, 76, 886-899.	3.8	555
1719	Amyloid- β metabolism in Niemann-Pick C disease models and patients. <i>Metabolic Brain Disease</i> , 2012, 27, 573-585.	1.4	39
1720	O1-01-01: Cerebrospinal fluid biomarkers for Alzheimer's disease are associated with neuropathology in cortical brain biopsy. , 2012, 8, P83-P84.		0
1721	Multiplexing and multivariate analysis in neurodegeneration. <i>Methods</i> , 2012, 56, 464-470.	1.9	11
1722	Fluid Biomarkers in Alzheimer Disease. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2012, 2, a006221-a006221.	2.9	159
1723	Alzheimer's disease markers, hypertension, and gray matter damage in normal elderly. <i>Neurobiology of Aging</i> , 2012, 33, 1215-1227.	1.5	61
1724	Amyloid-related biomarkers and axonal damage proteins in parkinsonian syndromes. <i>Parkinsonism and Related Disorders</i> , 2012, 18, 69-72.	1.1	39
1725	CSF Biomarkers Correlate with Cerebral Blood Flow on SPECT in Healthy Elderly. <i>Dementia and Geriatric Cognitive Disorders</i> , 2012, 33, 156-163.	0.7	14
1726	Fluid biomarkers for Alzheimer's disease: standardization and recent developments. <i>Biomarkers in Medicine</i> , 2012, 6, 363-364.	0.6	1
1727	Accuracy of a Panel of 5 Cerebrospinal Fluid Biomarkers in the Differential Diagnosis of Patients With Dementia and/or Parkinsonian Disorders. <i>Archives of Neurology</i> , 2012, 69, 1445.	4.9	407
1728	Determining cut-points for Alzheimer's disease biomarkers: statistical issues, methods and challenges. <i>Biomarkers in Medicine</i> , 2012, 6, 391-400.	0.6	52

#	ARTICLE	IF	CITATIONS
1729	Reference measurement procedures for Alzheimer's disease cerebrospinal fluid biomarkers: definitions and approaches with focus on amyloid β 42. <i>Biomarkers in Medicine</i> , 2012, 6, 409-417.	0.6	76
1730	Proficiency testing programs for Alzheimer's disease cerebrospinal fluid biomarkers. <i>Biomarkers in Medicine</i> , 2012, 6, 401-407.	0.6	24
1731	Clinical use of cerebrospinal fluid biomarkers in Alzheimer's disease. <i>Biomarkers in Medicine</i> , 2012, 6, 371-376.	0.6	4
1732	Analytical aspects of molecular Alzheimer's disease biomarkers. <i>Biomarkers in Medicine</i> , 2012, 6, 377-389.	0.6	26
1733	Cerebrospinal Fluid Biomarkers for Alzheimer's Disease: More to Come?. <i>Journal of Alzheimer's Disease</i> , 2012, 33, S361-S369.	1.2	22
1734	Comparison of Brief Cognitive Tests and CSF Biomarkers in Predicting Alzheimer's Disease in Mild Cognitive Impairment: Six-Year Follow-Up Study. <i>PLoS ONE</i> , 2012, 7, e38639.	1.1	73
1735	CSF T-Tau/ β 42 Predicts White Matter Microstructure in Healthy Adults at Risk for Alzheimer's Disease. <i>PLoS ONE</i> , 2012, 7, e37720.	1.1	84
1736	Peptidome Analysis of Cerebrospinal Fluid by LC-MALDI MS. <i>PLoS ONE</i> , 2012, 7, e42555.	1.1	57
1737	CSF-Biomarkers in Olympic Boxing: Diagnosis and Effects of Repetitive Head Trauma. <i>PLoS ONE</i> , 2012, 7, e33606.	1.1	231
1738	Extreme Stability of Chitotriosidase in Cerebrospinal Fluid makes it a Suitable Marker for Microglial Activation in Clinical Trials. <i>Journal of Alzheimer's Disease</i> , 2012, 32, 273-276.	1.2	26
1739	CSF biomarkers for Alzheimer disease correlate with cortical brain biopsy findings. <i>Neurology</i> , 2012, 78, 1568-1575.	1.5	208
1740	An online nano-LC-ESI-FTICR-MS method for comprehensive characterization of endogenous fragments from amyloid β 2 and amyloid precursor protein in human and cat cerebrospinal fluid. <i>Journal of Mass Spectrometry</i> , 2012, 47, 591-603.	0.7	78
1741	Cerebrospinal fluid biomarkers to monitor treatment effects in Alzheimer's disease and related conditions. <i>Neurodegenerative Disease Management</i> , 2012, 2, 117-123.	1.2	0
1742	Cerebrospinal Fluid Profiles of Amyloid β 2-Related Biomarkers in Alzheimer's Disease. <i>NeuroMolecular Medicine</i> , 2012, 14, 65-73.	1.8	70
1743	Cerebrospinal fluid levels of complement proteins C3, C4 and CR1 in Alzheimer's disease. <i>Journal of Neural Transmission</i> , 2012, 119, 789-797.	1.4	67
1744	Monte Carlo feature selection and rule-based models to predict Alzheimer's disease in mild cognitive impairment. <i>Journal of Neural Transmission</i> , 2012, 119, 821-831.	1.4	13
1745	A novel ARC gene polymorphism is associated with reduced risk of Alzheimer's disease. <i>Journal of Neural Transmission</i> , 2012, 119, 833-842.	1.4	27
1746	Measurement of β 42 in cerebrospinal fluid is influenced by matrix effects. <i>Journal of Neurochemistry</i> , 2012, 120, 325-333.	2.1	38

#	ARTICLE	IF	CITATIONS
1747	Levels of cerebrospinal fluid neurofilament light protein in healthy elderly vary as a function of TOMM40 variants. <i>Experimental Gerontology</i> , 2012, 47, 347-352.	1.2	25
1748	BACE1 Inhibition Induces a Specific Cerebrospinal Fluid β -Amyloid Pattern That Identifies Drug Effects in the Central Nervous System. <i>PLoS ONE</i> , 2012, 7, e31084.	1.1	68
1749	Antihypertensive Therapy Is Associated with Reduced Rate of Conversion to Alzheimer's Disease in Midregional Proatrial Natriuretic Peptide Stratified Subjects with Mild Cognitive Impairment. <i>Biological Psychiatry</i> , 2011, 70, 145-151.	0.7	24
1750	Characterization of the Brain β -Amyloid Isoform Pattern at Different Ages of Tg2576 Mice. <i>Neurodegenerative Diseases</i> , 2011, 8, 352-363.	0.8	18
1751	Cerebrospinal Fluid Matrix Metalloproteinases and Tissue Inhibitor of Metalloproteinases in Combination with Subcortical and Cortical Biomarkers in Vascular Dementia and Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2011, 27, 665-676.	1.2	150
1752	Screening for New Biomarkers for Subcortical Vascular Dementia and Alzheimer's Disease. <i>Dementia and Geriatric Cognitive Disorders Extra</i> , 2011, 1, 31-42.	0.6	35
1753	SILAC zebrafish for quantitative analysis of protein turnover and tissue regeneration. <i>Journal of Proteomics</i> , 2011, 75, 425-434.	1.2	56
1754	Increased levels of total tau protein in the cerebrospinal fluid in Huntington's disease. <i>Parkinsonism and Related Disorders</i> , 2011, 17, 714-715.	1.1	31
1755	Biomarker-based dissection of neurodegenerative diseases. <i>Progress in Neurobiology</i> , 2011, 95, 520-534.	2.8	82
1756	A novel pathway for amyloid precursor protein processing. <i>Neurobiology of Aging</i> , 2011, 32, 1090-1098.	1.5	136
1757	The Alzheimer's Association external quality control program for cerebrospinal fluid biomarkers. <i>Alzheimer's and Dementia</i> , 2011, 7, 386.	0.4	354
1758	Biomarkers for Microglial Activation in Alzheimer's Disease. <i>International Journal of Alzheimer's Disease</i> , 2011, 2011, 1-5.	1.1	23
1759	Cerebrospinal Fluid Levels of sAPP β and sAPP β in Lewy Body and Alzheimer's Disease: Clinical and Neurochemical Correlates. <i>International Journal of Alzheimer's Disease</i> , 2011, 2011, 1-6.	1.1	19
1760	Impaired Lipoprotein Receptor-Mediated Peripheral Binding of Plasma Amyloid- β is an Early Biomarker for Mild Cognitive Impairment Preceding Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2011, 24, 25-34.	1.2	63
1761	Discriminatory Analysis of Biochip-Derived Protein Patterns in CSF and Plasma in Neurodegenerative Diseases. <i>Frontiers in Aging Neuroscience</i> , 2011, 3, 1.	1.7	73
1762	Hypoxia Due to Cardiac Arrest Induces a Time-Dependent Increase in Serum Amyloid β Levels in Humans. <i>PLoS ONE</i> , 2011, 6, e28263.	1.1	149
1763	Novel A β Isoforms in Alzheimer's Disease - Their Role in Diagnosis and Treatment. <i>Current Pharmaceutical Design</i> , 2011, 17, 2594-2602.	0.9	66
1764	Amyloid- β 42 is Associated with Cognitive Impairment in Healthy Elderly and Subjective Cognitive Impairment. <i>Journal of Alzheimer's Disease</i> , 2011, 26, 135-142.	1.2	77

#	ARTICLE	IF	CITATIONS
1765	Cerebrospinal Fluid Biomarkers for Alzheimer's Disease: Diagnostic Performance in a Homogeneous Mono-Center Population. <i>Journal of Alzheimer's Disease</i> , 2011, 24, 537-546.	1.2	68
1766	Identification of Novel β -Synuclein Isoforms in Human Brain Tissue by using an Online NanoLC-ESI-FTICR-MS Method. <i>Neurochemical Research</i> , 2011, 36, 2029-2042.	1.6	99
1767	No Association of LOXL1 Gene Polymorphisms with Alzheimer's Disease. <i>NeuroMolecular Medicine</i> , 2011, 13, 160-166.	1.8	15
1768	Cerebrospinal Fluid Microglial Markers in Alzheimer's Disease: Elevated Chitotriosidase Activity but Lack of Diagnostic Utility. <i>NeuroMolecular Medicine</i> , 2011, 13, 151-159.	1.8	104
1769	S-100B is superior to NSE, BDNF and GFAP in predicting outcome of resuscitation from cardiac arrest with hypothermia treatment. <i>Resuscitation</i> , 2011, 82, 26-31.	1.3	87
1770	Miglustat Treatment May Reduce Cerebrospinal Fluid Levels of the Axonal Degeneration Marker Tau in Niemann-Pick Type C. <i>JIMD Reports</i> , 2011, 3, 45-52.	0.7	25
1771	New diagnostic criteria for Alzheimer's disease. <i>Biomarkers in Medicine</i> , 2011, 5, 407-409.	0.6	4
1772	Site-specific characterization of threonine, serine, and tyrosine glycosylations of amyloid precursor protein/amyloid β -peptides in human cerebrospinal fluid. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2011, 108, 11848-11853.	3.3	205
1773	CSF amyloid β 38 as a novel diagnostic marker for dementia with Lewy bodies. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2011, 82, 160-164.	0.9	50
1774	Memory in individuals with mild cognitive impairment in relation to APOE and CSF β 42. <i>International Psychogeriatrics</i> , 2010, 22, 598-606.	0.6	10
1775	Acute Effect on the β 2 Isoform Pattern in CSF in Response to β -Secretase Modulator and Inhibitor Treatment in Dogs. <i>Journal of Alzheimer's Disease</i> , 2010, 21, 1005-1012.	1.2	61
1776	PBT2 Rapidly Improves Cognition in Alzheimer's Disease: Additional Phase II Analyses. <i>Journal of Alzheimer's Disease</i> , 2010, 20, 509-516.	1.2	347
1777	Evaluation of CSF Biomarkers as Predictors of Alzheimer's Disease: A Clinical Follow-Up Study of 4.7 Years. <i>Journal of Alzheimer's Disease</i> , 2010, 21, 1119-1128.	1.2	110
1778	Mass spectrometric characterization of brain amyloid beta isoform signatures in familial and sporadic Alzheimer's disease. <i>Acta Neuropathologica</i> , 2010, 120, 185-193.	3.9	268
1779	Association of the RAGE G82S polymorphism with Alzheimer's disease. <i>Journal of Neural Transmission</i> , 2010, 117, 861-867.	1.4	47
1780	Amyloid β 2 and APP as biomarkers for Alzheimer's disease. <i>Experimental Gerontology</i> , 2010, 45, 23-29.	1.2	104
1781	Total and phosphorylated tau protein as biological markers of Alzheimer's disease. <i>Experimental Gerontology</i> , 2010, 45, 30-40.	1.2	330
1782	Neurogranin in cerebrospinal fluid as a marker of synaptic degeneration in Alzheimer's disease. <i>Brain Research</i> , 2010, 1362, 13-22.	1.1	180

#	ARTICLE	IF	CITATIONS
1783	Cerebrospinal fluid total tau as a marker of Alzheimer's disease intensity. <i>International Journal of Geriatric Psychiatry</i> , 2010, 25, 403-410.	1.3	109
1784	Distinct cerebrospinal fluid amyloid β peptide signatures in sporadic and PSEN1A431E-associated familial Alzheimer's disease. <i>Molecular Neurodegeneration</i> , 2010, 5, 2.	4.4	79
1785	BACE1 gene variants do not influence BACE1 activity, levels of APP or $A\beta$ isoforms in CSF in Alzheimer's disease. <i>Molecular Neurodegeneration</i> , 2010, 5, 37.	4.4	5
1786	Cerebrospinal fluid biomarkers of white matter lesions – cross-sectional results from the LADIS study. <i>European Journal of Neurology</i> , 2010, 17, 377-382.	1.7	100
1787	Biomarkers for Alzheimer's disease: academic, industry and regulatory perspectives. <i>Nature Reviews Drug Discovery</i> , 2010, 9, 560-574.	21.5	560
1788	High Education May Offer Protection Against Tauopathy in Patients with Mild Cognitive Impairment. <i>Journal of Alzheimer's Disease</i> , 2010, 21, 221-228.	1.2	25
1789	cNEUPRO: Novel Biomarkers for Neurodegenerative Diseases. <i>International Journal of Alzheimer's Disease</i> , 2010, 2010, 1-12.	1.1	16
1790	Neuroinflammation Screening in Immunotherapy Trials against Alzheimer's Disease. <i>International Journal of Alzheimer's Disease</i> , 2010, 2010, 1-3.	1.1	9
1791	To Know or Not to Know: Ethical Issues Related to Early Diagnosis of Alzheimer's Disease. <i>International Journal of Alzheimer's Disease</i> , 2010, 2010, 1-4.	1.1	48
1792	Confounding Factors Influencing Amyloid Beta Concentration in Cerebrospinal Fluid. <i>International Journal of Alzheimer's Disease</i> , 2010, 2010, 1-11.	1.1	161
1793	Cerebrospinal Fluid Analysis Should Be Considered in Patients with Cognitive Problems. <i>International Journal of Alzheimer's Disease</i> , 2010, 2010, 1-4.	1.1	6
1794	Converging Pathways of Chromogranin and Amyloid Metabolism in the Brain. <i>Journal of Alzheimer's Disease</i> , 2010, 20, 1039-1049.	1.2	19
1795	Lessons from Multicenter Studies on CSF Biomarkers for Alzheimer's Disease. <i>International Journal of Alzheimer's Disease</i> , 2010, 2010, 1-5.	1.1	27
1796	Inter-laboratory variation in cerebrospinal fluid biomarkers for Alzheimer's disease: united we stand, divided we fall. <i>Clinical Chemistry and Laboratory Medicine</i> , 2010, 48, 603-607.	1.4	78
1797	Correlation of Longitudinal Cerebrospinal Fluid Biomarkers With Cognitive Decline in Healthy Older Adults. <i>Archives of Neurology</i> , 2010, 67, 217-23.	4.9	99
1798	Diagnosis-Independent Alzheimer Disease Biomarker Signature in Cognitively Normal Elderly People. <i>Archives of Neurology</i> , 2010, 67, 949.	4.9	407
1799	Problems associated with fluid biomarkers for Parkinson's disease. <i>Biomarkers in Medicine</i> , 2010, 4, 671-681.	0.6	14
1800	Neuroinflammation in Lyme neuroborreliosis affects amyloid metabolism. <i>BMC Neurology</i> , 2010, 10, 51.	0.8	49

#	ARTICLE	IF	CITATIONS
1801	Effects of cerebrovascular disease on amyloid precursor protein metabolites in cerebrospinal fluid. <i>Cerebrospinal Fluid Research</i> , 2010, 7, 10.	0.5	51
1802	Converging molecular pathways in human neural development and degeneration. <i>Neuroscience Research</i> , 2010, 66, 330-332.	1.0	34
1803	Consecutive analyses of cerebrospinal fluid axonal and glial markers in Parkinson's disease and atypical parkinsonian disorders. <i>Parkinsonism and Related Disorders</i> , 2010, 16, 142-145.	1.1	80
1804	Proteomic profiling of cerebrospinal fluid in parkinsonian disorders. <i>Parkinsonism and Related Disorders</i> , 2010, 16, 545-549.	1.1	38
1805	Evaluation of plasma A β ²⁴⁰ and A β ²⁴² as predictors of conversion to Alzheimer's disease in patients with mild cognitive impairment. <i>Neurobiology of Aging</i> , 2010, 31, 357-367.	1.5	242
1806	Soluble TNF receptors are associated with A β ² metabolism and conversion to dementia in subjects with mild cognitive impairment. <i>Neurobiology of Aging</i> , 2010, 31, 1877-1884.	1.5	101
1807	Is there a CSF biomarker profile related to depression in elderly women?. <i>Psychiatry Research</i> , 2010, 176, 174-178.	1.7	40
1808	Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. <i>Nature Reviews Neurology</i> , 2010, 6, 131-144.	4.9	1,598
1809	CSF biomarkers predict a more malignant outcome in Alzheimer disease. <i>Neurology</i> , 2010, 74, 1531-1537.	1.5	182
1810	Identification of novel N-terminal fragments of amyloid precursor protein in cerebrospinal fluid. <i>Experimental Neurology</i> , 2010, 223, 351-358.	2.0	37
1811	Biological markers of amyloid β ² -related mechanisms in Alzheimer's disease. <i>Experimental Neurology</i> , 2010, 223, 334-346.	2.0	145
1812	Biochemical markers in Alzheimer's disease clinical trials. <i>Biomarkers in Medicine</i> , 2010, 4, 91-98.	0.6	14
1813	Low Incidence of Post-Lumbar Puncture Headache in 1,089 Consecutive Memory Clinic Patients. <i>European Neurology</i> , 2010, 63, 326-330.	0.6	99
1814	Is it time for biomarker-based diagnostic criteria for prodromal Alzheimer's disease?. <i>Alzheimer's Research and Therapy</i> , 2010, 2, 8.	3.0	19
1815	A novel A β ² isoform pattern in CSF reflects β ³ -secretase inhibition in Alzheimer disease. <i>Alzheimer's Research and Therapy</i> , 2010, 2, 7.	3.0	85
1816	Use of theragnostic markers to select drugs for phase II/III trials for Alzheimer disease. <i>Alzheimer's Research and Therapy</i> , 2010, 2, 32.	3.0	15
1817	A β ²⁴⁰ Oligomers Identified as a Potential Biomarker for the Diagnosis of Alzheimer's Disease. <i>PLoS ONE</i> , 2010, 5, e15725.	1.1	96
1818	Synaptic Retrogenesis and Amyloid- β ² in Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2009, 16, 1-14.	1.2	52

#	ARTICLE	IF	CITATIONS
1819	Magnetic Resonance Imaging Improves Cerebrospinal Fluid Biomarkers in the Early Detection of Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2009, 16, 351-362.	1.2	60
1820	Cerebrospinal Fluid Total Tau Is Associated with Shorter Survival in Dementia with Lewy Bodies. <i>Dementia and Geriatric Cognitive Disorders</i> , 2009, 28, 314-319.	0.7	32
1821	Subcortical Vascular Dementia Biomarker Pattern in Mild Cognitive Impairment. <i>Dementia and Geriatric Cognitive Disorders</i> , 2009, 28, 348-356.	0.7	45
1822	Identification of Novel APP/A β Isoforms in Human Cerebrospinal Fluid. <i>Neurodegenerative Diseases</i> , 2009, 6, 87-94.	0.8	64
1823	Rapid Progression from Mild Cognitive Impairment to Alzheimer's Disease in Subjects with Elevated Levels of Tau in Cerebrospinal Fluid and the ϵ 4/APOE ϵ 4 Genotype. <i>Dementia and Geriatric Cognitive Disorders</i> , 2009, 27, 458-464.	0.7	119
1824	Future Screening for Incipient Alzheimer's Disease – The Influence of Prevalence on Test Performance. <i>European Neurology</i> , 2009, 62, 200-203.	0.6	16
1825	Effects of β -Secretase Inhibition on the Amyloid β Isoform Pattern in a Mouse Model of Alzheimer's Disease. <i>Neurodegenerative Diseases</i> , 2009, 6, 258-262.	0.8	28
1826	Monitoring of brain interstitial total tau and beta amyloid proteins by microdialysis in patients with traumatic brain injury. <i>Journal of Neurosurgery</i> , 2009, 110, 1227-1237.	0.9	127
1827	Alzheimer's disease and CSF biomarkers: key challenges for broad clinical applications. <i>Biomarkers in Medicine</i> , 2009, 3, 735-737.	0.6	24
1828	Sustained release of neuron-specific enolase to serum in amateur boxers. <i>Brain Injury</i> , 2009, 23, 723-726.	0.6	60
1829	The Szilard Hypothesis on the Nature of Aging Revisited. <i>Genetics</i> , 2009, 182, 3-9.	1.2	6
1830	Amyloid and tau cerebrospinal fluid biomarkers in HIV infection. <i>BMC Neurology</i> , 2009, 9, 63.	0.8	126
1831	Validation of Alzheimer's disease CSF and plasma biological markers: The multicentre reliability study of the pilot European Alzheimer's Disease Neuroimaging Initiative (E-ADNI). <i>Experimental Gerontology</i> , 2009, 44, 579-585.	1.2	60
1832	CSF Biomarkers. <i>Annals of the New York Academy of Sciences</i> , 2009, 1180, 28-35.	1.8	60
1833	Combined rCBF and CSF biomarkers predict progression from mild cognitive impairment to Alzheimer's disease. <i>Neurobiology of Aging</i> , 2009, 30, 165-173.	1.5	69
1834	Levels of brain related proteins in cerebrospinal fluid: An aid in the differential diagnosis of parkinsonian disorders. <i>Parkinsonism and Related Disorders</i> , 2009, 15, 205-212.	1.1	52
1835	Elevated plasma levels of soluble CD40 in incipient Alzheimer's disease. <i>Neuroscience Letters</i> , 2009, 450, 56-59.	1.0	37
1836	Cerebrospinal fluid α -synuclein in neurodegenerative disorders – A marker of synapse loss?. <i>Neuroscience Letters</i> , 2009, 450, 332-335.	1.0	194

#	ARTICLE	IF	CITATIONS
1837	Update on amyloid homeostasis markers for sporadic Alzheimer's disease. <i>Scandinavian Journal of Clinical and Laboratory Investigation</i> , 2009, 69, 18-21.	0.6	7
1838	CSF Biomarkers and Incipient Alzheimer Disease in Patients With Mild Cognitive Impairment. <i>JAMA - Journal of the American Medical Association</i> , 2009, 302, 385.	3.8	1,009
1839	Cerebrospinal Fluid Biomarkers for Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2009, 18, 413-417.	1.2	122
1840	Effects of Memantine on Cerebrospinal Fluid Biomarkers of Neurofibrillary Pathology. <i>Journal of Alzheimer's Disease</i> , 2009, 18, 509-513.	1.2	6
1841	B-type natriuretic peptide plasma levels are elevated in subcortical vascular dementia. <i>NeuroReport</i> , 2009, 20, 825-827.	0.6	28
1842	Longitudinal Study of CSF Biomarkers in Patients with Alzheimer's Disease. <i>PLoS ONE</i> , 2009, 4, e6294.	1.1	79
1843	Effect of phenserine treatment on brain functional activity and amyloid in Alzheimer's disease. <i>Annals of Neurology</i> , 2008, 63, 621-631.	2.8	124
1844	Targeted proteomics in Alzheimer's disease: focus on amyloid- β . <i>Expert Review of Proteomics</i> , 2008, 5, 225-237.	1.3	49
1845	Clinical proteomics in neurodegenerative disorders. <i>Acta Neurologica Scandinavica</i> , 2008, 118, 1-11.	1.0	85
1846	Safety, efficacy, and biomarker findings of PBT2 in targeting A β as a modifying therapy for Alzheimer's disease: a phase IIa, double-blind, randomised, placebo-controlled trial. <i>Lancet Neurology</i> , The, 2008, 7, 779-786.	4.9	657
1847	Amyloid β Protein Dimer-Containing Human CSF Disrupts Synaptic Plasticity: Prevention by Systemic Passive Immunization. <i>Journal of Neuroscience</i> , 2008, 28, 4231-4237.	1.7	293
1848	Hyperphosphorylation of tau protein in superficial CNS siderosis. <i>Journal of the Neurological Sciences</i> , 2008, 273, 130-132.	0.3	17
1849	Association of APOE with age at onset of sporadic amyotrophic lateral sclerosis. <i>Journal of the Neurological Sciences</i> , 2008, 273, 67-69.	0.3	35
1850	Core candidate neurochemical and imaging biomarkers of Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2008, 4, 38-48.	0.4	447
1851	Characterization of Tau in Cerebrospinal Fluid Using Mass Spectrometry. <i>Journal of Proteome Research</i> , 2008, 7, 2114-2120.	1.8	74
1852	Biological CSF Markers of Alzheimer's Disease. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2008, 89, 261-268.	1.0	9
1853	Elevated Cerebrospinal Fluid BACE1 Activity in Incipient Alzheimer Disease. <i>Archives of Neurology</i> , 2008, 65, 1102-7.	4.9	193
1854	Study bridges the gap between advanced mass spectrometry and immuno-based multiplex assays. <i>Biomarkers in Medicine</i> , 2008, 2, 219-219.	0.6	0

#	ARTICLE	IF	CITATIONS
1855	Is Plasma Amyloid- β a Reliable Biomarker for Alzheimer's Disease?. <i>Recent Patents on CNS Drug Discovery</i> , 2008, 3, 109-111.	0.9	16
1856	What is the future for CSF biomarkers in the prediction of cognitive decline and Alzheimer's disease?. <i>Aging Health</i> , 2008, 4, 213-215.	0.3	0
1857	Methylenetetrahydrofolate Reductase Genetic Polymorphisms in Patients with Primary Open-Angle Glaucoma. <i>Ophthalmic Genetics</i> , 2007, 28, 47-50.	0.5	21
1858	Identification of a β -amyloid-binding plasma protein, LRP1: implications for biomarker research and therapy in Alzheimer's disease. <i>Biomarkers in Medicine</i> , 2007, 1, 347-348.	0.6	2
1859	No neurochemical evidence for brain injury caused by heading in soccer. <i>British Journal of Sports Medicine</i> , 2007, 41, 574-577.	3.1	52
1860	Prediction of Alzheimer's Disease Using the CSF A β ₄₂ /A β ₄₀ Ratio in Patients with Mild Cognitive Impairment. <i>Dementia and Geriatric Cognitive Disorders</i> , 2007, 23, 316-320.	0.7	248
1861	Novel Panel of Cerebrospinal Fluid Biomarkers for the Prediction of Progression to Alzheimer Dementia in Patients With Mild Cognitive Impairment. <i>Archives of Neurology</i> , 2007, 64, 366.	4.9	131
1862	Kinesin gene variability may affect tau phosphorylation in early Alzheimer's disease. <i>International Journal of Molecular Medicine</i> , 2007, 20, 233.	1.8	6
1863	Characterization of Amyloid β Peptides in Cerebrospinal Fluid by an Automated Immunoprecipitation Procedure Followed by Mass Spectrometry. <i>Journal of Proteome Research</i> , 2007, 6, 4433-4439.	1.8	135
1864	Longitudinal stability of CSF biomarkers in Alzheimer's disease. <i>Neuroscience Letters</i> , 2007, 419, 18-22.	1.0	169
1865	Aspects of β -amyloid as a biomarker for Alzheimer's disease. <i>Biomarkers in Medicine</i> , 2007, 1, 59-78.	0.6	73
1866	Intra-Individual Stability of CSF Biomarkers for Alzheimer's Disease over Two Years. <i>Journal of Alzheimer's Disease</i> , 2007, 12, 255-260.	1.2	117
1867	Cerebrospinal fluid neurofilament light levels in amyotrophic lateral sclerosis: impact of SOD1 genotype. <i>European Journal of Neurology</i> , 2007, 14, 1329-1333.	1.7	118
1868	Alzheimer's disease. <i>Lancet</i> , The, 2006, 368, 387-403.	6.3	3,074
1869	The Role of Biomarkers in Clinical Trials for Alzheimer Disease. <i>Alzheimer Disease and Associated Disorders</i> , 2006, 20, 6-15.	0.6	203
1870	Determination of β -Amyloid Peptide Signatures in Cerebrospinal Fluid Using Immunoprecipitation-Mass Spectrometry. <i>Journal of Proteome Research</i> , 2006, 5, 1010-1016.	1.8	187
1871	An Alzheimer's disease-specific β -amyloid fragment signature in cerebrospinal fluid. <i>Neuroscience Letters</i> , 2006, 409, 215-219.	1.0	114
1872	Neurochemical aftermath of amateur boxing. <i>Scandinavian Journal of Medicine and Science in Sports</i> , 2006, 16, 470-470.	1.3	2

#	ARTICLE	IF	CITATIONS
1873	Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study. <i>Lancet Neurology</i> , The, 2006, 5, 228-234.	4.9	1,494
1874	Plasma A β 2 in Alzheimer's disease—up or down?. <i>Lancet Neurology</i> , The, 2006, 5, 638-639.	4.9	48
1875	Cerebrospinal fluid A β 1-42 concentration may predict cognitive decline in older women. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2006, 78, 461-464.	0.9	189
1876	Neurochemical Aftermath of Amateur Boxing. <i>Archives of Neurology</i> , 2006, 63, 1277.	4.9	310
1877	Evaluation of Factors of Importance for Clinical Dementia Diagnosis. <i>Dementia and Geriatric Cognitive Disorders</i> , 2005, 19, 289-298.	0.7	3
1878	Functional interaction of Oct transcription factors with the family of repeats in Epstein-Barr virus oriP. <i>Journal of General Virology</i> , 2005, 86, 1261-1267.	1.3	13
1879	Diagnostic value of 14-3-3beta immunoblot and T-tau/P-tau ratio in clinically suspected Creutzfeldt-Jakob disease. <i>International Journal of Molecular Medicine</i> , 2005, 16, 1147-9.	1.8	44
1880	The methylenetetrahydrofolate reductase C677T polymorphism is a major determinant of coffee-induced increase of plasma homocysteine: A randomized placebo controlled study. <i>International Journal of Molecular Medicine</i> , 2004, 13, 811.	1.8	7
1881	Methylenetetrahydrofolate reductase and transcobalamin genetic polymorphisms in human spontaneous abortion: biological and clinical implications. <i>Reproductive Biology and Endocrinology</i> , 2004, 2, 7.	1.4	52
1882	Increased cerebrospinal fluid levels of transforming growth factor- β 21 in Alzheimer's disease. <i>Neuroscience Letters</i> , 2004, 367, 194-196.	1.0	96
1883	Multiple EBNA1-binding sites within oriP are required for EBNA1-dependent transactivation of the Epstein-Barr virus C promoter. <i>International Journal of Oncology</i> , 2004, 25, 693-6.	1.4	2
1884	Cerebrospinal fluid markers for prediction of Alzheimer's disease. <i>Neuroscience Letters</i> , 2003, 352, 67-69.	1.0	157
1885	The Transcobalamin (TC) Codon 259 Genetic Polymorphism Influences Holo-TC Concentration in Cerebrospinal Fluid from Patients with Alzheimer Disease. <i>Clinical Chemistry</i> , 2003, 49, 1195-1198.	1.5	35
1886	Gene-gene interaction between fetal MTHFR 677C>T and transcobalamin 776C>G polymorphisms in human spontaneous abortion. <i>Human Reproduction</i> , 2003, 18, 1948-1950.	0.4	37
1887	Increased frequency of combined methylenetetrahydrofolate reductase C677T and A1298C mutated alleles in spontaneously aborted embryos. <i>European Journal of Human Genetics</i> , 2002, 10, 113-118.	1.4	130
1888	The transcobalamin codon 259 polymorphism influences the risk of human spontaneous abortion. <i>Human Reproduction</i> , 2002, 17, 3033-3036.	0.4	32
1889	No association between the MTHFR A1298C and transcobalamin C776G genetic polymorphisms and hyperhomocysteinemia in thrombotic disease. <i>Thrombosis Research</i> , 2002, 108, 127-131.	0.8	33
1890	Influence of the apolipoprotein E ϵ 4 allele on human embryonic development. <i>Neuroscience Letters</i> , 2002, 324, 189-192.	1.0	50

#	ARTICLE	IF	CITATIONS
1891	Reply to MTHFR C677T and A1298C polymorphisms and mutated sequences occurring in cis. European Journal of Human Genetics, 2002, 10, 579-582.	1.4	8
1892	The Epstein-Barr virus ZEBRA protein activates transcription from the early lytic F promoter by binding to a promoter-proximal AP-1-like site. Journal of General Virology, 2002, 83, 2007-2014.	1.3	4
1893	Diagnosis and biomarkers: CSF. , 0, , 97-108.		0
1894	Increased frequency of combined methylenetetrahydrofolate reductase C677T and A1298C mutated alleles in spontaneously aborted embryos. , 0, .		1
1895	Cerebrospinal fluid neurofilament light chain levels in CLN2 disease patients treated with enzyme replacement therapy normalise after two years on treatment. F1000Research, 0, 10, 614.	0.8	2
1896	Neurological Involvement in COVID-19 Among Non-Hospitalized Adolescents and Young Adults. Frontiers in Neurology, 0, 13, .	1.1	10
1897	Factors influencing resilience to postoperative delirium in adults undergoing elective orthopaedic surgery. British Journal of Surgery, 0, , .	0.1	2
1898	Reply to Dr. Arieli regarding our article protein tau concentration in blood increases after SCUBA diving: an observational study published in European journal of applied physiology 2022;122:993-1005. European Journal of Applied Physiology, 0, , .	1.2	0